 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 1 
Title Page  
Protocol Title:   Phase 1/1b Study of the Safety of TTX -030 as a Single Agent and 
in Combination with Pembrolizumab or Chemotherapy in Patients  
with Lymphoma or Solid Tumor Malignancies  
Protocol Number:    TTX -030-001 
Amendment Number:  Version 8.0, December 15, 2020  
Compound :    TTX -030 
Study Phase:    1/1b  
Sponsor Name:    Trishula  Therapeutics , Inc.  
Legal Registered Address:    4000 Shoreline Court, Suite 200  
South San Francisco, CA 94080  
Regulatory Agency   IND Number 138313  
Identifier Number(s) : 
Approval Date:    October 1, 2018   Version 1.0  
   October 24, 2018   Version 1.1  
   December 28, 2018   Version 2.0  
   September 12, 2019   Version 3.0  
   October 21, 2019   Version 4.0  
   November 22, 2019   Version 5.0  
   January 2, 2020   Version 6.0  
   Octo ber 12, 2020   Version 7.0 
   December  15, 2020   Version 8.0 
 
CONFIDENTIAL  
This document and all copies thereof are the property of Trishula  Therapeutics , Inc . This 
document contains valuable trade secrets and proprietary information and may not be 
disclosed to others without prior written authorization from Trishula  Therapeutics , Inc.  
and may only be used for purposes intended by the document.   
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 3 
PROTOCOL ACCEPTANCE FORM  
 
PROTOCOL TITLE:  
Phase 1/1b Study of the Safety of TTX -030 as a Single Agent and in Combination with 
Pembrolizumab or Chemotherapy in Patients  with Lymphoma or Solid Tumor 
Malignancies  
 
PROTOCOL NUMBER:    TTX -030-001 
 
STUDY TREATMENT:    TTX -030 
 
IND NUMBER:     138313  
 
SPONSOR:      Trishula  Therapeutics , Inc.  
      4000 Shoreline Court, Suite 200  
      South San Francisco, CA 94080  
  
DATE FINAL:     December  15, 2020  Version 8.0 
 
By my signature below, I hereby state that I have read and agree to abide by the instructions, 
conditions, and restrictions of the protocol, in accordance with Good Clinical Practice guidelines, 
the Declaration of Helsinki, and all applicable laws and regu lations.  
 
             
Name of investigator (print)      Name of investigator (signature)  
 
     
Date   
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 4 
Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY  
Document  Date  
Version 8.0 Amendment 8 (Trishula)  15 Dec 2020  
Version 7.0 Amendment 7 (Trishula)  12 Oct 2020  
Version 6.0 Amendment 6 2 Jan 2020  
Version 5.0 Amendment 5  22 Nov 2019  
Version 4.0 Amendment 4  21 Oct 2019  
Version 3.0 Amendment 3  12 Sep 2019  
Version 2.0 Amendment 2  28 Dec 2018  
Version 1.1 Amendment 1  24 Oct 2018  
Version 1.0 Original Protocol  01 Oct 2018  
Amendment 8 (15 December 2020 ) 
Overall Rationale for the Amendment:  
Section #  Description of Change  Brief Rationale  
Entire document  Minor spelling, grammar, punctuation, 
capitalization, abbreviations, and other 
formatting edits were made throughout 
the document  Consistency  
Section 1.3  Schedule of Activities – update 
footnote s Clarity  
Section 1.1  
Section 3.0  
Section 4.1.1.2  
Section 5.1  
Section 9.2  Remove the number of prior lines 
requirement for RCC  population  Population consideration  
Section 5. 2 
Section 5.3  Inclusion Criterion #22  
Exclusion Criterion #27  
-Update  washout requirement from 28 
to 14 days  Treatment consideration for 
advanced cancer population  
 
Section 6.1.13  
Table 11  -Update TTX -030 administration 
guidance to follow the Pharmacy 
Manual  Clarity  
The rationale for prior amendments is included in Section 11.1.  
  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 5 
Tabl e of Contents  
1. Protocol Summary  ................................ ................................ ................................ ........ 14 
1.1. Synopsis  ................................ ................................ ................................ .......................... 14 
1.2. Schema  ................................ ................................ ................................ ............................ 19 
1.3. Schedule of Activ ities ................................ ................................ ................................ .....20 
2. Introduction  ................................ ................................ ................................ ................... 34 
2.1. Study Rationale  ................................ ................................ ................................ ............... 35 
2.2. Backgro und ................................ ................................ ................................ ..................... 37 
2.2.1.  Nonclinical Data  ................................ ................................ ................................ ............. 37 
2.2.2.  Clinical Data  ................................ ................................ ................................ ................... 48 
2.2.3.  Rationale for TTX -030 Dose and Schedule  ................................ ................................ ....49 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 50 
3. Objectives and Endpoints  ................................ ................................ ............................ 51 
4. Study Design  ................................ ................................ ................................ .................. 53 
4.1. Overall Design  ................................ ................................ ................................ ................ 53 
4.1.1.  Overview  ................................ ................................ ................................ ......................... 53 
4.1.2.  Cohort Revi ew Committee  ................................ ................................ ............................. 55 
4.2. Justification for Dose in FIH study  ................................ ................................ ................. 56 
4.2.1.  Rationale for TTX -030 Starting Dose and Dosing Schedule ................................ .......... 56 
4.2.2.  Selection of Agents in Combination with TTX -030 ................................ ....................... 56 
4.3. Treatment Assignment  ................................ ................................ ................................ ....57 
4.4. Dose Levels ................................ ................................ ................................ ..................... 57 
4.5. Dose Escalation and Safety Lead -In Arms  ................................ ................................ .....58 
4.6. Dose Escalation Using Modified Continual Reassessment 
Method  ................................ ................................ ................................ ............................ 58 
4.7. Dose Escalation Using 3 + 3 Design  ................................ ................................ .............. 59 
4.8. Dose -Toxicity Modeling  ................................ ................................ ................................ .59 
4.9. Early Stopping  ................................ ................................ ................................ ................ 59 
4.10.  Initiation of Safety Lead -In Combination Therapies (Arms 2 & 
4) ................................ ................................ ................................ ................................ .....59 
4.11.  Maximum Tolerated Dose and Recommended Phase 2 Dose  ................................ ........ 60 
4.12.  Definition of Dose -limiting Toxicity  ................................ ................................ .............. 60 
4.13.  Dosing Delays  ................................ ................................ ................................ ................. 61 
4.14.  Safety C riteria for Adjustment or Stopping Doses  ................................ ......................... 62 
4.15.  Pharmacokinetic Criteria for Adjustment or Stopping Doses  ................................ ........ 62 
4.16.  Intra -subject Dose Escalation  ................................ ................................ ......................... 62 
4.17.  Expansion Arms  ................................ ................................ ................................ .............. 63 
4.18.  Retrea tment Criteria  ................................ ................................ ................................ ........ 63 
4.19.  Follow -Up Safety and Survival Contact  ................................ ................................ ......... 63 
4.20.  Study Completion  ................................ ................................ ................................ ........... 64 
5. Study Population  ................................ ................................ ................................ ........... 65 
5.1. Target Population and Arm -Specific Eligibility Criteria  ................................ ................ 65 
5.2. Common Inclusion Criteria  ................................ ................................ ............................ 66 
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 6 
5.3. Common Exclusion Criteria  ................................ ................................ ........................... 67 
5.4. Screen Failures  ................................ ................................ ................................ ................ 68 
5.5. Subject Adherence to Protocol Schedule  ................................ ................................ ........ 68 
6. Investigational Product  ................................ ................................ ................................ 69 
6.1. Investigational Product Description and Administration  ................................ ................ 69 
6.1.1.  Investigational Product Description  ................................ ................................ ................ 69 
6.1.2.  Other Study Treatments  ................................ ................................ ................................ ..69 
6.1.3.  Investigational Product Administration  ................................ ................................ .......... 69 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 70 
6.2.1.  Study Treatment Packaging and Labeling  ................................ ................................ ......70 
6.2.2.  Study Treatment Storage ................................ ................................ ................................ .70 
6.2.3. Study Treatment Preparation  ................................ ................................ .......................... 71 
6.2.4.  Study Treatment Accountability  ................................ ................................ ..................... 71 
6.2.5.  Study Treatment Handling and Disposal  ................................ ................................ ........ 71 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 71 
6.4. Treatment Compliance  ................................ ................................ ................................ ....71 
6.5. Concomitant Therapy  ................................ ................................ ................................ .....72 
6.5.1.  Concomitant Medications Allowed During the Study  ................................ .................... 72 
6.5.2.  Concomitant Medications Prohibited During the Study  ................................ ................. 72 
7. Discontinuation of Study Treatment and Subject 
Discontinuation  ................................ ................................ ................................ ............. 73 
7.1. Discontinuation of Study Trea tment  ................................ ................................ ............... 73 
7.2. Subject Discontinuation/Withdrawal from the Study  ................................ ..................... 73 
7.3. Lost to Follow -up................................ ................................ ................................ ............ 74 
8. Study Assessments and Procedures ................................ ................................ ............. 75 
8.1. Study Visits  ................................ ................................ ................................ ..................... 75 
8.1.1.  Study Visits for Arms 1 and 2 Safety Lead -in and Expansion  ................................ .......75 
8.1.2.  Study Visits for Arm 4 (TTX -030 Q2W, 28 -Day Cycle)  ................................ ............... 76 
8.2. Efficacy Assessments  ................................ ................................ ................................ .....77 
8.2.1.  Tumor Assessment/Tumor Response Assessment ................................ .......................... 77 
8.3. Safety Assessments  ................................ ................................ ................................ ......... 78 
8.3.1.  Demographic/Medical History ................................ ................................ ........................ 78 
8.3.2.  Physical Examinations (Including Symptom -focused 
Examination)  ................................ ................................ ................................ ................... 78 
8.3.3.  Vital Signs  ................................ ................................ ................................ ....................... 78 
8.3.4.  Electrocardiograms  ................................ ................................ ................................ ......... 78 
8.3.5.  Laboratory Assessments  ................................ ................................ ................................ .78 
8.3.6.  Adverse Events and Serious Adverse Events  ................................ ................................ .80 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 95 
8.4.1.  Pharmacokinetic Blood Sample Collection  ................................ ................................ ....95 
8.4.2.  Pharmacokinetic Sample Analysis  ................................ ................................ .................. 95 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 96 
8.5.1.  Pharmacodynamic Blood Samples  ................................ ................................ ................. 96 
8.5.2.  Pharmacodynamic Tissue Samples  ................................ ................................ ................. 96 
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 7 
8.6. Immunogenicity Assessments ................................ ................................ ......................... 97 
8.6.1.  Anti-drug Antibody Assessments  ................................ ................................ ................... 97 
8.6.2.  Blood Sample Collection  ................................ ................................ ................................ 97 
8.6.3. Analysis of ADA Formation  ................................ ................................ ........................... 98 
9. Statistical Considerations  ................................ ................................ ............................. 99 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....99 
9.2. Statistical Considerations for Arm 1 and 2 Expansion Cohorts  ................................ ...100 
9.3. Populations for Analyses  ................................ ................................ .............................. 102 
9.4. Interim Analyses  ................................ ................................ ................................ ........... 102 
10. Regula tory, Ethical, and Study Oversight Considerations  ................................ .....103 
10.1.  Criteria for Study Termination  ................................ ................................ ..................... 103 
10.2.  Protocol Adherence and Amendment  ................................ ................................ ........... 103 
10.3.  Investigator Compliance  ................................ ................................ ............................... 103 
10.4. Institutional Review Board or Independent Ethics Committee  ................................ ....104 
10.5.  Financial Disclosure  ................................ ................................ ................................ .....104 
10.6.  Informed Consent  ................................ ................................ ................................ ......... 104 
10.7.  Data Protection  ................................ ................................ ................................ ............. 105 
10.8.  Committee Structure  ................................ ................................ ................................ .....105 
10.9.  Dissemination of Clinical Study Data  ................................ ................................ .......... 105 
10.10.  Data Quality Assurance  ................................ ................................ ................................ 106 
10.11.  Inspection of Records  ................................ ................................ ................................ ...106 
10.12.  Retention of Records  ................................ ................................ ................................ ....106 
10.13.  Study and Site Start and Closure  ................................ ................................ .................. 107 
10.14.  Publication Policy  ................................ ................................ ................................ ......... 107 
11. Appendices  ................................ ................................ ................................ ................... 109 
11.1.  Appendix 1: Protocol Amendment History  ................................ ................................ ..110 
11.2.  Appendix 2: Eastern Cooperative Oncology Group Performance 
Status  ................................ ................................ ................................ ............................. 115 
11.3.  Appendix 3: RECIST and iRECIST  ................................ ................................ ............. 116 
11.4.  Appendix 4: Response Criteria for Metastatic P rostate Cancer 
(Based on Prostate Cancer Clinical Trials Working Group 3 
Criteria)  ................................ ................................ ................................ ......................... 117 
11.5.  Appendix 5: Response Criteria for Lympho ma ................................ ............................ 119 
11.6.  Appendix 6: Adaptive Design Report for the Phase I Dose 
Escalation Study of TTX -030 in Patients with Lymphoma or 
Solid Tumor Malignancies ................................ ................................ ............................ 125 
12. References  ................................ ................................ ................................ .................... 145 
 
  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 8 
 
List of Tables  
Table 1:  Arms 1 and 2: Schedule of Assessments (Screening Through Treatment Period 
Cycle 1 and Cycle 2) – Q3W Dosing Schedule (21 -Day Cycle)  ................................ ..................  20 
Table 2:  Arms 1 and 2: Schedule of Assessments (Treatment Extension Cycles Through 
Post-Treatment) – Q3W Dosing Schedule (21-Day Cycle)  ................................ ..........................  24 
Table 3:  Arm 4: Schedule of Assessments (Screening Through Treatment Period 1 
(Cycle 1) – Q2W Dosing Schedule (28 -Day Cycle)  ................................ ................................ ..... 26 
Table 4:  Arm 4: Schedule of Assessments (Treatment Extension Cycles Through Post -
Treatment) – Q2W Dosing Schedule (28 -Day Cycle)  ................................ ................................ .. 29 
Table 5:  PK Sampling Intervals During Treatment (21 -day treatment schedule Q3W)  . 32 
Table 6:  PK Sampling Intervals During Treatment (28 -day treatment cycle, Q2W)  ...... 33 
Table 7:  Procedures and Parameters for the 28 -Day GLP Toxicology Study of the 
Administration of TTX -030 to Male and Female Cynomolgus Monkeys  ................................ .... 38 
Table 8:  Dose -Escalation and Safety Lead -In Arms  ................................ .......................  58 
Table 9:  Criteria for Adjusting or Stopping Doses of TTX -030 ................................ ..... 62 
Table 10:  Investigational Product  ................................ ................................ ......................  69 
Table  11: Treatment Regimen Description  ................................ ................................ ....... 70 
Table 12:  Clinical Laboratory Tests  ................................ ................................ ..................  79 
Table 13:  Serum Pharmacokinetic Parameters to be Computed  ................................ ....... 96 
Table 14:  Efficacy Endpoints  ................................ ................................ ..........................  100 
Table 15:  Power for Study Design for Several Possible True Underlying Delt a ORR 
Values  101 
Table 16:  Analysis Populations  ................................ ................................ .......................  102 
 
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 9 
List of Figures  
Figure 1:  Study Schema  ................................ ................................ ................................ .... 19 
Figure 2:  Short -Term Inhibition of CD39 by TTX -030 on Human and Cynomolgus 
Monocytes  40 
Figure 3:  TTX -030 Reduces CD39 -Mediated Adenosine Production and Preserves ATP 
in SK -MEL -28 Cells  ................................ ................................ ................................ .....................  41 
Figure 4:  TTX -030 Reverses Suppression of IFN -γ Response in a CMV Recall Assay  .. 42 
Figure 5:  TTX -030 Increases the Proliferation of Stimulated CD8+ and CD4+ T Cells in 
the Presence of ATP ................................ ................................ ................................ ......................  43 
Figure 6: TTX -030 Induces IL -2 Release by Stimulated PBMCs in Dose -Dependent 
Manner  44 
Figure 7:  Anti-Mouse CD39 Antibody B66 Inhibits MC38  Tumor Growth as Single 
Agent and in Combination with Anti -PD-1 ................................ ................................ ..................  45 
Figure 8:  Combinatorial Anti -Tumor Efficacy of Anti -PD-1 and Anti -Mouse CD39 
Antibody B66 in an Immunotherapy -Resistant SM1WT1 Tumor Cell Line  ...............................  46 
Figure 9:  Anti-CD39 Antibody Inhibits Lung Metastas is Formation in Models of 
Disseminated Disease  ................................ ................................ ................................ ...................  47 
Figure 10:  Receptor Occupancy Analysis for 10 mg/kg Group in Cynomolgus Monkeys  48 
Figure 11:  Algorithmic Approach to Risk Assessment of Tumor Lysis Syndrome  ...........  87 
Figure 12:  Transmission of Electronic Data  ................................ ................................ ..... 105 
  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 10 
List of Abbreviations  
5-PS 5-point scale  
A2AR  adenosine A2A receptor  
ACTH  adrenocorticotropic hormone  
ADA  anti-drug antibod ies 
ADP  adenosine diphosphate  
AE adverse event  
ALT  alanine aminotransferase  
ALP  
AMP  alkaline phosphatase   
adenosine monophosphate  
ANOVA  analysis of variance  
aPTT  activated partial thromboplastin time  
AST  aspartate aminotransferase  
ATP  adenosine triphosphate  
AUC  area under the serum concentration curve  
AUC 0-t area under the serum concentration curve (AUC) from time zero to the last time of the last 
quantifiable concentration  
AUC 0-∞ area under the serum concentration curve (AUC) from time zero extrapolated to infinity  
B-LCL  Epstein Barr virus-transformed lymphoblastoid B cell line  
BOR  best overall response  
BP blood pressure  
BUN  
C blood urea nitrogen  
Cycle 
CA19 -9 carbohydrate antigen  
CBC  complete blood count  
CD cluster of differentiation  
CD39-/- cluster of differentiation 39 deficient  
CEA  carcinoma embryonic antigen  
cIg isotype control  
CL apparent total body clearance of the drug from serum  
Cmax maximum serum observed concentration  
Cmin  minimum serum observed concentration  
CMV  cytomegalovirus  
CNS  central nervous system  
CRS  cytokine release syndrome  
CT computed tomography  
D day 
DCR  disease control rate  
DLT  dose-limiting toxicity  
DOR  duration of response  
DVT  deep vein thrombosis  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 11 
eATP  extracellular ATP  
EC 50 half-maximal effective  concentration  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EHNA  erythro -9-(2-hydroxy -3-nonyl)adenine  
ELISA  enzyme -linked immunosorbent assay  
ENTPDase  ectonucleoside triphosphate diphosphohydrolase  
EOI end of infusion  
EOT  end of treatment  
FDG  fluorodeoxyglucose  
FIH first-in-human  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GGT  
GH gamma -glutamyl transferase  
growth hormone  
GLP  Good Laboratory Practice  
Hgb hemoglobin  
HgbA1c  hemoglobin A1c  
HED  human equivalent dose  
HR heart rate  
IB Investigator Brochure  
IC50 half-maximal inhibition concentration  
ICF informed consent form  
IEC Independent Ethics Committee  
IFN interferon  
Ig immunoglobulin  
IL interleukin  
IND Investigational New Drug  
INR international normalized ratio  
IR immune response  
irAE  immune -related adverse event  
IRB Institutional Review Board  
iRECIST  immune -related Response Evaluation Criteria in Solid Tumors  
IV intravenous(ly)  
LD longest diameter  
LDi longest transverse diameter of a lesion  
LFT liver function tests  
LH luteinizing hormone  
LYRIC  LYmphoma Response to Immunomodulatory Therapy Criteria  
mAb  monoclonal antibody  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 12 
mCRM  modified continual reassessment method  
mCRPC  metastatic castration -resistant prostate cancer  
MFI mean fluorescence intensity  
MRI  magnetic resonance imaging  
MRSD  maximum recommended starting dose  
MTD  maximum tolerated dose  
N/A not applicable  
NCI CTCAE  National Cancer Institute Common Terminology Criteria  
NP 
NHP  Nab-paclitaxel (Abraxane®) 
non-human primate  
NOAEL  no-observed -adverse -effect level  
O2 oxygen  
ORR  objective response rate  
OS overall survival  
PAD  pharmacologically active dose  
PBMC  peripheral blood mononuclear cell  
PCWG3  Prostate Cancer Clinical Trials Working Group 3  
PD progressive disease  
PD-1 programmed cell death protein -1 
PD-L1 programmed cell death protein ligand -1 
PET positron -emission tomography  
PFS progression -free survival  
PLT platelets  
PK pharmacokinetic(s)  
PPD cross product of the LDi and perpendicular diameter  
PSA prostate -specific antigen  
PT prothrombin time  
PTT partial thromboplastin time  
Q every  
RCC  renal cell carcinoma  
RECIST  Response Evaluation Criteria in Solid Tumors  
RP2D  recommended Phase 2 dose  
SAE  serious adverse event  
SDi shortest axis perpendicular to the LDi  
SPD sum of the product of the perpendicular diameters for multiple lesions  
t1/2 terminal elimination half -life 
TEAE  treatment -emergent adverse event  
TIL tumor infiltrating leukocytes  
Tizona  Tizona Therapeutics, Inc.  
TK toxicokinetics  
TKI tyrosine kinase inhibitor  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 13 
TLS tumor lysis syndrome  
Tmax time at which C max is reached  
TME  tumor microenvironment  
Treg regulatory T cells  
Trishula  Trishula Therapeutics, Inc.  
TSH  thyroid stimulating hormone  
TTP time to progression  
TTR  time to tumor response  
Tx treatment  
ULN  upper limit of normal  
Vss volume of distribution at steady state  
W week(s)  
WT wild type  
 
  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 14 
1. Protocol Summary  
1.1. Synopsis  
Protocol Title:   
Phase 1/1b Study of the Safety of TTX -030 as a Single Agent and in Combination with 
Pembrolizumab or Chemotherapy in Patients  with Lymphoma or Solid Tumor Malignancies  
Rationale : 
There are compelling preclinical data to support the hypothesis that cluster  of differentiation 
(CD)39-mediated reduction of adenosine triphosphate (ATP ) and accumulation of adenosine 
both play a central role in establishing and maintaining the immunosuppressive 
microenvironment within solid tumors. CD39 expression is associated with worse outcomes in 
several cancer types. The enzymatic inhibition of CD39 maintains high levels of 
pro-inflammatory extracellular ATP (eATP), leading to immune activation and significant 
anti-tumor immune responses. The CD39 pathway contributes to T-cell exhaustion and limits the 
immunogenicity of chemotherapy, which provides th e rationale for combining CD39 inhibition 
with checkpoint blockade and conventional cytotoxic therapies.  
Targeting CD39 is a rational strategy for the treatment of subject s with cancer, and blockade of 
CD39 may result in less potential for autoimmune side effects compared with rates seen with 
other immunotherapy agents. Although regulatory T cells (T reg) from CD39 -deficient (CD39-/-) 
knockout mice have impaired suppressive activity, the mice do not show autoimmunity  (Sun et 
al. 2010 ). TTX -030, as a single agent or in combination, is expected  to have a manageable safety 
profile, thereby providing additional therapeutic options for subject s whose malignancies are 
otherwise refractory to or relapsed on current standard of care therapies.  
The indications selected were defined based on expression of CD39 on tumor infiltrating 
leukocytes (TIL), expression of CD39 on tumor cells, and tumor types that are amenable to be 
combined with chemotherapy or anti -programmed cell death protein -1 (PD-1) therapy.  
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 16 
Objectives  Endpoints  
• To evaluate the pharmacokinetics 
(PK) of TTX -030 • Serum  PK parameters for TTX -030 
following single and multiple doses 
including the  maximum serum 
observed concentration  (Cmax),  time at 
which C max is reached (T max), 
minimum  serum  observed 
concentration (C min), volume of 
distribution at steady state (V SS), 
apparent total body clearance of the 
drug from serum  (CL), terminal 
elimination half -life (t 1/2), area under 
the serum  concentration curve (AUC) 
to last quantifiable concentration 
(AUC 0-t), and AUC from time zero 
extrapolated to infinity  (AUC 0−∞) for 
TTX -030 
• To assess the effects of TTX -030 on 
pharmacodynamic biomarkers relating 
to mechanism of action and immune 
responses  • Immunogenicity (detection  of 
anti-drug antibodies [ ADA ]) 
• Expression of CD39  
• Exploratory pharmacodynamic 
biomarkers  
 
Overall Design  
Study Design:  
This is a Phase 1/1b, open -label, and multicenter  study of TTX -030 in adult subject s with 
lymphoma or solid tumor malignancies. The study will evaluate the safety and tolerability of:  
• TTX -030 as a single agent, and  
• TTX -030 in combination with pembrolizumab, a PD -1 inhibitor, and  
• TTX -030 in combination with specified chemotherapy regimens  
Number of Subjects:  
Up to 43 subjects may be enrolled across 1 dose escalation and 2 safety lead -in arms.  
TTX -030 will first be evaluated in the monotherapy dose escalation (Arm 1). Once the RP2D of 
TTX -030 has been determined in the monotherapy dose -escalation arm, the combination -therapy  
safety lead -in arms (Arms 2 and 4) can be initiated. For the safety lead -in arms, the TTX -030 
starting dose wi ll be the RP2D identified during monotherapy dose escalation; de -escalation to 
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 17 
one dose level below the RP2D is permitted. Upon completion of the monotherapy dose -
escalation and combination -therapy  safety lead -in arms, each of those arms may have the optio n 
to enroll additional subjects per expansion cohort at the RP2D.  
As of Jan 2020, a RP2D was determined to be 40 mg/kg loading dose 7 days prior to Cycle 1 
Day 1 , followed by either 30 mg/kg Q3W or 20 mg/kg Q2W.  
Arm 1 (single agent), n = up to 21 
• TTX -030 single -agent  dose escalation  (several doses and schedules may be 
evaluated)  
Arm 1 ( expansion ), n = 25  
• TTX -030 single -agent ; loading dose 7 days prior to Cycle 1 Day 1, followed b y 30 
mg/kg Q3W  
Arm 2 (anti -PD-1 combination ), n = up to 6 
• Pembrolizumab 200 mg every (Q) 3 weeks (W) in combination with TTX -030 Q3W 
safety lead -in 
Arm 4 (chemotherapy combination ), n = up to 6 
• Gemcitabine 1000 mg/m2 + nab -paclitaxel 125 mg/m2 Days 1, 8, and 15 every 
28 days + TTX -030 Q2W safety lead -in (Note: d ose modification allowed for 
gemcitabine 1000 mg/m2 + nab -paclitaxel 125 mg/m2 (e.g., modify to Days 1 and 8  
or Days 1 and 15  every 2 8 days + TTX -030 Q2W ) 
Expansion cohorts, n = 25 each in Arm s 1 and 2 and n = up to 20 in Arm 4 . The number of 
subjec ts evaluated in the combination -therapy  safety lead -in Arm 4 may count toward the total 
number of subjects in an expansion cohort.  
Note: The sponsor  may choose not to open one of the safety lead -in arms and/or expansion 
cohorts.  
Reference Therapy and Mode of Administration:   
• TTX -030 IV infusion Q3W for Arm 1  Dose Escalation (21 -day cycle)  
• TTX -030 IV infusion Q3W for Arms 1  and 2 Safety Lead -in and Expansion (21-day 
cycle  + a 7 -day loading dose  prior to C1D1 ) 
• TTX -030 IV infusion Q2W for Arm 4 (28 -day cycle  + a 7 -day loading dose prior to 
C1D1 ) 
The investigational formulation of TTX -030 will be supplied as a sterile, single -use, 
preservative -free liquid containing 200 mg of antibody. The dosage form of TTX -030 is a liquid 
formulation containing 30 mg/mL  of TTX -030 in 10 mM sodium citrate, 280 mM sucrose, 
0.02% polysorbate 20, and 1.0 mM methionine, with a pH of 6.5. The liquid TTX -030 will be 
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 18 
filled into a Type 1 glass serum vial with an elastomeric stopper and aluminum over seal with a 
plastic flip top.  The fill volume will be 6.7 mL in a 10-cc glass vial stored at temperatures of 2°C 
to 8°C. TTX -030 will be administered IV Q3W  or Q2W according to  the study  treatment  arm 
schedule . 
Duration of Treatment:  
If well tolerated, treatment with TTX -030 may cont inue until disease progression, drug toxicity, 
or death. For combination arms, if a subject discontinues the pembrolizumab or chemotherapy 
regimens, treatment with TTX -030 may continue if it is well tolerated and if both the investigator 
and sponsor approv e. 
Criteria for Evaluation:  
Safety:  Clinical adverse events (AEs) will be graded according to the National Cancer Institute 
Common Terminology Criteria (NCI CTCAE) Version 5.0. AEs are to be monitored and 
collected for the duration of study treatment until 90 days after the last dose. A DLT  is defined as 
any cl inically significant AE that occurs during Treatment Cycle 1, is considered related to 
TTX -030 as a single agent or the combination of TTX -030 and other agent(s), and meets the 
criteria outlined in the protocol. In the dose escalation arm, for the Q3W dose schedule, the cycle 
length is 3 weeks and the DLT period will be the first cycle (21 days).  
In the safety lead -in Arm  2, the DLT evaluation period is 21-day (TTX -030 regimen given every 
3 weeks [Q3W ]) plus a 7-day of loading dose . In the safety lead -in Arm 4, f or the Q2W  dose 
schedule, the cycle length is 4 weeks and the DLT period will be 28-day (TTX -030 regimen 
given every 2 weeks [Q2W ]) plus a 7-day of loading dose . 
Pharmacokinetics:  PK analyses will be conduct ed using samples drawn based on the provided 
schedule of assessments. TTX -030 concentrations will be measured by validated 
electrochemiluminescence -based method and used to calculate PK parameters including t 1/2, 
Cmax, Tmax, Cmin, CL, V ss, AUC 0-t, and AUC 0-∞. 
Pharm acodynamics:  Pharmacodynamic analyses will be performed using blood and tissue 
samples taken at designated time point s. Parameters to be assessed include target and mechanism 
of action -related biomarkers, ADA formation, and pro -inflammatory cytokine releas e. 
Additionally, several exploratory analyses are planned, including immunoprofiling, target 
receptor coverage, and serum metabolomics. Detailed instructions for pharmacodynamic blood 
sample collection, processing,  and shipping will be provided to the stud y sites in a separate 
laboratory manual.  
Early Signals of Activity:  Anti-tumor activity , including BOR , ORR, DOR, TTR, DCR, TTP, 
PFS, and OS , will be assessed based on iRECIST, LYmphoma Response to Immunomodulatory 
Therapy Criteria (LYRIC), or Prostate Can cer Clinical Trials Working Group 3 (PCWG3) 
response criteria when applicable.  
Statistical Methods:  
A primary objective of the trial is to determine the MTD and/or RP2D for each arm. Dose 
escalation  (Arm 1)  will be conducted according to a modified continual reassessment method 
(mCRM) for doses up to 10 mg/kg and according to a 3  + 3 design for doses > 10 mg/kg, with 
the aim of estimating the dose -toxicity relationship and determining the MTD. The MTD will b e 
 TTX-030-001 Versio n 8 (December  15, 2020)  
CONFIDENTIAL  
 
 19 
defined as the dose that has a model -estimated DLT rate closest to 30% and has less than 55% 
probability of a DLT rate exceeding 30%.  
Dose -toxicity modeling will be used to estimate the log -odds of DLT across dose levels and  will 
be conducted using a 2-parameter logistic regression model . A detailed adaptive design and 
simulation report is included in Section  11.6.  
The RP2D will be determined based on the totality of data, including the estimated MTD, plus 
other endpoints such as observed efficacy, PK, and other AEs.  
Descriptive summary statistics will be presented. Longitudinal data will be presented by 
approp riate time intervals, such as monthly or quarterly, dep ending on the nature of the data.  
1.2. Schema  
The study schema is depicted in Figure 1.  
Figure 1:  Study Schema  
Abbreviations: Gem = gemcitabine, NP = nab -paclitaxel, Q  = every, RCC  = renal cell carcinoma; 
RP2D  = recommended Phase 2 dose, Q3W = every 3 weeks , Q2W = every 2 weeks  
Note :    Arm 3 is removed as a similar population is being evaluated in another protocol (TTX -030-002). 

  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 20 
 
1.3. Schedule of Activities  
The study -specific assessments and procedures are outline d in Table 1/Table 2, and Table 3/Table 4. 
Table 1: Arms 1 and 2: Schedule of Assessments (Screening Through Treatment Period Cycle 1 and  Cycle 2)  – Q3W 
Dosing Schedule  (21-Day Cycle)  
Assessment  Pretreatment  Loading 
Dose   Study Treatment Period = 2 cycles  
(1 cycle = 21 days)  
Screeninga 
(up to 28 
days prior  
to loading 
dose)  Baseline  
(up to 3 
days prior 
to loading 
dose)  Day -7a Cycle 1  Cycle 2  
Day 1  Day 2  Day 3  Day 8  Day 15  Day 22  
(+ 2 days)  Day 29  
(± 2 days)  
Pre-C1D1  
C1D1  C1D2  C1D3  C1D8  C1D15  C2D1  C2D8  
Informed consent  X  
        
Inclusion/Exclusion  X  
        
Demograph ics X  
        
Medical history & prior anti-
cancer treatments  X  
        
Physical examination  X X X      
X  
Symptom -directed 
examination     
 X X  
X X  
X 
Vital signs (temperature, O 2, 
HR, BP, weight, height)  X X X X X  
X X X X 
12-lead ECG  X  
        
HgbA1c  X          
ECOG performance status  X  
 X     
X  
Tumor assessment  
(CT or PET -CT)b X          
Serum tumor -associated 
markers as applicable ( eg, 
CEA, CA19 -9, PSA)  X          
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 21 
 
Assessment  Pretreatment  Loading 
Dose   Study Treatment Period = 2 cycles  
(1 cycle = 21 days)  
Screeninga 
(up to 28 
days prior  
to loading 
dose)  Baseline  
(up to 3 
days prior 
to loading 
dose)  Day -7a Cycle 1  Cycle 2  
Day 1  Day 2  Day 3  Day 8  Day 15  Day 22  
(+ 2 days)  Day 29  
(± 2 days)  
Pre-C1D1  
C1D1  C1D2  C1D3  C1D8  C1D15  C2D1  C2D8  
Thyroid function testsc  X X        
Clinical laboratory tests (CBC, 
LFTs, chemistry) ; LDH at 
Screening only   X X X X  
X X X X  
Measurements of ACTH, 
FSH, LH, GH, amylase, lipase   X         
Coagulation profiled (PT/INR, 
PTT, fibrinogen)  X X X    
X X X  
Pregnancy teste X X X      
X  
Arm 1: TTX -030 only 
infusion    X X     X  
Arm 2: TTX -030 and 
pembrolizumab infusion    TTX -030 
only X     X  
PK blood samplesf  
X pre & post  multiple  X X X X pre & post   
ADA blood samples   X  X X    X  
Pharmacodynamic and 
correlative blood samplesg  
X  X X  
X X X  
Tumor biopsyh  
(optional for dose escalation, 
mandatory for safety lead -
in/cohort expansion)  X  
      
X (-7 
days)   
Concomitant medicationsi X X X X X X X X X X 
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 22 
 
Assessment  Pretreatment  Loading 
Dose   Study Treatment Period = 2 cycles  
(1 cycle = 21 days)  
Screeninga 
(up to 28 
days prior  
to loading 
dose)  Baseline  
(up to 3 
days prior 
to loading 
dose)  Day -7a Cycle 1  Cycle 2  
Day 1  Day 2  Day 3  Day 8  Day 15  Day 22  
(+ 2 days)  Day 29  
(± 2 days)  
Pre-C1D1  
C1D1  C1D2  C1D3  C1D8  C1D15  C2D1  C2D8  
AEsj  X X X X X X X X X X 
Abbreviations: ACTH = adrenocorticotropic hormone, ADA = anti -drug antibodies, AE = adverse event, BP = blood pressure, C = cycle, CA19 -9 = carbohydrate antigen, 
CBC  = complete blood count, CEA = carcinoma embryonic antigen , CT = computed tomography, D = d ay, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology 
Group, FSH = follicle -stimulating hormone, GH  = growth hormone, HgbA1c = hemoglobin A1c, HR = heart rate, INR = international normalized ratio, LDH = Lactate 
Dehydrogenase, LFT = liver functi on test, LH  = luteinizing hormone, O 2 = oxygen, PD-L1 = programmed cell death protein ligand -1, PET = positron -emission tomography, 
PK = pharmacokinetic, PSA = prostate -specific antigen, PT = prothrombin time, PTT  = partial thromboplastin time, Q = every, RP2D = recommended Phase 2 dose, TSH = 
thyroid stimulating hormone , W = weeks . 
 
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 23 
 
a Screening assessments and enrollment should occur prior to loading dose/first dose of TTX -030. Assessments done up to 3 days prior to each dosing  visit do not need to be 
repeated.   
b Subjects with solid tumors will require CT scans of the chest, abdomen, and pelvis  unless contraindicated . Sub jects with prostate cancer will also require bone scan. Brain scans 
and bone scans will be performed at screening if disease is suspected and on study as appropriate to follow disease. Subjects with lymphoma will require CT or PET -CT; 
however, the method f or each subject’s tumor assessments should remain consistent.  
c Thyroid function tests are to be performed at baseline , at the loading dose /first dose , and then every 3 months: TSH, T3, free T4, and thyroid antibody.   
d See Section  8.3.5 . Fibrinog en is only requi red for eligibility.  
e Pregnancy test is for women of childbearing potential only.  
f Timing of PK draws: See Table 5. If using the same infusion filter line for PK draw, flushing is required.  
g Pharmacodynamic blood draws should occur at the same time as PK blood draws and tumor biopsy when applicable.   When multiple PK s are collected , collect PD with the 
pre-dose PK . 
h Subjects enrolled in the safety lead -in and expansion arms will be required t o have a site of disease that is safely  accessible for biopsy (paired) upon enrollment. If a subject has 
had a biopsy within 90 days with no intervening treatment  prior to the loading dose/first dose of TTX -030, that tissue can be used for this study and t he subject does not need to 
repeat a baseline biopsy. Invasive procedures that require general anesthesia should not be performed to obtain a biopsy specimen. If a surgical proced ure is performed for a 
clinical indication , a sample may be used for research purposes. During the course of treatment , a decision may be made to perform the on -treatment biopsy earlier than C2D1 
(-7 days) if  there will be no available tumor for biopsy due to a rapid clinical response. Similarly, t umor biopsy may be delayed if there is evidence of a delayed response.  
Accessible  lesions are defined as those that can be biopsied (at screening) and are amenable to repeat biopsy at C2D1  (-7 days ), unless clinically contraindicated. It is optimal to 
have  the screening and on -treatment biopsy  obtained from the same lesion if possible.  
i Concomitant medications are to be collected from screening  through 30 days after the last dose of study treatment.  
j Adverse events (e.g., including COVID -19 symptoms) and AESIs are to be collected from the time subject provides written informed consent through 90 days after the last 
dose of TTX -030 or until initiation of a new systemic anticancer therapy,  whichever occurs first. Posit ive COVID -19 test result will be collected as a medical event and 
submitted as SAE . 
  
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 24 
 
Table 2: Arms 1  and 2: Schedule of Assessments (Treatment Extension Cycles Through Post -Treatment)  – Q3W Dosing 
Schedule  (21-Day Cycle)  
Assessments  21-Day Study Treatment Extension Period   
(Dosing Q3W)   
Post-Treatment  
Cycle 3  Cycles 4+  EOT Visit  Follow -Up Safety 
Contact  Follow -up Survival 
Contact  
Day 43 ( ± 2 days)  Day 64 ( ± 2 days) and 
Q21D thereafter  30 (± 9) Days  
After Last Dosea 60 and 90 (± 7) days 
After Last Dose  180 ( ± 15) Days After  
Last Dose  C3D1  C4D1  
Physical examination  X X X   
Symptom -directed examination      
  
Vital signs (temperature, O 2, HR, 
BP, weight, height)  X X X   
12-lead ECG     
  
ECOG performance status  X X X   
Clinical laboratory tests (CBC, 
LFTs, chemistry)  X X X   
Coagulation profile  
(PT/INR, PTT)  X X X   
Pregnancy testb X X X   
Tumor assessment  
(CT or PET -CT)   Q9W (- 7D) 
starting on C4D1  
  
Serum tumor -associated markers 
as applicable (eg, CEA, CA19 -9, 
PSA)   Q9W (- 4D) 
starting on C4D1    
Arm 1: TTX -030 infusion  X X  
  
Arm 2: TTX -030 and 
pembrolizumab infusion  X X    
PK blood samplesc multiple  pre X   
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 25 
 
Assessments  21-Day Study Treatment Extension Period   
(Dosing Q3W)   
Post-Treatment  
Cycle 3  Cycles 4+  EOT Visit  Follow -Up Safety 
Contact  Follow -up Survival 
Contact  
Day 43 ( ± 2 days)  Day 64 ( ± 2 days) and 
Q21D thereafter  30 (± 9) Days  
After Last Dosea 60 and 90 (± 7) days 
After Last Dose  180 ( ± 15) Days After  
Last Dose  C3D1  C4D1  
Pharmacodynamic, ADA, and 
correlative blood samplesd  X X X   
Tumor biopsy (optional for dose 
escalation, mandatory for safety 
lead-in/cohort expansion)     
  
Concomitant medicationse X X X   
AEsf X X X X  
Post-treatment anti -cancer 
therapy    
X X X 
Follow -up contact    X X X 
Abbreviations: ADA = anti -drug antibodies, AE = adverse event, BP = blood pressure, C = cycle, CA19 -9 = carbohydrate antigen, CBC = complete blood count, CEA = carcinoma 
embryonic antigen, CT = computed tomography , D = day, ECG  = electrocardiogram, ECOG  = Eastern Cooperative Oncology Group, EOT = End of Treatment, HR = heart 
rate, INR  = international normalized ratio, LFT = liver function test, O 2 = oxygen, PET = positron -emission tomography, PK = pharmacokinetic, PSA = prostate -specific 
antigen, PT = prothrombin time, PTT = partial thromboplastin time, Q = every, W = weeks.  
 
a EOT laboratory assessment  do not need to be repeated if laboratory assessments were collected in the  study within the past 5 days.  
b Pregnancy test is for  women of childbearing potential only.  
c Timing of PK draws: See Table 5. If using the same infusion filter line for PK draw, flushing is required.  
d Pharmacodynamic blood draws should occur at the same time as PK blood draws and tumor biopsy when applicable.  When multiple PKs are collected, collect PD with the pre -
dose PK . 
e Concomitant medications are to be collected from screening  through 30 days after the last dose of study treatment.  
f Adverse events (e.g., including COVID -19 symptoms) and AESIs are to be collected from the time subject provides written informed consent through 90 days after the last 
dose of TTX -030 or until initiation of a new systemic anticancer therapy, whichever occurs first. Positive COVID -19 test result will be collected as a medical event and 
submitted as SAE.  
  
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 26 
 
Table 3: Arm 4: Schedule of Assessments (Screening Through Treatment Period 1 (Cycle 1)  – Q2W Dosing Schedule  (28-
Day Cycle)  
Assessment  Pretreatment  Loading 
Dosea   28-Day Study Treatment Period (Dosing Every 14 Days)  
Cycle 1 
Screeninga 
(up to 28 
days prior 
to loading 
dose)  Baseline  
(up to 3 
days prior 
to loading 
dose)  Day -7 Day 1  Day 2  Day 3  Day 8  Day 15  Day 22  
Pre-C1D1  
C1D1  C1D2  C1D3  C1D8  C1D15  C1D22  
Informed consent  X  
       
Inclusion/Exclusion  X  
       
Demograph ics X  
       
Medical history & prior anti -cancer treatments  X  
       
Physical examination  X X X     
X  
Symptom -directed examination    
 X X  
X  
X 
Vital signs  
(temperature, O 2, HR, BP, weight, height)  X X X X X  
X X X 
12-lead ECG  X  
       
HgbA1c  X         
ECOG performance status  X  
 X      
Thyroid function testsb  X X       
Clinical laboratory tests  
(CBC, LFTs, chemistry ); LDH  at Screening only  X X X X  
X X X X 
Measurements of ACTH, FSH, LH, GH, 
amylase, lipase   X        
Coagulation profile (PT/INR, PTT, fibrinogenc) X X X    
X X X 
Pregnancy test d X X X     
X  
Tumor assessment (CT or PET -CT)e X  
       
Serum tumor -associated markers as applicable 
(eg, CEA, CA19 -9, PSA, CA 125)  X         
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 27 
 
Assessment  Pretreatment  Loading 
Dosea   28-Day Study Treatment Period (Dosing Every 14 Days)  
Cycle 1 
Screeninga 
(up to 28 
days prior 
to loading 
dose)  Baseline  
(up to 3 
days prior 
to loading 
dose)  Day -7 Day 1  Day 2  Day 3  Day 8  Day 15  Day 22  
Pre-C1D1  
C1D1  C1D2  C1D3  C1D8  C1D15  C1D22  
Arm 4: TTX -030 and gemcitabine + 
nab-paclitaxel infusionf   TTX -030 
only X   Gem/nab 
only X  
PK blood samplesg  
X pre & post  multiple  X X X pre & 
post X 
Pharmacodynamic, ADA, and correlative blood 
samplesh  
X X X X  X X  
Tumor biopsy (optional for dose escalation, 
mandatory for safety lead -in/cohort expansion)i X  
       
Concomitant medicationsj X X X X X X X X X 
AEsk X X X X X X X X X 
Abbreviations: ACTH = adrenocorticotropic hormone, ADA = anti -drug antibodies, AE = adverse event, BP = blood pressure, C = cycle, CA19 -9 = carbohydrate antigen, 
CBC  = complete blood count, CEA = carcinoma embryonic antigen , CT = computed tomography, D = day, ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology 
Group, EOT = End of Treatment, FSH  = follicle -stimulating hormone, GH  = growth hormone, HgbA1c = hemoglobin A1c, HR = heart rate, INR = international normaliz ed 
ratio, LDH = Lactate Dehydrogenase, LH = luteinizing hormone, LFT = liver function test, O2 = oxygen, PD-L1 = programmed cell death protein  ligand -1, PET = positron -
emission tomography, PK = pharmacokinetic, PT = prothrombin time, PTT = partial thrombop lastin time, Q = every, RP2D = recommended Phase 2 dose, TSH  = thyroid 
stimulating hormone , W = weeks . 
 
a Screening assessments and enrollment should occur prior to loading dose/first dose of TTX -030. Assessments done up to 3 days prior to each dosing  visit do not need to be 
repeated.  
b Thyroid function tests are to be performed at baseline , at the loading dose,  and then every 3 months: TSH, T3, free T4, and thyroid antibody.  
c See Section  8.3.5 . Fibrinog en is only required for eligibility.  
d Pregnancy test is for women of childbearing potential only.  
e Subjects with solid tumors will require CT scans of the chest, abdomen, and pelvis unless contraindicated. Subjects with pros tate cancer will also require bone scan. Brain scans 
and bone scans will be performed at screening if disease is suspected and on s tudy as appropriate to follow disease. Subjects with lymphoma will require CT or PET -CT; 
however, the method for each subject’s tumor assessments should remain consistent.  
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 28 
 
f Gemcitabine + nab -paclitaxel are administered on Days 1, 8, and 15  every 28 days. After the loading dose, TTX -030 will be administered every 14 days.  (Note: dose 
modification allowed for gemcitabine 1000 mg/m2 + nab -paclitaxel 125 mg/m2 (e.g, Days 1 and 8 or Days 1 and 15 every 28  days) + TTX -030 every 14 days).  
g Timing of PK draws: See Table 6. If using the same infusion filter line for PK draw, flushing is required.  
h Pharmacodynamic  blood draws should occur at the same time as PK  blood draws and tumor biopsy when applicable.  When multiple PKs are collected, collect PD with the pre -
dose PK . 
i Subjects enrolled in the safety lead -in and expansion arms will be required to have a site of disease that is safely  accessible for biopsy (paired) upon enrollment. If a subject has 
had a biopsy within  90 days with no intervening lines of therapy prior to the loading dose/first dose of TTX -030, that tissue can be used for this study and the subject does not 
need to repeat a baseline bi opsy. Accessible lesions are defined as those that can be biopsied (at screening) and are amenable to repeat biopsy on  C2D1 ( -7 days) , unless 
clinically contraindicated. It is optimal to have the screening and on -treatment biopsy obtained from the same les ion if possible.  Invasive procedures that require general 
anesthesia should not be performed to obtain a biopsy specimen. If a surgical procedure is performed for a clinical indicatio n, a sample may be used for research purposes. 
During the course of treat ment , a decision may be made to perform the on -treatment biopsy earlier than C2D1 ( -7 days)  if there is evidence to suggest a possibility that there 
will be no available tumor for biopsy due to a rapid clinical response. Similarly, tumor biopsy may be delayed if there is ev idence of a delayed response.  
j Concomitant medications are to be collected from screening  through 30 days after the last dose of study treatment.  
k Adverse events (e.g., including COVID -19 symptoms) and AESIs are to be collected from the time subject provides written informed consent th rough 90 days after the last 
dose of TTX -030 or until initiation of a new systemic anticancer therapy, whichever occurs first. Positive COVID -19 test result will be collected as a medical event and 
submitted as SAE.  
  
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 29 
 
Table 4: Arm 4 : Schedule of Assessments (Treatment Extension Cycles Through Post -Treatment)  – Q2W Dosing 
Schedule  (28-Day Cycle)  
Assessment  28-Day Treatment Extension Period  (Dosing Q2W)  Post-Treatment  
Cycle 2  Cycle 3 + 
EOT Visit 
30 (± 7) 
Days 
After Last 
Dose  Follow -
Up Safety 
Contact 
60 and 90 
(± 7) Days 
After Last 
Dose  Follow -up 
Survival Contact 
180 (±  15) Days 
After Last Dose  Day 29  
(+ 2 days)  Day 36  
(± 2 days)   Day 43  
(± 2 days)  Day 57  
(± 2 days)  
and Every 
Cycle X Day 
1 Thereafter  Day 64 
(± 2 days)  
and Every 
Cycle X Day 
8 Thereafter  Day 71 (± 2 
days) and 
Every Cycle X 
Day 15  
Thereafter  
C2D1  C2D8  C2D15  C3D1  C3D 8 C3D15  
Physical examination  X X X X X X X   
Symptom -directed 
examination    
     
  
Vital signs  
(temperature, O 2, HR, BP, 
weight, height)  X X X X X X X   
12-lead ECG    
     
  
ECOG performance status  X X X X X X X   
Clinical laboratory tests 
(CBC, LFTs, chemistry)  X X X X X X X   
Coagulation profile 
(PT/INR, PTT)  X X X X X X X   
Pregnancy test a X  
X X  
X X   
Tumor assessment  
(CT or PET -CT)b   
 Q8W  
(-7D) 
starting on 
C3D1    
  
Serum tumor -associated 
markers as applicable (eg, 
CEA, CA19 -9)    X 
(Q8W)    
     
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 30 
 
Assessment  28-Day Treatment Extension Period  (Dosing Q2W)  Post-Treatment  
Cycle 2  Cycle 3 + 
EOT Visit 
30 (± 7) 
Days 
After Last 
Dose  Follow -
Up Safety 
Contact 
60 and 90 
(± 7) Days 
After Last 
Dose  Follow -up 
Survival Contact 
180 (±  15) Days 
After Last Dose  Day 29  
(+ 2 days)  Day 36  
(± 2 days)   Day 43  
(± 2 days)  Day 57  
(± 2 days)  
and Every 
Cycle X Day 
1 Thereafter  Day 64 
(± 2 days)  
and Every 
Cycle X Day 
8 Thereafter  Day 71 (± 2 
days) and 
Every Cycle X 
Day 15  
Thereafter  
C2D1  C2D8  C2D15  C3D1  C3D 8 C3D15  
Arm 4: TTX -030 and 
gemcitabine + nab -
paclitaxel infusionc X Gem/nab 
only X X Gem/nab 
only X    
PK blood samples d multiple   
pre pre  
pre X   
ADA blood samples  X   X  X X   
Pharmacodynamic and 
correlative blood samplese X  
 X  
X X   
Tumor biopsy  
(optional for dose 
escalation, mandatory for 
safety lead -in/cohort 
expansion)f X 
(-7 days)   
     
  
Concomitant medicationsg X  X X X X X   
AEsh X  X X X X X X  
Post-treatment anti -cancer 
therapy        X X X 
Follow -up contact        X X X 
Abbreviations: ADA = anti -drug antibodies, AE = adverse event, BP = blood pressure, C = cycle, CA19 -9 = carbohydrate antigen, CBC = complete blood count, CEA = carcinoma 
embryonic antigen , CT = computed tomography, D  = day, ECG  = electrocardiogram, ECOG = Eastern Cooperative Oncology Group, EOT = End of Treatment, HR = heart 
rate, INR  = international normalized ratio, LFT = liver function test, O 2 = oxygen, PET = positron -emission tomography, PK = pharmacokinetic, PSA = prostate -specific 
antigen, PT = proth rombin time, PTT = partial thromboplastin time, Q = every, W = week s. 
 
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 31 
 
a Pregnancy test is for women of childbearing potential only.  
b Subjects with solid tumors will require CT scans of the chest, abdomen, and pelvis unless contraindicated. Subjects with pros tate cancer will also require bone scan. Brain scans 
and bone scans will be performed at screening if disease is suspected and on s tudy as appropriate to follow disease. Subjects with lymphoma will require CT or PET -CT; 
however, the method for each subject’s tumor assessments should remain consistent.  
c Gemcitabine + nab -paclitaxel are administered on Days 1, 8, and 15 every 28 days. After the loading dose, TTX -030 will be administered every 14 days.  Cycle 4 and beyond 
also requires a dosing visit at Days 1, 8 , and 15 for gem citabine /nab-paclitaxel  and Day 15 for TTX -030. (Note: dose modification allowed for gemcitabine 1000 mg/m2 + nab-
paclitaxel 125 mg/m2 (e.g., Days 1 and 8 or Days 1 and 15 every 28  days) + TTX -030 every 14 days).  
d Timing of PK draws: See Table 6. If using the same infusion filter line for PK draw, flushing is required.  
e Pharmacodynamic blood draws should occur at the same time as PK blood draws and tumor biopsy when applicable.  When multiple PKs are collected, collect PD with the pre -
dose PK . 
f     Subjects enrolled in the safety lead -in and expansion arms will be required to have a site of disease that is safely accessible for biopsy (paired) upon enrollmen t. If a subject has 
had a biopsy within 90 days with no intervening lines of therapy prior to  loading dose/first dose of TTX -030, that tissue can be used for this study and the subject does not need 
to repeat a baseline biopsy. Accessible lesions are defined as those that can be biopsied (at screening) and are amenable to repeat biopsy on  C2D1 ( -7 days) , unless clinically 
contraindicated. It is optimal to have the screening and on -treatment biopsy obtained from the same lesion if possible. Invasive procedures that require general anesthesia 
should not be performed to obtain a biopsy specimen. If a s urgical procedure is performed for a clinical indication , a sample may be used for research purposes. During the 
course of treatment , a decision may be made to perform the on -treatment biopsy earlier than C2D1 ( -7 days)  if there is evidence to suggest a po ssibility that there will be no 
available tumor for biopsy due to a rapid clinical response. Similarly, tumor biopsy may be delayed if there is evidence of a  delayed response. 
g Concomitant medications are to be collected from screening  through 30 days aft er the last dose of study treatment.  
h Adverse events (e.g., including COVID -19 symptoms) and AESIs are to be collected from the time subject provides written informed consent through 90 days after the last 
dose of TTX -030 or until initiation of a new systemic anticancer therapy, whichever occurs first. Positive COVID -19 test result will be collected as a medical event and 
submitted as SAE.  
  
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 32 
 
Table 5: PK Sampling Intervals During Treatment ( 21-day treatment schedule Q3W)  
Visit Id entifier  Pre-C1D1 
Loading Dose  Cycle 1  Cycle 2  Cycle 3  Cycle s 4+ EOT  
Study Day  -7 1 2 3 8 15 22 (+ 2) 43 (±  2) 64 (±  2) and 
Q21D 
thereafter  30 days 
after last 
Tx 
Hours Before/After Dose  0a EOIb 0a EOIb 4 8 24 48 168 336 0a EOIb 0a EOIb 4 8 0a 0 
PK blood serum samplingc X X X X X X X X X X X X X X X X X X 
Abbreviations: C = cycle , D = day (s), EOI = end of infusion, EOT = End of Treatment, PK = pharmacokinetics , Q = every , Tx = treatment , W = weeks . 
a Predose sample collection 
b Sample to be collected at the EOI; specifically, collect the PK sample 15 ± 5 minutes after infusion of TTX -030 has completed.  
c Blood will be collected for determining the concentration of TTX -030: Loading  Dose ( pre-C1D1): predose  (if not already drawn with baseline  assessments) and at EOI 
(15 ± 5 minutes after end of TTX -030 infusion ); Dose 2 (C1D1): predose, EOI (15 ± 5 minutes after end of TTX -030 infusion), and 4, 8, 24 , and 48 hours (± 30 minutes) from  
start of TTX -030 infusion and on Day 8  and Day 15 ; Dose 3 (C 2D1): predose and at EOI (15 ± 5 minutes after end of TTX -030 infusion) ; Dose 4 (C3D1): predose and at EOI 
(15 ± 5 minutes after end of TTX -030 infusion), and 4 and 8 hours (± 30 minutes) from start of TTX -030 inf usion; Dose 5 and beyond  (Cycle s 4+): predose . Detailed 
instruction s for sample collection, processing , and shipment will be provided in a separate laboratory manual . 
 
 
  
  TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
  
 33 
 
Table 6: PK Sampling Intervals During Treatment (28-day treatment cycle, Q2W)  
Visit Identifier  Pre-C1D1  
Loading Dose  Cycle 1  Cycle 2  Cycle s 3+ EOT  
Study Day  -7 1 2 3 8 15 22 29 (+ 2) 43 (±  2) 57 (±  2) and 
Q28D 
thereafter  30 days 
after last 
Tx 
Hours Before/After Dose  0a EOIb 0a EOIb 4 8 24 48 168 0a EOIb 0 0a EOIb 4 8 0a 0a 0 
PK blood serum samplingc X X X X X X X X X X X X X X X X X X X 
Abbreviations: C = cycle , D = day(s), EOI = end of infusion, EOT = End of Treatment, PK = pharmacokinetics , Q = every , Tx = treatment, W = weeks.  
a Predose sample collection 
b Sample to be collected at the EOI; specifically, collect the PK sample 15 ± 5 minutes after infusion of TTX -030 has completed.  
c Blood will be collected for determining the concentration of TTX -030: Loading Dose ( pre-C1D1): predose (if not already drawn with baseline  assessments), and at EOI 
(15 ± 5 minutes after end of TTX -030 infusion) ; Dose 2 (C1D1): predose, EOI (15 ± 5 minutes after end of TTX -030 infusion), and 4, 8, 24, and 48 hours (± 30 minutes) from 
start of TTX -030 infusion and on Day 8; Dose 3 (C1D15): predose and at EOI (15 ± 5 minutes after end of TTX -030 infusion)  and on Day 22 ; Dose 4 (C2D1): predose , EOI 
(15 ± 5 minutes after end of TTX -030 infusion), and 4 and 8 hours (± 30 minutes) from start of TTX -030 infu sion; Dose 5 (C2D15) and beyond (Cycle s 3+): predose. Detailed 
instruction s for sample collection, processing , and shipment will be provided in a separate laboratory manual . 
 
 
 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
34 
2. Introduction  
Adenosine Pathway  
Purinergic signaling plays a key role in regulation of immune response in the tumor 
microenvironment (TME). eATP released during cell death and/or apoptosis serves as an 
immu ne cell activator through interaction with and downstream signaling of P2 purinergic 
receptors ( Yip et al.  2009 ; Schenk et al.  2008 ; Bours et al.  2006 ). Pro -inflammatory adenosine 
triphosphate (ATP) can be converted to adenosine via an enzymatically c ontrolled 
phospho hydrolytic cascade, leading to the accumulation of adenosine in the TME. Adenosine 
exerts its suppressive function  by binding to A2A receptors (A2AR) on multiple immune cells 
such as phagocytes, dendritic cells, natural killer cells, T cells, and B cells and inhibiting their 
pro-inflammatory properties ( Eppell et al.  1989 ; Haskó et al.  1996 ; Hask ó et al.  2000 ; Zhang et 
al. 2004 ; Lappas et al.  2005 ; Minguet et al.  2005 ; Deaglio et al.  2007 ; Ohta et al.  2009 ). 
CD39  
CD39, the cell surface -located prototypic member of the ectonucleoside triphosphate 
diphosphohydrolase (ENTPD ase) family, is an integral membrane protein that is responsible for 
phosphohydrolysis of eATP to yield adenosine diphosphate (ADP) and adenosine 
monophosphate (AMP) ( Kaczmarek et al.  1996 ; Dwyer et al.  2007 ). AMP is further converted to 
adenosine via another ecto -enzyme, CD73 (ecto -5, ecto-nucleotidase). CD39 and CD73 have a 
major impact on the dynamic balance of pro -inflammatory eATP and ADP nucleotides compared 
with the i mmunosuppressive adenosine nucleosides ( Takenaka et al.  2016 ). Moreover, evidence 
supports CD39 and CD73 ectonucleotidases having an involvement in the reg ulation of other 
aspec ts of T -cell biology, such as naïve cell homeostatic survival, memory cell survival, and 
differentiation ( Bono et al.  2015 ). CD39 is constitutively expressed on immune cell populations, 
such as B cells, natural killer cells, dendritic cells , Langerhans cells, monocytes, macrophages, 
mesangial cells, neutrophils, and T reg as well as normal endothelial cells and platelets 
(Koziak  et al. 1999 ). 
In the TME, CD39 expression is most prominent on T reg and myeloid derived suppressor cells 
(Whiteside 2015 ). Additionally, exhausted CD8+ T cells upregulate CD39 in the context of the 
tumor, which is accompanied by reduced functional capacity ( Canale et al.  2018 ). CD39 has 
been recognized as an activation marker and  is increasingly appreciated as a regulatory marker 
(Zhao et al.  2017 ). 
Increasing or inhibiting CD39 can i nterfere with the abnormal pathophysiol ogical process of 
disorders, especially inflammation and tumor ( Zhao et al.  2017 ). 
CD39 and Tumor Activity  
One mechanism by which immunotherapies modulate  an individual’s  immune system is through 
the b locking of suppressive pathways, thus making the adenosine pathway a promising 
therapeutic target in this area of clinical research. Reportedly, both CD39 and CD73 are elevated 
in blood neoplasias such as leukemia and lymphoma, as well as in multiple solid  tumor settings 
(Bastid  et al. 2013 ). In solid tumors, ATP is abundantly released in the extracellular space , 
achieving concentrations more than a thousand times higher than in healthy tissues. This is 
 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
35 
primarily due to cell death in the t umor core, metabolic or hypoxic stress, and pro-inflammatory 
signals that stimulate active export of ATP ( Pellegatti et al.  2008 ; Di Virgilio et al.  2016 ). In 
addition, immunogenic cell death mediated by chemotherapy is in part mediated by increasing 
extracellular ATP. Tumors are proficient at converti ng ATP into adenosine via CD39 and CD73 
on malignant cells, regulatory immune cells, and the vasculature . These ectonucleotidases 
modulate purinergic signaling by scavenging mainly pro -inflammatory ATP and generating 
immunosuppressive adenosine ( Allard et al.  2017 ). 
CD39, the main rate -limiting enzyme of this cascade, has an important role in tumor progression. 
Blockade of CD39 enzymatic activity may then stim ulate anti -tumor immunity across a wide 
range of tumors by preventing the production of immunosuppressive adenosine and by 
promoting the accumulation of ATP in the TME. CD39 can be viewed as an immunological 
switch that shifts ATP -driven pro -inflammatory immune cell activity toward an 
anti-inflammatory state mediated by aden osine and is, therefore, a unique therapeutic target for 
oncology indications ( Antonioli et al.  2014 ; Cai et al.  2016 ). 
TTX -030 
TTX -030 is a novel, fully human anti -CD39 antibody that inhibits CD39 ATPase enzymatic 
function allosterically with sub-nanomolar affinity and potency. The constant domain of 
TTX -030 is a hinge stabilized (S228P) human immunoglobulin (Ig)G4 containing the S228P 
mutation, which reduces antigen -binding fragment  arm exchange by stabilizing the disulfides in 
the core -hinge of the IgG4 molecule, which has low/no effector function.  
TTX -030 is specific to CD39 and does not bind to other ENTPD ase family member proteins. 
This antibody does bind to and inhibit cynomolgus monkey CD39 but is not cross -reactive with 
murine CD39. Trishula Therapeutics , Inc.  (Tizona Therapeutics , Inc. ’s spin -out company ) 
(hereafter referred to as Trishula ) has conducted studies demonstrating that TTX -030 binds to 
CD39+ cancer cell lines and primary human and cynomolgus monkey monocytes and T cells 
with high affinity. TTX -030 specifically and potently inhibits CD39 -driven processing of ATP 
by tumor and immune cells and by CD39+ tumor tissues, as demonstrated by a tumor tissue slice 
immunohistochemistry assay. In addition to preserving pro -inflammatory ATP  by inhibiting 
CD39 ATPase activity, TTX -030 inhibits downstream adenosine production in SK -MEL -28 
melanoma cell line. Functionally, TTX -030 reverses adenosine -driven suppression of 
proliferation of activated CD4+ and CD8+ human T cells in a dose -dependent  manner. Inhibition 
of CD39 by TTX -030 in CD3/CD28 stimulated peripheral blood mononuclear cells (PBMCs) in 
the presence of exogenous ATP increased proliferation of both CD4+ and CD8+ T cells from 
multiple donors. TTX -030 incubation with stimulated PBMCs l ed to increased secretion of pro -
inflammatory cytokines interferon (IFN) -γ, interleukin (IL) -2, and tumor necrosis factor -α. 
Additionally, TTX -030 reversed adenosine -driven suppression of T -cell IFN -γ responses in 
cytomegalovirus (CMV) peptide recall assay  (see also Section 2.2.1.3.3 ). 
2.1. Study Rationale  
The goal of this first -in-human (FIH) Phase 1/1b study is to evaluate the safety, tolerability, and 
preliminary anti -tumor activity  of intravenous ( IV) TTX -030 as monotherapy or in combination 
regimens in adults with unresectable or metastatic solid tumor malignancy, including 
 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
36 
relapsed -refractory lymphoma. There are compelling preclinical data to support the hypothesis 
that CD39 -mediated reduction of adenosine triphosphate (ATP ) and accumulation of adenosine 
both play a central role in establishing and main taining the immunosuppressive 
microenvironment within solid tumors. CD39 expression is associated with worse outcomes in 
several cancer types. The enzymatic inhibition of CD39 maintains high levels of pro -
inflammatory extracellular ATP (eATP), leading to i mmune activation and significant anti -tumor 
immune responses. The CD39 pathway contributes to T -cell exhaustion and limits the 
immunogenicity of chemotherapy, which provides the rationale for combining CD39 inhibition 
with checkpoint blockade and conventio nal cytotoxic therapies.  Targeting CD39 is a rational 
strategy for the treatment of patients with cancer. TTX -030, as a single agent or in combination, 
is expected  to have a manageable safety profile, thereby providing additional therapeutic options 
for su bjects whose malignancies are otherwise refractory to or relapsed on current standard of 
care therapies.  The indications selected were defined based on the following criteria: expression 
of CD39 on TIL, expression of CD39 on tumor cells, and tumor types th at are amenable to be 
combined with chemotherapy or anti -PD-1 therapy.  
While impressive and durable responses are observed in subsets of patients treated with 
anti-PD-1 agents, response rates are rarely > 50%, and for most patients, a response is short 
lasting. Thus, a synergistic strategy may be beneficial for patients. Co -expression of PD -1 and 
CD39 is highly prevalent on TILs and marks exhausted effector T -cell subsets in multiple tumor 
types ( Canale et al.  2018 ; Trishula  data on file Study No.  18-006-TRL). The rationale for 
combining with an anti -PD-1 antibody is that CD39 in hibition and subsequent ATP 
accumula tion and adenosine reduction in the TME may make the tumor more susceptible to 
anti-PD-1 therapy. This combination strategy is supported by the in vivo data generated in using 
an anti -murine CD39 antibody B66 in multiple syngeneic tumor models ( Section 2.2.1.4 ). 
Combining anti -CD39 therapy with an anti -PD-1 antibody in an MC38 syngeneic colorectal 
tumor model resulted in a significant decrease in tumor growth compared with the control or 
either mono therapy. Anti -PD-1 treatment of SM1WT1, which is generally refractory to 
immunotherapies, including anti -PD-1, shows marked tumor growth inhibition when anti -PD-1 
treatment is combined with an antibody capable of inhibiting enzymatic function of CD39, 
sugg esting that the latter treatment sensitizes an otherwise refractory tumor to checkpoint 
blockade. These findings are consistent with previously reported data in CD39-/- animals that 
suggested that anti -PD-1 treatment of MCA205 resulted in a more pronounced  tumor growth 
inhibition and increased number of complete responders in CD39-/- mice compared with the same 
treatment in wild -type mice ( Lapierre et al.  2016 ). 
Similarly, treatment with oxaliplatin either alone or in combination with an anti -PD-1 antibody 
resulted in regression of MCA2 05 tumors in CD39-/- mice but not in wild -type mice 
(Boyd -Tressler et al.  2014 ). A study by Michaud et al.  2012  compared the effects of treatment 
with the anthracycli ne mitoxantrone on tumor growth of MCA205 tumor cells versus MCA205 
expressing mouse CD39. Tumor cells were pretreated with mitoxantrone prior to injection into 
wild-type mice – only MCA205 tumor cells  expressing mouse CD39 grew ( Michaud et al.  2012 ). 
Chemotherapy drugs such as oxaliplatin, cisplatin, and mitoxantrone have been shown to induce 
the release of  ATP from dying tumor cells ( Boyd -Tressler et al.  2014 ); CD39 then processes 
ATP in concert with CD73 resulting in the generation of immune -suppressive adenosine. 
Inhibition of CD39 prevents phosphohydrolytic processing and maintains high levels of 
 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
37 
pro-inflammatory ATP i n the TME and can lead to immune activation. These data support the 
potential synergy of the combination of chemotherapy and TTX -030. 
2.2. Background  
2.2.1.  Nonclinical Data  
2.2.1.1.  Non-human Primate Pharmacokinetic Study with TTX -030 
Multiple non -Good Laboratory Practice ( GLP ) pharmacokinetic (PK) studies were conducted 
with TTX -030, including a  single -dose study at 10 mg/kg IV and multiple -dose studies at 
30 mg/kg and 100 mg/kg. Titers of TTX -030 were measured using an antigen -down 
enzyme -linked immunosorbent assay (ELISA) met hod and used for PK parameter calculations. 
Linear PK was observed for doses starting at 10 mg/kg, 30 mg/kg , and 100  mg/kg. In addition to 
PK parameters, blood samples were collected for assessment of treatment -related clinical 
observations and clinical pa thology parameters (hematology, clinical chemistry, and 
coagulation). There were no treatment -related effects noted for clinical observations or for the 
hematology and clinical chemistry parameters collected in any of the cynomolgus monkeys in 
either the s ingle - or multiple -dose cohorts.  
 
 
 
 
 
 
 
2.2.1.2.  Non-human Primate Good Lab oratory Practice Toxicology  
Since TTX -030 has equivalent binding and functional potency on both human and cynomolgus 
monkey CD39, testing TTX -030 in healthy male and female cynomolgus monkeys allowed for 
the characterization of effects of TTX -030 on immune  cells, endothelial cells, and other tissues.  
A multiple -dose 28 -day GLP toxicology study with 28 -day recovery period was performed in 
cynomolgus monkeys , and no TTX -030-related findings were observed. The animals were IV 
dosed with 0, 30, or 100 mg/kg of TTX -030 once per week for 4 weeks (5 doses total). The main 
study groups consisted of 3 males and 3 females with an additional 2 males and 2 females 
included as part of the control and high -dose recovery groups.  
Three animals per sex from each group were sacrificed at the end of the dosing period. The 
2 remaining animals of each sex from each group were allowed to recover for 4 additional weeks 
and then were sacrificed. The 4 -week recovery period provides approximately 5 to 6 half -lives 
for TTX -030 elimina tion, based on the preliminary PK measured in the pilot tolerability study. 
The recovery cohorts served to determine whether any toxicities observed at the end of the 
30-day dosing period are reversible.  

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
38 
Data collected from this toxicology study are summar ized in Table 7. Gross observations on 
animal health (body weight, food consumption, and behavior) were collected and a battery of 
serological analyses from blood samples (hematology, blood chemistry, toxic okinetics, ADA, 
and cytokine analysis ) were performed throughout the course of the study. In addition, a set of 
safety pharmacology assessments were conducted, including evaluation of heart rate and blood 
pressure, body temperature measurements, quality an d rate of respiration, ophthalmology 
examinations , and neurological/central nervous system behavior evaluations. At sacrifice, a 
comprehensive examination of all animals (necropsy, urinalysis, and histopathology) was 
performed. The groups were compared usi ng a parametric dose -response curve or 
non-parametric analysis of variance (ANOVA) method, as appropriate.  
 
 
 
 
 
 
 
 
Table 7: Procedures and Parameters for the 28 -Day GLP Toxicology Study of the 
Administrat ion of TTX -030 to Male and Female Cynomolgus Monkeys  
Procedure/Parameters  Time  Point s 
Mortality/morbidity 
observations  All animals: Twice daily, beginning Day -7 and continuing through the 
End of Study  
Cage -side observations  All animals: Twice daily, beginning Day -14 and continuing through the 
End of Study  
Postdose  observations  All animals: For 1 continuous hour following dose  
Body weight  All animals: Twice pre -study (Weeks -2 and -1) and weekly thereafter 
starting on Day 7  
Food consumption 
(qualitative)  All animals: Daily beginning Day -14 and continuing through the End of 
Study  
Clinical pathology 
(hematology)  All animals: Predose on Days 1, 15, and 29  
Clinical pathology (serum 
chemistry, and coagulation 
[PT/INR, aPTT])  All ani mals: Predose and postdose on Days 1, 15, and 29  
Recovery animals: Day 56  
TK All animals: Day 1 pre dose and 0.5, 4, 12, 24, 96, and 168 hours 
postdose ; Day 15: p redose ; Day 29: predose and 0.5, 4, 12, 24, 96, and  
168 hours postdose  
ADA  All animals: Day -2 and predose on Days 15 and 29  
Recovery animals: At the end of recovery period on Day 56  
Cytokines  All animals: Predose, and multiple time point s in 24 hours following first 
and last dose  

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
39 
Procedure/Parameters  Time  Point s 
Electrocardiograms  All animals: Once pretreatm ent (Week -2), on Day 1 (1 to 4, 12, and  24 
hours postdose), and at Week 4 (1 to 4, 12, and 24 hours postdose) 
Recovery animals: At the end of the recovery period prior to necropsy  
Blood pressure measurements  All animals: Once during acclimation and at m ultiple time points within 
24 hours after first and last dose  
Respiratory examinations  All animals: By visual assessment pretreatment (Week -1), predose, and 
2, 6, and 24 hours postdose on Days 1, 8, 15, and 22  
Recovery animals: At the end of the recovery period prior to necropsy  
Neurological / CNS behavior 
examinations  All animals: Once pretreatment (Week -1), on Day 1 (1 to 4 hours 
postdose), and on Day 22 (predose and 1 to 4 hours postdose)  
Recovery animals: At the end of the recovery period p rior to necropsy  
Body temperature  All animals: Using infrared monitor, pretreatment (Week -1), and 
predose and 2, 6, and 24 hours postdose on Days 1, 8, 15, and 22  
Recovery animals: At the end of the recovery period prior to necropsy  
Ophthalmology ex aminations  All animals: Assessed pretreatment and during Week 4  
Recovery animals: Additionally, at the end of the recovery period prior 
to necropsy  
Examinations were performed by a board -certified veterinarian 
ophthalmologist  
Urinalysis  All animals: At necropsy  
Necropsy  Full necropsy of 12 main study animals on Day 30 and 8 recovery 
animals on Day 56  
Organ weights  Standard organs measured  
Histopathology  Full histopathologic evaluation on all animals  
Abbreviations: ADA = anti -drug antibodies, aPTT = activated partial thromboplastin time, CNS = central nervous 
system, INR  = international normalized ratio, PT = prothrombin time, TK = toxicokinetics.  
Trishu la data on file Study No. 18 -002-TOX.  
2.2.1.3.  Modeling and In Vitro  Studies  
2.2.1.3.1.  Enzymatic Inhibition of CD39 by TTX -030 
TTX -030 was evaluated for its ability to inhibit enzymatic activity of endogenous CD39 
expressed on human and cynomolgus monkey primary cells and mu ltiple tumor cell lines. CD39 
expressing cells were pretreated with TTX -030 before administering ATP; phosphate release 
resulting from enzymatic phosphohydrolysis was subsequently measured. TTX -030 inhibited 
CD39 activity in multiple cell types with sub -nanomolar half -maximal inhibition concentration 
(IC 50) values, ranging from 51.4% inhibition in primary human artery endothelial cells to 85.3% 
in the SK -MEL -28 cell line. TTX -030 also inhibited activity of CD39 in human monocytes and 
in cynomolgus monkey mo nocytes with similar IC 50 values ( Figure 2). 
 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
40 
Figure 2: Short -Term Inhibition of CD39 by TTX -030 on Human and Cynomolgus 
Monocytes  
 
Abbreviation: IC 50 = half -maximal inhibition concentration.  
Trishula  data on file Study No. 17 -001-IVT: TTX -030 inhibits CD39 enzymatic activity on human and cynomolgus 
monkey monocytes. Inhibition curves of ATPase activity by TTX -030 on human (A) and cynomolgus monkey 
(B) monocytes (average and standard deviation are shown, n = 2). Enzymatic inhibition on human monocytes 
was calculated at 72.0 ± 1.1% with an IC 50 of 0.02 nM. For cynomolgus monocytes, enzymatic inhibition was 
98.7 ± 8.8%, with IC 50 of 0.01 nM.  
2.2.1.3.2.  TTX -030 Reduces Adenosine and Preserves ATP in SK -MEL -28 Cancer Cell Line  
To assess functional effect of CD39 inhibition by TTX -030, the antibody was evaluated for its 
ability to inhibit CD39 -mediated adenosine production o n tumor cell lines. The melanoma cell 
line SK -MEL -28 (CD39 and CD73 positive) was pretreated with TTX -030 and adenosine 
production following ATP addition was measured by liquid chromatography -tandem mass 
spectrometry. TTX -030 (100 nM) inhibited 73.0 ± 7% o f CD39 -mediated adenosine production 
by SK -MEL -28 cells compared with cells treated with ATP only. TTX -030 also preserved ATP 
levels in the supernatant of SK -MEL -28 cells by preventing ATP processing by CD39 (Figure  
3). ATP was not hydrolyzed by SK -MEL -28 cells that had CD39 expression ablated by 
Clustered Regularly Interspaced Short Palindromic Repeats (designated as CD39KO). 
Additionally, adenosine le vels were lower in supernatants of CD39KO cells, indicating that 
CD39 is critical for ATP processing to adenosine by SK -MEL -28. These data demonstrate th at 
inhibition of CD39 enzymatic activity by TTX -030 is sufficient to impact downstream 
immunosuppressiv e adenosine production while simultaneously preserving pro -inflammatory 
ATP.  

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
41 
Figure 3: TTX -030 Reduces CD39 -Mediated Adenosine Production and Preserves ATP 
in SK -MEL -28 Cells  
 
Abbreviations: ATP = adenosine triphosphate, EHNA = 41rythron o-9-(2-hydroxy -3-nonyl)adenine . 
Trishula  data on file Study No. 17 -012-IVT: Average and standard deviation of adenosine production from 
SK-MEL -28 (n = 3) and average and standard deviation of ATP accumulation in SK -MEL -28 (n = 6). Dotted 
line denotes the adenosine production and ATP accumulation from CD39KO SK -MEL -28 cells. Adenosine was 
measured by liquid chromatography -tandem mass spectrometry. ATP was measured by EnzyLight Kit. The 
nonspecific small molecule inhibitors ARL67156 and POM -1 were used a s positive controls. EHNA is an 
adenosine deaminase inhibitor.  
2.2.1.3.3.  TTX -030 Induces IFN -γ in CMV Recall Assay  
Human PBMCs express both CD39 and CD73 and stimulation of T-cell proliferation in the 
presence of ATP results in generation of immunosuppressive adenosine. Adenosine can lead to 
decrease in pro -inflammatory cytokine release by activated T cells. The effect of TTX -030 on 
T-cell response was measured using human PBMCs th at were stimulated with a mixture of 
immunogenic CMV peptides. Following an initial recall stimulation period of 5 days using 
PBMC s, T cells were purified and rested overnight, prior to treatment with TTX -030. T cells 
were then re -stimulated with CMV pepti des in the presence of autologous CD39+ Epstein Barr 
virus-transformed lymphoblastoid B cell lines (B -LCLs) and ATP ( Figure 4). Addition of ATP in 
this system led to suppression of IFN -γ responses by CD4+ and CD8+ T cells, which was nearly 
completely reversed by TTX -030 treatment (25 μg/mL).  

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
42 
Figure 4: TTX -030 Reverses Suppression of IFN -γ Response in a CMV Recall Assay  
 
Abbreviat ions: ATP = adenosine triphosphate, B -LCL = Epstein Barr virus-transformed lymphoblastoid B cell line, 
CMV = cytomegalovirus, IFN = interferon, PBMC = peripheral blood mononuclear cell.  
Trishula  data on file Study No. 17 -011-IVT: TTX -030 reverses adenosine -driven suppression of IFN -γ response in 
T-cell CMV recall assay. Human PBMC s were stimulated with CMV peptides and rested prior to re -stimulation 
with the same peptides in the presence of ATP, autologous B -LCL, and TTX -030. Levels of IFN -γ produc ed by 
CD4+ and CD8+ T cells were analyzed by intracellular cytokine staining (* P < 0.05 by t test). 
2.2.1.3.4.  TTX -030 Induces T  Cell Proliferation and Cytokine Response  
The impact of TTX -030 treatment on CD39 -mediated adenosine production in PBMCs was 
measured usin g functional readouts of CD4+ and CD8+ T-cell proliferation and cytokine 
expression. Addition of ATP to activated PBMCs decreased proliferation, which was reversed 
through addition of TTX -030 in a dose -dependent manner compared with isotype control and 
untreated T cells ( Figure 5). Similar results were obtained with TTX -030 without the addition of 
exogenous ATP (data are not presented).  

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
43 
Figure 5: TTX -030 Increases the Proliferation of Stimulated CD8+ and CD4+ T Cells 
in the Presence of ATP  
 
Abbreviations: ATP = adenosine triphosphate, PBMC = peripheral blood mononuclear cell.  
Trishula  data on file Study No. 17 -014-IVT: PBMCs isolated from human donor were fluorescently labeled, 
stimulated with anti -CD3/anti -CD28 antibody cocktail, and incubated with TTX -030 and ATP for 96 hours. 
Proliferation of CD4+ and CD8+ T cells was assessed by flo w cytometry gating on the specific T-cell 
populations. Dotted line depicts baseline level of proliferation without the addition of exogenous ATP or 
antibody.  
The effects of TTX -030 treatment on pro -inflammatory cytokines secretion by 
anti-CD3/anti -CD28 act ivated PBMC was measured using a multi -cytokine 
electrochemiluminescent assay. TTX -030 increased IL -2 secretion by stimulated PBMCs 
compared with isotype control in a dose -dependent manner with a half -maximal effective 
concentration (EC 50) of 129.10 ± 43.9 9 nM (19.37 μg/mL) when 50 μM ATP was added to the 
culture and an EC 50 of 155.20 ± 24.47 nM (23.30 μg/mL) without the addition of exogenous 
ATP ( Figure 6). 

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
44 
Figure 6: TTX -030 Induces IL -2 Release by Stimulated PBMCs in Dose -Dependent 
Manner  
 
Abbreviations: ATP = adenosine triphosphate, IL -2 = interleukin -2, PBMC = peripheral blood mononuclear cell.  
Trishula  data on file Study No. 17 -014-IVT: TTX -030 induces dose -dependent IL -2 production by 
anti-CD3/anti -CD28 stimulated PBMC. Assay performed with addition of 50 μM ATP ( left) and without 
exogenous ATP ( right ) is shown. TTX -030 indicated by black squares while gr ay squares indica te isotype 
control. Data are representative of 3 independent PBMC donors.  
2.2.1.4.  In Vivo  Studies: Mouse  
The impact of CD39 on tumor growth and anti -tumor immunity has previously been studied 
using  CD39-/- knockout mice . Published data suggest that growth of syngeneic tumors, including 
MC38 and B16F10 ( Sun et al.  2010 ; Feng et al.  2011 ), is reduced in these mice. These effects are 
more pronounced when combined with therapeutic intervention  via anti -programmed cell death 
ligand -1 (PD -L1) ( Lapierre et al. 2016 ) or chemotherapeutic agents ( Michaud et al.  2012 ; 
Lapierre et al.  2016 ). In both cases, combinatorial efficacy  was observed in tumor -bearing 
CD39-/- mice but not in matched wild -type C57BL/6 animals.  
To test the effect of therapeutic inhibition of CD39 enzymatic activity on tumor growth and to 
complement findings from the CD39-/- mouse studies, Trishula  has genera ted antibody clone 
B66, an antibody specific for murine CD39 with the ability to inhibit CD39 -mediated ATP 
hydrolysis ( Trishula  data on file Study No. 18 -001-IVT). This antibody was used to characterize 
the role of pharmacologic al inhibition of CD39 activi ty on tumor growth. B66 was used both as a 
single agent and in combination with anti -PD-1 in the syngeneic MC38 mouse tumor model 
(Figure 7). In single -agent studies, treatment with B66 significantly decreased tumor growth of a 
subcutaneous murine colorectal tumor cell line in a dose -dependent fashion ( Figure 7A). 
Therefore, inhibition of CD39 enzymatic activity in the MC38 syngeneic mouse tumor model by 
B66 monoclonal antibody (mAb) is sufficient to decrease tumor growth as a single agent. Th ese 
data agree with the previous findings from MC38 tum ors grown in the CD39-/- mice.  
Given the single -agent efficacy observed with B66, a suboptimal dosing strategy with a delayed 
treatment schedule (100 μg/dose on Days 12, 15, 18, and 21) was employed to maximize the 
window for seeing therapeutic combination  effects ( Figure 7B). Employing this treatment 

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
45 
regimen, efficacy was reduced but was still significant versus isotype control for B66 
monotherapy. Addi tionally, the anti -tumor effect was similar to that seen for anti -PD-1 treatment 
alone. In combination, anti -PD-1 and B66 resulted in a highly significant increase in anti -tumor 
efficacy compared with either monotherapy or isotype control.  
Figure 7: Anti -Mouse CD39 Antibody B66 Inhibits MC38 Tumor Growth as Single 
Agent and in Combination with Anti -PD-1 
 
Abbreviations: ANOVA = analysis of variance, cIg = isotype control , PD-1 = programmed cell death protein -1. 
Trishula  data on file Study No.17 -015-IVO: MC38 cells were injected subcutaneously on Day 0.  
A) B66 was administered intraperitoneally at 20, 100, or 200 μg , and cIg was administered at 20  μg/dose on 
Days 7, 10, 13, and 16.  
B) B66 was administered intraperitonea lly 100 μg/dose and anti-PD-1 at 250 μg/dose on Days 12, 15, 18, and 21 
(*** P < 0.001, **** P < 0.0001 by 2 -way ANOVA). Arrows indicate dosing days.  
Similar responses were observed in an immunotherapy -resistant melanoma tumor model 
SM1WT1 ( Figure 8). Treatment with B66 demonstrated a slight, but statistically significant 
effect on subcutaneous SM 1WT1 tumor growth alone, while anti -PD-1 treatment demonstrated 
no single -agent efficacy. In combination, B66 and anti -PD1 led to significant tumor growth 
reduction compared with either agent alone. Therefore, combination treatment of anti -PD1 and 
B66 in both anti -PD1-sensitive MC38 and anti -PD1-resistant SM1WT1 tumors resulted in an 
additive and potentially synergistic impact on tumor growth. These findings suggest that 
PD-1/PD -L1 and CD39/adenosine represent non -overlapping immune resistance mechanisms.  

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
46 
Figure 8:  Combinatorial An ti-Tumor Efficacy of Anti -PD-1 and Anti -Mouse CD39 
Antibody B66 in an Immunotherapy -Resistant SM1WT1 Tumor Cell Line  
 
Abbreviations: ANOVA = analysis of variance,  cIg = isotype control,  PD-1 = programmed cell death protein . 
Trishula  data on file Study No. 17-015-IVO: SM1WT1 cells were injected subcutaneously on Day 0. B66 and cIg 
were administered intraperitoneally at 200 μg/dose and anti -PD1 was administered at 250 μg/dose on Days 6, 9, 
12, and 14. (* P < 0.05, **** P < 0.0001 by 2 -way ANOVA ). Arrows indicate dosing days.  
To assess the impact of inhibition of CD39 enzymatic function on models of disseminated 
disease, the anti -mouse CD39 inhibitory antibody B66 was tested in lung metastasis seeding 
models of 2 melanoma -derived tumors, LWT1 and B16F10. T reatment with B66 significantly 
inhibited lung metastasis of LWT1 in wild -type mice in a dose -dependent fashion – the 50 μg 
dose of B66 was sufficient to mediate significant reduction in lung metastatic burden; maximal 
inhibition of metastasis formation wa s observed at the 200 μg dose of antibody in this model 
(Figure 9A). Therapeutic inhibition of CD39 activity by B66 antibody in wild -type mice had a 
more pronounced effect on metastasis compared with metastasis observed in CD39-/- mice. This 
effect of B66 was not limited to LWT1 as similar results were observed in B16F10 metastasis 
model ( Figure 9B). Anti -CD39 inhibitory antibody treatment in wild -type mice in the B16F10 
model was more efficacious in reducing metastasis compared with CD39-/- animals. However, 
there was no benefit observed between B66 tre atment and the control treatment groups in the 
CD39-/- background, suggesting that the observed reduction of lung metastatic burden is 
dependent on CD39 inhibition.  
Inhibition of CD39 enzymatic activity in mouse metastasis models of cancer is sufficient to  
reduce number of lung metastasis in vivo . Reduction in number of lung metastasis by B66 
antibody in both LWT1 and B16F10 models resulted in a more pronounced effect compared with 
decreases in metastasis observed in CD39-/-. 

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
47 
Figure 9:  Anti -CD39 Antibody Inhibits Lung Metastasis Formation in Models of 
Disseminated Disease  
 
Abbreviations: ANOVA = analysis of variance, cIg = isotype control, IV = intravenously, WT = wild type.  
Trishula  data on file Study No. 17 -016-IVO: Anti -tumor efficacy of B66 in disseminated models of disease.  
A) LWT1 cells were injected IV on Day 0. Mice were injected intraperitoneally with B66 or cIg at indicated 
doses (all doses are in μg) on Day 0 and on Day 3. Lungs were collected on Day 14 and perfused with India ink 
and analyzed for number of metastasis.  
B) B16F10 cells were injected IV on Day 0. Mice were injected intraperitoneally with B66 or cIg at 200 μg/dose 
on Days 0 and 3. Lungs were collected on Day 1 4 and perfused with India ink and analyzed for number of 
metastasis. (* P < 0.05, *** P < 0.001, **** P < 0.0001 by one -way ANOVA).  
2.2.1.5.  In Vivo  Studies: Cynomolgus Monkey  
TTX -030 has been tested in vivo in cynomolgus monkeys in single -dose (10 mg/kg) and 
multip le-dose non -GLP and GLP (30 and 100 mg/kg) studies. No adverse effects have been 
observed; all clinical chemistry, hematology, and coagulation results were within the normal 
range for cynomolgus monkeys.  
CD39 receptor occupancy by TTX -030 in cynomolgus mon keys was analyzed as part of a 
non-GLP study. Target coverage was assessed by flow cytometry using fluorescently labeled 
TTX -030 on whole blood samples and gated on monocyte population. Free CD39 receptor was 
calculated relative to baseline  (mean fluoresce nce intensity [MFI] of an unblocked sample at  

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
48 
predose). The percent of free receptor at each time point  was calculated using the following 
formula:  
% of Free 
Receptor =  (MFI of Unblocked Sample MFI of Pre -Blocked Sample)  
÷ 
(MFI of Unblocked Sample at Predose —- MFI of Pre -Blocked Sample)  
 
Receptor occupancy exceeding 90% was achieved following TTX -030 dosing at 10 mg/kg. 
Occupancy was 91.1% 24 hours postdose  and remained high (83% ± 3%) through Day 14 
(Figure 10) with C max for that group calculated as 19.8  μg/mL.  
Figure 10:  Receptor Occupancy Analysis for 10 mg/kg Group in Cynomolgus Monkeys  
 
Trishula  data on file Study No. 17 -019-PK: TTX -030 covers CD39 cynomolgus monkey peripheral blood 
monocytes for > 2 weeks at 10 mg/kg. Cynomolgus monkey whole blood was incubated in fluorescently labeled 
TTX -030 for 30 minutes and analyzed by flow cytometry.  
2.2.2.  Clinical Data  
As of the data cutoff date of 10 January 2020, 21 subjects in Study TTX -030-001 have received 
TTX -030 monotherapy every 3 weeks (Q3W) at the following escalating doses: 0.5  mg/kg 
(n = 1), 1.5  mg/kg (n = 2), 3.0 mg/kg (n = 2), 6.0 mg/kg (n = 4), 10 mg/kg (n = 3),  20 mg/kg (n = 
3), or 40  mg/kg (n = 6) . 
As of 10 January 2020, 17 of 21 subjects in Study TTX -030-001 experienced treatment -emergent 
adverse events (TEAEs). A majority of the TEAEs were of Grade 1 or 2 severity. TEAEs of 
≥ Grade 3 severity were reported in  6 subjects: Grade 3 lipase increase (1.5 mg/kg cohort), Grade 
3 hyperbilirubinemia (3.0 mg/kg cohort), Grade 3 gamma -glutamyltransferase (GGT) increase 
(10 mg/kg cohort), Grade 3 bilateral lower extremity muscle weakness (10  mg/kg cohort), Grade 
3 dyspnea , ascites, increased alkaline phosphate, esophageal hemorrhage, upper gastrointestinal 
(GI) bleed, and decreased lymphocyte count (40 mg/kg cohort), and Grade  5 sepsis (6.0 mg/kg 
cohort). There were no Grade 4 events. Treatment -related TEAEs were reported in 9 subjects and 
included arthralgia in 2  subjects and malaise, myalgia, worsening back pain, intermittent rib 
pain, dizziness, worsening diarrhea, foot maculo -papular rash, bruising left hand, vaginal 
discharge, nausea, headache, creatine phosphokinase ( CPK) increased, and fatigue in 1 subject 

 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
49 
each; all of these events were of Grade 1 or 2 severity. Five subjects experienced a total of 
6 serious adverse events (SAEs): Grade 2 bee sting reaction (1.5 mg/kg cohort), Grade 3 
hyperbilirubinemia (3.0 mg/kg coh ort), Grade 3 bilateral lower extremity muscle weakness (10 
mg/kg cohort), Grade 3 dyspnea and esophageal hemorrhage (40 mg/kg cohort), and Grade 5 
sepsis (6.0 mg/kg cohort). None of the SAEs were considered to be treatment -related by the 
Investigator. No dose-limiting toxicities (DLTs) were observed, and the maximum tolerated dose 
has not been determined.  
As of 08 January 2020 , PK data are available for 21 subjects treated at TTX -030 doses through 
40 mg/kg.  Overall, t he 2-compartment model was consistent w ith the individual subject data . 
Clearance appears to be independent of dose at doses  6 mg/kg suggesting linear or dose -
proportional PK.  For doses from 6 to 40 mg/kg, there was reasonable consistency among doses 
and subjects with respect to the PK parame ters. The elimination half -life over that dose range 
averaged 18.9 days.  
Refer to the TTX -030 Investigator Brochure (IB) for more information.  
2.2.3.  Rationale  for TTX -030 Dose and Schedule  
Based on the current PK, receptor occupancy data and safety from the ongoing first -in-human 
Phase 1 study (TTX -030-001) that is evaluating TTX -030 as monotherapy and in combination 
with other agents in subjects with advanced solid tumor malignancies or lymphoma, a RP2D was 
determined to be 40 mg/kg loading dose 7 days prior  to Cycle 1 Day 1 and then either 30 mg/kg 
Q3W or 20 mg/kg Q2W.  
As of the clinical data cut -off date of 10 January 2020, doses of TTX -030 monotherapy up to 4 0 
mg/kg  Q3W have been evaluated in Study TTX -030-001 and demonstrated to be well tolerated. 
No DLTs  have been reported ( Section  2.2.2 ). 
PK demonstrated that a dose of 40 mg/kg Q3W achieved a minimal functional trough  level  based 
on activity of TTX -030 in preclinic al human functional assays (i .e., enhancement of IL -2 from 
PBMCs and inflammasome activation) . Clearance appears to be independent of dose at doses  6 
mg/kg, suggesting linear or dose -proportional PK. The half -life was 18.9 days . After the 
completion of t he dose escalation portion of the study, the totality of the PK data was used for 
PK modeling for the RP2D. Based on the simulations, it was determined that a loading dose of 
40 mg/kg one week prior to Cycle 1, Day 1 dosing of 30 mg/kg Q3W or 20 mg/kg Q2W will 
provide a minimal functional trough level in greater than 80% of patients before Cycle 1, Day 1 
and in cycles thereafter.  
In the 0.5, 1.5, 3.0, 6.0, 10.0 and 20.0 mg/kg Q3W dose groups, receptor occupancy data 
demonstrated that doses greater than or equal to 6 mg/kg achieved and maintained higher levels 
of peripheral blood receptor occupancy through 21 days post -Cycle 1 on CD39+ monocytes, B 
cells, and regulatory T cells. At doses less than or equal to 3 mg/kg, receptor occupancy levels 
were lower and decreased 7 -14 days post -Cycle 1.   
Refer to the TTX -030 Investigator’s Brochure for more information.  
 TTX-030-001 Version 8 (December  15, 2020 ) 
CONFIDENTIAL  
 
50 
2.3. Benefit/Risk Assessment  
Blockade of CD39 may result in less potential for autoimmune side effects compared with rates 
seen with other immunotherapy ag ents. Although T reg from CD39-/- knockout  mice have 
impaired suppressive activity, the mice do not show autoimmunity ( Sun et al.  2010 ). 
TTX -030 has a different mechanism of action from each of the regimens in the combination 
arms (Arms 2 and 4, presented in Table 8), and toxicities are ant icipated to be manageable and 
nonoverlapping. Conversely, it is also possible that TTX -030 could potentiate some of the 
existing toxicities of the combination regimens.  
The clinical risks and benefits of TTX -030 are unknown at this time; however, several 
investigational agents targeting A2AR and CD73 in the adenosine pathway have reportedly 
entered Phase 1 trials and may offer insights on potential risks and benefits of targeting the 
adenosine pathway. Clinical data from an ongoing Phase 1 trial with CPI -444 ([STUDY_ID_REMOVED]), 
an oral small molecule inhibitor of the A2A receptor, suggest that inhibiting adenosine -mediated 
suppression can be achieved with a favorable safety profile ( Hotson et al.  2017 ). Similarly, no 
SAEs were reported in a Phase 1b/II study in Parkinson’s Disease with the same compound 
(Pinna 2014 ). A similar safety profile was observed with NIR178 (previously known as 
PBF-509), also a small molecule inhibitor of A2AR, which has be en evaluated in both healthy  
volunteers ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]) and subject s with advanced non -small -cell lung 
cancer ([STUDY_ID_REMOVED]). NIR178 was reportedly well -tolerated. Adverse events (AEs) were 
manageable , and there were no Grade 4 drug -related AE s; immune -related AEs (irAEs) may 
indicate immune stimulation ( Chiappori et al.  2018 ). 
Antibodies targeting CD73 have also recently entered cli nical development. Data from 
NZV930/SFF3737 ([STUDY_ID_REMOVED]) and CPI -006 ([STUDY_ID_REMOVED]) have not been reported. The 
anti-CD73 antibody MEDI9447 ( oleclumab) was evaluated for safety, efficacy, and PK alone or 
in combination with the anti -PD-L1 antibody ( IMFINZI®, 201 8) in advanced pancr eatic cancer 
or colorectal cancer ([STUDY_ID_REMOVED]). No treatment -related deaths or DLTs were re ported, and 
no SAEs were reported in any of the oleclumab monotherapy dose -escalation cohorts. Overall, 
treatment with oleclumab alone or wit h durvalumab demonstr ated a manageable safety profile as 
measured by low incidence of treatment -related discontinuation and SAEs 
(Overman  et al. 2018 ). 
Overall, clinical experience  with other in vestigational agents targeting A2AR and CD73 in the 
adenosine pathway were shown to be well tolerated. Publicly disclosed safety data have been 
summarized in more detail in the I B. 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
52 
to mechanism of action and immune 
responses  • Exploratory pharmacodynamic 
biomarkers  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
53 
4. Study Design  
4.1. Overall  Design  
4.1.1.  Overview  
This is a Phase 1/1b, FIH , open -label, and multicenter study to investigate the safety, tolerability, 
PK, pharmacodynam ic, and preliminary clinical activity of TTX -030 in adult subject s with 
advanced solid tumor malignancies or lymphoma. The study will evaluate the safety and 
tolerability of:  
• TTX -030 as a single agent, and  
• TTX -030 in combination with pembrolizumab, a PD -1 inhibitor, and  
• TTX -030 in combination with specified chemotherapy regimens.  
The study consists of 2 stages: dose escalation /safety lead -in and dose expansion Figure 1. Dose 
escalation /safety lead -in comprises Part A (1 dose -escalation arm of TTX -030 monotherapy 
[Arm 1]) and Part B ( 2 safety lead -in arms of combination therapy [TTX -030 with other agents; 
Arms 2 and 4]). Arm 3 is removed from study design as similar population is being evaluated in 
another Trishula protocol, TTX -030-002. 
Up to 43 subjects may be enrolled across the  dose-escalation and safety lead -in arms. Cohort 
expansions of n=25 subjects eac h in Arms 1 and 2 and n=up to 20 in Arm 4 . The number of 
subjects evaluated in the combination -therapy  safety lead -in Arm 4 may count toward the total 
number of subjects in an expansion cohort. Note: The sponsor  may choose not to open one of the 
safety lead -in arms and/or expansion cohorts.  
The study includes pretreatment ( screening  and baseline ), study treatment, treatment extension, 
and post -treatment (end -of-treatment and follow -up) periods.  
4.1.1.1.  Dose Escalation a nd Safety Lead -in 
Dose escalation (Arm 1) will be conducted according to a mCRM for doses up to 10 mg/kg (see 
Section  4.4 for details) and according to a traditional 3 + 3 design for doses > 10 mg/kg (see 
Section  4.7 for details) to estimate the dose -toxici ty relationship and determine the MTD 
(defined as the dose that has a model -estimated DLT rate closest to 30% and also has less than 
55% probability that the DLT rate exceeds 30%). The study will be overseen by a Cohort 
Review Committee.  
A DLT is defined as any clinically significant AE that occurs during Treatment Cycle 1, is 
considered related to TTX -030 as a single agent or the combination of TTX -030 and other 
agent(s), and meets the criteria outlined in Section  4.12. In Arm 1 dose escalation, f or the Q3W 
dose schedule, the DLT period will be the first cycle (21 days).  
In the safety lead -in Arm 2, the DLT evaluation period is 21-day (TTX -030 regimen given every 
3 weeks [Q3W ]) plus a 7 -day of loading dose . In the safety lead -in Arm 4, f or the Q2W dose 
schedule, the cycle length is 4 weeks and the DLT period will be 28-day (TTX -030 regimen 
given every 2 weeks [Q2W ]) plus a 7 -day of lo ading dose.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
54 
Safety and tolerability will be assessed by physical examination (including symptom -directed 
examinations), vital signs, and clinical laboratory tests and evaluated as the incidence, severity, 
duration, seriousness, type, and relationship of AEs that occur during the treatment and 
follow -up periods. Subjects will be followed for determination of AE incidence through  
through 90 days after the last dose of TTX -030 or until initiation of a new systemic anticancer 
therapy, whichev er occurs first . Clinical AEs will be graded according to the NCI CTCAE 
Version 5.0.  
TTX -030 will first be evaluated in monotherapy dose escalation (Arm 1). Once the RP2D of 
TTX -030 has been determined in the monotherapy dose -escalation arm, the combinatio n-therapy  
safety lead -in arms (Arms 2 and 4) can be initiated. For the safety lead -in arms, the TTX -030 
starting dose will be the RP2D identified during monotherapy dose escalation; de -escalation to 
1 dose level below the RP2D is permitted. Upon completion  of the dose -escalation and safety 
lead-in arms, each of those arms may have the option to enroll up to 20 to 25  additional subjects 
per expansion cohort. The number of subjects evaluated in the combination -therapy  safety 
lead-in Arm 4 may count toward the  total number of subjects in an expansion cohort.  
Dose escalation and safety lead -in arms are presented in Table 8, and dosing regimens are 
presented in  Table  11. Subjects in Arms 1  and 2, are to be dosed Q3W on a 21 -day schedule 
(Table 1/Table 2). Subjects in Arm 4 may be dosed Q2W on a 28 -day schedule (Table 3/Table 
4).  
As of Jan 2020, a RP2D was determined to be 40 mg/kg loading dose 7 days prior to Cycle 1 
Day 1, followed by either 30 mg/kg Q3W or 20 mg/kg Q2W.  
Enrollment will continue in the monotherapy dose -escalation arm (Arm 1) until the MTD is 
determined or the highest dose level has been reached and deemed safe by the Cohort Review 
Committee. The Cohort Review Committee may select interim dose levels as recommended by 
the mCRM for doses up to 10  mg/kg and by the 3  + 3 design fo r doses > 10 mg/ kg and  deemed 
appropriate.  
4.1.1.2.  Expansion Phase  
Once a dose level in the dose -escalation arm has been declared safe, that particular dose level 
may be expanded to further explore the PK/pharmacodynamics of TTX -030 in the  tumor cohorts 
listed bel ow (see Section 5 for disease -specific eligibility criteria for each cohort). A total of up 
to 90 subjects ( 20 to 25  subjects per cohort ) may be enrol led for PK/pharmacodynamic 
explorat ion. 
The expansion phase includes 3 arms , as described below. Multiple expansion cohorts may 
enroll in parallel.  
Arm 1 and 2 Expansion Cohorts  
In Arm 1 and 2 Expansion Cohorts, 50 subjects (25 subjects in each arm) with advanced or 
metastatic renal cell carcinoma with a clear -cell component and previously treated with anti-PD-
(L)1 therapy and tyrosine kinase inhibitor (TKI) therapy, will be randomized 1:1 to TTX -030 or 
TTX -030 and pembrolizumab . These agents will be administered at the doses and schedules 
identified in the safety lead -in. 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
55 
• Arm 1 Expansion : TTX -030 (n = 25)  
• Arm 2 Expansion : TTX -030 and pembrolizumab (n = 25)  
Expansion Arm  4 
In Expansion Arm 4, up to 20 subject s will receive TTX -030 40 mg/kg 7 -day prior to C1D1 , 
followed by 20 mg/kg  Q2W  in combination with gemcitabine + nab -paclitaxel  at a dosing 
schedule equivalent to that evaluated in the safety lead -in.  
• Expansion Arm 4: Histologically or cytologically confi rmed diagnosis of locally advanced, 
unresectable, or metastatic pancreatic adenocarcinoma, naïve to any prior treatment for 
metastatic disease. Prior adjuvant therapy (including chemotherapy and/or radiotherapy) is 
permitted if neoadjuvant or adjuvant ther apy was completed at least 6 months prior to study 
enrollment.  
4.1.2.  Cohort Review Committee  
The Cohort Review Committee is composed of study investigators, the sponsor’s medical 
monitor (or qualified delegate), and a statistician. Treatment cohorts will be dosed in escalating 
order as determined by the mCRM (for doses up to 10 mg/kg) or 3 + 3 des ign (for doses 
> 10 mg/kg) and with approval from the Cohort Review Committee, only after the safety of each 
dose level has been established, or until the MTD has been determined. Subsequent cohorts will 
not be dosed until safety data from the Study Treatm ent Period are obtained from subjects in the 
current cohort.  
A review of the safety data for each cohort will be conducted by the Cohort Review Committee. 
The Cohort Review Committee will be fully aware of clinical and laboratory data, the mCRM 
recommendat ion (where applicable), and will determine whether dose escalation to the next 
cohort is appropriate. Safety will be evaluated based on AEs, clinical laboratory test results, and 
other relevant clinical findings observed during the Study Treatment Period, as well as data from 
the Treatment Extension Period for prior cohorts. PK and pharmacodynamic data that are 
available will also be reviewed but are not required to make a dose -escalation decision.  
No dose escalation will take place until the Cohort Review Committee has reviewed the safety 
data and approved escalation. Cohort Review Committee evaluations will determine whether a 
DLT has occurred. Cohort Review Committee evaluations are also required to open combination 
treatment in Arms 2 through 4. The mCRM for doses up to 10 mg/kg and 3 + 3 design for doses 
> 10 mg/kg will be applied to each treatment arm independently; however, the Cohort Review 
Committee will be made aware of all safety data acros s all arms and cohorts. The Cohort Review 
Committee may choose to apply safety knowledge gained from one arm to more conservatively 
manage other arms.  
Any toxicity occurring within an earlier dose level after formal Cohort Review Committee 
review will be r eviewed by the Cohort Review Committee along with safety data from the 
current dose level and used to make decisions regarding further dose escalation.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
56 
4.2. Justification for Dose  in FIH study  
4.2.1.  Rationale for TTX -030 Starting Dose and Dosing Schedule  
To inform se lection of the starting dose for a FIH study, Trishula  will primarily employ the 
no-observed -adverse -effect level ( NOAEL) method from the Good Laboratory Practice ( GLP ) 
toxicology studies in non-human primates ( NHPs ) (FDA, 2005 ). Additionally , the 
pharmacologically active dose (PAD) method was used to independently calculate a starting dose 
value, with both methodologies arriving at similar dose levels.   
No adverse effects were observed in the non -GLP and GLP NHP multi -dose studies performed 
with TTX -030. As such, Trishula  proposes to calcul ate the maximum recommended starting dose 
(MRSD) for TTX -030 based on a 10 -fold safety factor over the NOAEL. A multi ple-dose GLP 
NHP study found no observed toxicities at a maximum dose level of 100 mg/kg, administered 
weekly for a total of 5 doses. The human equivalent dose (HED) based on the body size mg/kg 
scaling factor is calculated at 32.36 mg/kg. Coupled with a 1 0-fold safety factor, the resulting 
MRSD for TTX -030 is 3.23 mg/kg.  
A PAD level was calculated based on in vitro functional data to derive the FIH starting dose. In 
vitro human PBMC bioactivity assays (IL -2 release from stimulated PBMC in the presence of 
TTX-030) predict that a minimum exposure concentration of 10 µg/mL of TTX -030 is required 
to maintain efficacy ( Section 2.2.1.3.4 ). In this assay, the half maximal do se of TTX -030 needed 
for increased cytokine release was calculated at 19.37 µg/mL when 50 µM ATP was added to the 
culture and 23.3 µg/mL without the addition of exogenous ATP; cytokine release dropped off 
when TTX -030 concentration was below 10 µg/mL ( see Figure 6). By combining these in vitro  
results with exposure levels in NHP studies and allometric scaling from cynomolgus monkey to 
human, a 1.8 mg/kg Q3W HED do se was calculated as the PAD, which is almost 2 -fold lower 
than MRSD.  
A dose of 0.5 mg/kg given Q2W or Q3W is 2 to 3 dose levels below the predicted PAD dose and 
below the 10 -fold safety margin based on NOAEL. The FIH starting dose of 0.5 m g/kg Q3W 
initiated in the single -agent arm.  
4.2.2.  Selection of Agents in Combination with TTX -030 
TTX -030 is postulated to potentiate the effectiveness of each of these combination -therapy 
regimens.  
The backbone regimens chosen for each combination arm are appr oved and/or standard of care 
for several indications, and the regimens all have a well -character ized safety profile. TTX -030 
has a different mechanism of action from each of the regimens in the combination arms , and 
toxicities are anticipated to be managea ble and nonoverlapping.  
Treatment with pembrolizumab 200 mg every 21 days has been approved for multiple oncology 
indications , including melanoma, non -small -cell lung cancer, small -cell lung cancer, head and 
neck squamous cancer, classical Hodgkin lymphoma , primary mediastinal large B -cell 
lymphoma, urothelial carcinoma, MSI -H/MMR deficient malignancies, gastric cancer, 
esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, RCC , and 
endometrial carcinoma ( KEYTRUDA ®, 2019 ). 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
57 
Treatment with docetaxel 75 mg/m2 every 21 days is widely used in lung, breast, prostate, 
bladder, and other cancers ( TAXOTERE®, 2015 ).  
Treatment with gemcitabine 1000 mg/m2 + nab -paclitaxel 125 mg/m2 is widely used in treatment 
of metastatic pancreatic cancer ( GEMZAR® , 2017  and ABRAXANE®, 2018 ). 
4.3. Treatment Assignment  
This is an open -label study with multiple arms. At times, multiple arms may be enrolling in 
parallel. Investigators are responsible for contacting the sponsor, or delegate, for treatment 
assignment before treating subjects with TTX -030. The sponsor will have records of the number 
of subjects treated within a spec ific cohort and will determine which treatment cohort to assign 
the newly enrolled subjects.  
Subject’s treatment assignment/randomization may be done  in EDC  or alternative randomization 
system upon enrollment confirmation by the sponsor or designee. Subjec ts in Arm 1 and 2 
Expansion Cohorts will be randomized (as described in Section  4.1.1.2 ). A separate instruction 
manual  will be provided to each site. A subject is co nsidered entered into the study once the 
investigator  (or designee) confirms eligibility and notifies the sponsor that the subject is enrolled 
in the study.  
4.4. Dose Levels  
The doses for this trial will include a set of primary doses (0.5, 1.5, 3, 6, 10 , 20, and 40  mg/kg) 
as well as several intermediate doses. As mentioned above, dose escalation (Arm 1) will be 
conducted according to a mCRM for doses up to 10 mg/kg and according to a 3  + 3 design for 
doses > 10 mg/kg. Not all dose levels may be explored as dos e levels may be skipped during 
escalation based on mCRM recommendation. A detailed adaptive design and simulation report is 
included in Section  11.6. 
TTX -030 will first be evaluated  as a single agent  (Arm 1) . Subjects will be enrolled into the 
study sequentially beginning with a single -subject cohort at 0.5 mg/kg. Beginning with 
1.5 mg/kg,  subjects will be enrolled in dosing cohorts of 2 subjects each. If no Grade 2 toxicities 
(related to TTX -030) and no DLTs are observed, the trial may enroll 2 subjects each to the 
primary dose levels (1.5, 3, 6, 10 , 20, and 40  mg/kg). Upon the first insta nce of a DLT or a 
Grade 2 or above toxicity that is related to TTX -030, that cohort and subsequent cohorts 
receiving higher doses will enroll at least 3 subjects each. Each dosing cohort must complete its 
DLT observation period (see Section  4.12 for discussion of D LT) of 1 cycle before enrollment of 
the next dosing cohort.  
Based on  clinical data as of 10 Jan 2020 , a loading dose of 40 mg/kg one week prior to Cycle 1, 
Day 1 followed by dosing of 30 mg/kg Q3W or 20 mg/kg Q2W has been established .  See 
Section 2.2.3  for RP2D dose selection  details . 
Subjects who discontinue from the study for reasons other than a DLT ( eg, noncompliance, 
subject request, or disease progression), and are not evaluable for at least a single complete cycle 
of TTX -030 as single agent or  in combination, will be replaced. Subjects who discontinue after 
Cycle 1 will not be replaced.  For the cohort expansion, subjects will not be replaced.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
58 
4.5. Dose Escalation and Safety Lead -In Arms  
Up to 43 subjects across 1 dose escalation and 2 safety lead -in arms are planned.  The 3 arms are 
summarized in Table 8. 
Refer to Section  5 for details on subject eligibility.  
Table 8: Dose -Escalation and Safety Lead -In Arms  
 
Arm Monotherapy or 
Combination 
Therapy  Examples 
of Eligible 
Indications   
Treatment  Number of 
Subjects  
Dose -Escalation Arm  
1 Monotherapy  All tumors  TTX -030 Up to 21 
Safety Lead -In Arm  
2 Anti-PD-1 
Combination  Indicated 
tumors  TTX -030 with pembrolizumab  Up to 6 
4 Chemotherapy 
Combination  Pancreas  TTX -030 with gemcitabine + 
nab-paclitaxel  Up to 6 
Abbreviation: PD -1 = programmed cell death protein -1 
4.6. Dose Escalation Using Modified Continual Reassessment Method  
Dose escalation will be conducted according to the mCRM, with the aim of estimating the 
dose-toxicity relationship and determining the MTD. The MTD will be defined as the dose that 
has a model -estimated  DLT rate closest to 30% and has less than 55% probability of a DLT rate 
higher than 30%.  
The starting dose for TTX -030 will be 0.5 mg/kg. Ascending IV doses of TTX -030 as a single 
agent will be administered to subjects on the first day of each 21 -day treatment cycle. See 
Section 4.4 for dose levels.  
Subjects in Arm 1 will be enrolled sequentially beginning with a single subject at 0.5 mg/kg and 
followed by dosing cohorts of 2 subjects each. Upon the first instance of a DLT or a Grade 2 or 
above toxicity that is related to TTX -030, that cohort and subsequ ent cohorts receiving higher 
doses will be expanded to a minimum of 3 subjects each.  
Each dosing cohort must be completed through the DLT observation window before escalation 
can be allowed within its arm. After 1.5 mg/kg, untried dose levels may be skippe d if they are 
deemed safe by the dose -toxicity model and are no more than a 100% increase (a doubling) from 
the current dose. If the dose -toxicity model (described in Section  4.8) deems the current dos e to 
be unsafe and de -escalation is required, the dose will be decreased t o the highest safe dose level. 
Thus, if no DLTs are observed in Arm 1, the trial would enroll 1 subject to 0.5 mg/kg followed 
by 2 subjects each to 1.5 m g/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 20 mg/kg, and then proceed to the 
highest dose, 40 mg/kg.  
If the dose -toxicity model deems all doses up to 40 mg/kg to be safe, the Cohort Review 
Committee will have the option to dose escalate above 40 mg/kg, or a comparable flat dose, in  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
59 
appropriate increments (no more than a 100% increase) if it is felt a higher dose would be safe 
and potentially beneficial to study subjects.  
4.7. Dose Escalation Using 3  + 3 Design  
Escalation of doses > 10 mg/kg will pro gress according to a traditional 3  + 3 design. This design 
proceeds with cohorts of 3 subjects; the first cohort is treated at the starting dose , and subsequent 
cohorts are treated at increasing dose levels.  
• If none of the 3 subjects in a cohort experience s a DLT, dose escalation may proceed 
to the next higher dose level ( ie, another 3 subjects will be treated at the next higher 
dose level).  
• If 1 of the first 3 subjects in a cohort experiences a DLT, 3 more subjects will be 
treated at the same dose level.  
• Dose escalation continues until ≥  2 subjects in a cohort of 3 to 6 subjects experience 
a DLT ( ie, ≥ 33% of subjects with a DLT at that dose level). The MTD is defined as 
the dose level just below this toxic dose level.  
The recommended RP2D of TTX -030 was selected base d on the overall safety/tolerability and 
available PK/ pharmacodynamic  data. The RP2D may or may not be the same as the MTD 
identified during dose escalation. For example, if the MTD is not reached despite increasing drug 
dose, or if exposure at the MTD is much higher t han the level believed to be required for 
efficacy, or if subsequent cycles of treatment provide additional insight regarding the safety 
profile, then the RP2D may be a different dose.  
4.8. Dose -Toxicity Modeling  
Dose -toxicity modelin g will be used to estimate the log -odds of a DLT across the dose levels and 
to guide dose recommendation. The model is a 2 -parameter logistic regression model. Full 
details of the statistical model are provided in Section  11.6. 
4.9. Early Stopping  
The trial may be stopped early if all doses are considered unsafe (that is, if all doses have more 
than 55% probability that the DLT rate exceeds 30%). Conversely, the study may be stopped 
early for having sufficiently characterized the MTD if at least 6 subjects have been enrolled to 
the current highest safe dose level, have completed the DLT observation period, and additional 
dose escalation is not recommended. After the highest  safe dose level is identified, the Cohort 
Review Committee will have the option to explore a comparable flat dose.  
4.10. Initiation of Safety Lead -In Combination Therapies (Arms 2 & 4) 
Enrollment into combination Arms 2 and 4 will be initiated once the RP2D of TTX -030 has been 
determined in monotherapy dose escalation in Arm 1. For each of Arms 2 and 4, the TTX -030 
starting dose will be the RP2D identified in Arm 1.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
60 
In Arm 2, eligible pembrolizumab -naive subjects and other el igible subjects with pembrolizumab 
experience may be entered into the study. Subjects who tolerated prior PD -(L)1-containing 
regimens, and now want to try a new PD -(L)1 regimen again, can enter.  
Treatment in Arm 4 is planned to be TTX -030 in combination wi th separate chemotherapy 
regimens used for selected malignancies. The chemotherapy regimens suggested for combination 
with TTX -030 will be considered standard of care for the planned subject populations in the 
respective arms. Pembrolizumab will not be inc luded in Arm 4.  
In Arm 4, TTX -030 is planned to be administered with gemcitabine + nab -paclitaxel.  
In each safety lead -in cohort, all subjects will be treated and closely monitored for the occurrence 
of DLTs. If ≥ 2 of up to 6 subjects experience a DLT dur ing the DLT period, the Cohort Review 
Committee will discuss whether dose de -escalation to a lower dose of TTX -030 will be evaluated 
as appropriate and if further addition of subjects is needed to re -assess the RP2D.  
4.11. Maximum Tolerated Dose and Recommended Phase 2 Dose  
Dose escalation  (Arm 1)  will be conducted according to a mCRM for doses up to 10 mg/kg and 
according to a 3  + 3 design for doses > 10 mg/kg, with the aim of estimating the dose -toxicity 
relationship and determining the MTD. The MTD will be def ined as the dose that has a 
model -estimated DLT rate closest to 30% and has less than 55% probability of a DLT rate higher 
than 30%. Escalation will continue until the MTD has been determined for TTX -030 as a single 
agent or the highest dose level has been  reached and deemed safe by the Cohort Review 
Committee  using either the 3  + 3 design or mCRM . 
The RP2D may be defined as any dose level that is either explored using the mCRM or 3 + 3 
design or determined using PK modeling equal to or below the determined  MTD. The RP2D 
determination may also depend on PK, pharmacodynamic, efficacy, and other safety data as well 
as the MTD.  
4.12. Definition of Dose -limiting Toxicity  
A DLT is defined as any clinically significant AE that occurs during Treatment Cycle 1 that the 
investigator  or sponsor considers as possibly or likely related to TTX -030 as a single agent, or 
the combination of TTX -030 and other agent(s), and meets the following criteria: NCI CTCAE 
Version 5.0 Grade 5 event, Grade 4 hematological or ≥ Grade 3 non -hematological toxicities, or  
≥ Grade 3 irAEs. Laboratory abnormalities that are asymptomatic and deemed not clinically 
significant will not be regarded as a DLT, unless specified below.  
DLTs include the following:  
• Grade ≥ 3 neutropenia lasting ≥ 5 days  
• Any febrile neutropenia  
• Grade ≥ 3 thrombocytopenia with clinically significant hemorrhage  
• Grade 4 thrombocytopenia  
• Grade ≥ 3 non -hematologic adverse events, except the following  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
61 
- Grade ≥ 3 nausea, vomiting , or diarrhea lasting < 72  hours  in the absence of 
maxim al medical therapy.  
- Grade ≥ 3 abnormal laboratory values that are not clinically significant and 
corrected within 72  hours  
- Grade ≥ 3 fatigue lasting < 5 days  
- Grade 3 asparta te aminotransferase ( AST ) or alanine aminotransferase ( ALT ) 
elevations lasting < 7 days 
- Grade 3 non -hepatic -related increases in alkaline phosphatase will not be 
considered a DLT  
• AST or ALT >  3 x upper limit of normal ( ULN ) (> 2 x baseline AND >  3 x ULN in 
subject s with baseline elevation) AND total bilirubin >  2 x ULN (>  2 x baseline AN D 
> 2 x ULN in subject s with baseline elevation) or clinical jaundice, without initial 
findings of cholestasis AND no other immediately apparent identifiable possible 
causes of elevated liver enzymes and hyperbilirubinemia  
Safety data will be evaluated by the Cohort Review Committee (described in Section  4.1.2 ). 
Delayed DLTs will be evaluated on a case -by-case basis. If 2 or more delay ed DLTs are noted 
within a d ose-escalation/safety lead -in arms, further accrual will be held pending safety analysis 
of the AEs and  will be restarted only with Cohort Review Committee review and approval. For 
the Q3W dose escalation dosing schedule, the cy cle length is 3 weeks and the DLT period will 
be the first cycle (21 days). For the safety lead -in Q2W dosing schedule, the cycle length is 4 
weeks and the DLT period will be the first cycle (28 days)  plus a 7 -day of loading dose . 
For the safety lead -in Q3W dosing  schedule, the cycle length is 3 weeks and the DLT period will 
be the first cycle (21 days)  plus a 7 -day of loading dose . 
The DLT  must either return to the baseline  level at which the subject was enrolled or to a 
Grade  1 or less pr ior to subsequent administration of TTX -030 or a TTX -030 combination.  
If an AE does not meet the DLT criteria but  is deemed clinically significant and one that can 
require a change in the dosing interval, then the investigator is asked to contact the medic al 
monitor to develop a subject management plan. With mutual agreement, such a case may lead to 
the dosing interval being prolonged for an additional 21 days without the AE being deemed a 
DLT. If the AE leads to the dosing interval being extended beyond th e additional 21 days, then 
the event will be deemed a DLT.  
4.13. Dosing Delays  
During the dose -escalation/safety lead -in period, prolonging infusion times and treatment delays 
are allowed in response to treatment toxicity. Delays of more than one month necessita te medical 
monitor discussion and approval for continuation of therapy . 
Any necessary interim visits will be captured as unscheduled visits on the electronic case report 
form (eCRF).  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
62 
If toxicity is attributed by the investigator as likely related to TTX -030, the administration of 
TTX -030 should be managed per  Table 9. The dose adjustment criteria apply whether TTX -030 
is administered as a single agent or in combination therapy.  Please refer to Section  8.3.6.5  for 
details on adverse events of special interest , including immune -related adverse event (irAE ) 
management.  
4.14. Safety Criteria for Adjustment or Stopping Dose s 
If toxicity is attributed by the investigator as likely related to TTX -030, the administration of 
TTX -030 should be managed per Table 9. The dose adjustment criteria apply whether TTX -030 
is administered as a single agent or in combination th erapy. Please refer to Section  8.3.6.5  for 
details on toxicity management, including irAE management.  
If toxicity is attributed by the investigator as likely related to chemotherapy in the combina tion 
arms, and unlikely related to TTX -030, the subject  should be medically managed per standard of 
care, and the dose and schedule of chemotherapy should be managed per institutional guidelines. 
Administration of TTX -030 may continue as long as the invest igator feels TTX -030 is unlikely 
contributing to toxicity. If the subject  continues to experience significant toxicities despite 
medical management and after dose/schedule adjustment of chemotherapy, then TTX -030 must 
be managed per Table 9. 
If an irAE  is observed in Arm 2, the AE should be attributed to the combination of 
pembrolizumab and TTX -030, and not pembrolizumab alone. Management of pembrolizumab 
dosing should follow institutional guidelines. Management of TTX -030 should follow Table 9. 
Table 9: Criteria for Adjusting or Stopping Doses of TTX -030 
 Management/Next Dose for TTX -030 
≤ Grade 1  No change in dose; medical management per standard of care.  
Grade 2  If Grade 2 AE despite medical management, hold TTX -030 until ≤ Grade 1. 
Resume at same dose level.  
Grade 3  If Grade 3 AE despite medical management, hold TTX -030. Discontinuation 
or dose modification to be determined by investigator and Cohort Review 
Committee on a case -by-case basis.  
Grade 4  Discontinue TTX -030. 
4.15. Pharmacokinetic Criteria for Adjustment or Stopping Doses  
Toxicity -based dose escalation /safety lead -in decisions may depend on PK parameters like C max, 
Cmin, and AUC that correlate with desired target stimulation or suppression. For example, C max 
may correlate with toxicity and t 1/2 may predict recovery from toxicity. Available PK data will be 
reviewed by the Cohort Review Committee but is not required for dose escalation /safety lead -in 
decisions.  
4.16. Intra -subject Dose Escalation  
Subjects in their Treatment Extension Period may be eligible to receive study treatment at a 
higher dose level that has been deemed safe. If there are multiple successful dose escalations 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
63 
throughout the study, subjects who started with lower doses may be eligible for multiple 
intra-subject dose escalations  up to 40 mg/kg . Each case of intra -subject dose escalation must be 
approved by the Cohort Review Committee ( Section  4.1.2 ) and may not exceed the current 
highest dose level deemed safe. The first subject treated on the study at 0.5 mg/kg is the 
exception; in the absence of toxicity during their first cycle, the subject may initiate doses of 
1.5 mg/kg Q3W without prior approval from the Cohort Review Committee.  
Safety data from intra -subject dose escalation will not be assessed by the  mCRM or 3 + 3 
method but will be reviewed and assessed by the Cohort Review Committee.  
4.17. Expansion  Arms  
Upon completion of dose escalation  (Arm 1) and safety lead -in (Arms 2 and 4), each arm may 
have the option to enroll additional subjects per expansion co hort at the RP2D. Arm 1 and Arm 2 
Expansion Cohorts will enroll an additional 50 total subjects (25 per randomized treatment arm) , 
and Expansion Arm 4 will enrol l up to 2 0 subjects. The number of subjects evaluated in the 
safety lead -in of Arm 4 may count toward the total number of subjects in an expansion  arm. The 
sponsor will determine the eligible patient population for each expansion cohort after discussion 
with the Cohort Review Committee. Each dose -escalation and safety lead -in arm may lead to 
more than one expansion cohort if different patient populations will be studied.  
Monitoring of all safety and toxicity data are performed by the investigator and the Cohort 
Review Committee. The Cohort Review Committee may choose to apply safety knowledge 
gained from any arm or cohort to more conservatively manage other arms or cohorts.  
4.18. Retreatment Criteria  
After safely completing the Study Treatment Period, each subject may continue to receive dosing 
during the Treatment Extension Period until discontinuati on for any reason. Upon 
discontinuation, the subject has a Post -treatment Period that includes an End of Treatment ( EOT ) 
Visit, and post -treatment evaluations , including both follow -up safety and survival contact 
(Table 2 and Table 4). 
Arm 1 dose escalation has a 21 -day cycle.  
Arm 1  Expansion and Arm 2 have a 21 -day cycle  plus a 7 -day of loading dose . 
Arm 4 has a 28 -day cycle  plus a 7 -day of loading dose.  
4.19. Follow -Up Safety and Survival Contact  
Subjects will be followed for a minimum of 30 days from the last dose of TTX -030 (EOT Visit). 
Scheduled follow -up safety contact will be scheduled for 60 and 90 days after the last dose and a 
follow -up survival contact will be scheduled for  180 days after the last dose . 
Subjects removed from study for unacceptable AE(s) will be followed until resolution or 
stabilization of t he AE.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
64 
4.20. Study Completion  
A subject is considered to have completed the study if he or she has completed the 
protocol -defined activities f or the EOT Visit shown in the Schedule of Activities ( Table 2 and 
Table 4). 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
65 
5. Study P opulation  
5.1. Target Population and Arm -Specific Eligibility Criteria  
Arm 1 (Escalation) : Single -Agent TTX -030 Q3W 
1. Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy, 
or relapsed/refractory lymphoma, for which all standard therapies have been previously 
given . 
2. Meets all Common Inclusion and Exclusion Criteria below . 
Arm 2 (Safety Lead -In): Pembrolizumab 200 mg Q3W + TTX -030 Q3W  
3. Histologically confirmed diagnosis of unresec table or metastatic solid tumor malignancy, 
or relapsed/refractory lymphoma . 
4. Subjects must fulfill one of the following criteria:  
a) Eligible to receive single -agent pembrolizumab as standard of care . 
b) Received prior anti -PD-(L)1 containing regimen and had refractory or relapsed 
disease, for which all standard therapies have been previously given . 
5. Subject s who experienced immune -related or other AEs on prior anti -PD-(L)1 therapy 
that required discontinuation or modification are no t eligible for this study . 
6. Meets all Common Inclusion and Exclusion Criteria listed below . 
Arm 1 and 2 Expansion Cohorts  
Randomized 1:1 to TTX -030 Q3W or TTX -030 Q3W + Pembrolizumab 200 mg Q3W  
7. Histologically or cytologically confirmed diagnosis of advanced  (not amenable to 
curative surgery or radiation therapy) or metastatic (AJCC stage IV) RCC with a 
clear -cell component.  
8. Failed any anti-PD-(L)1 and TKI agents. Subjects refractory /relapsed  to an anti -PD-(L)1-
containing regimen must have confirmed radiographic disease progression no earlier than 
4 weeks after initial disease progression.  
Arm 4 (Safety Lead -In and Expansion ): Gemcitabine 1000 mg/m2 + nab -paclitaxel 
125 mg/m2 Days 1,  8, and 1 5 every 28  days + TTX -030 Q2W  
9. Histologically or cytologically confirmed diagnosis of locally advanced, unresectable, or 
metastatic pancreatic adenocarcinoma . 
10. Naïve to any prior treatment for metastatic disease. Prior adjuvant therapy (including 
chemotherapy and/or radiotherapy) is permitted if neoadjuvant or adjuvant therapy was 
completed at least 6 months prior to study enrollment.  
11. Eligible to receive gemcitabine + nab -paclitaxel as standard of care . 
12. Meets all Common Inclusion and Exclusion Criteria listed below . 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
66 
All Expansion Cohorts  
13. At least one tumor site (primary or metastasis) that is amenable to biopsy, and subject  
must be willing to consent for both pretreatment (screening) and on -treatment biopsy.  
14. Meets eligibility criteria for subject  population(s) specified by sponsor . 
15. Meets all Common Inclusion and Exclusion Criteria listed below . 
5.2. Common Inclusion Criteria  
16. Age 18 years or older and is willing and able to provide informed consent . 
17. Fresh and/or archival tumor tissue is optional for dose -escalation; fresh  and/or archival  
tumor biops ies at screening and on -treatment are mandatory for safety lead -in arms and 
expansio n cohorts.  
18. Evidence of measurable disease by CT, CT -positron -emission tomography (PET -CT) for 
dose escalation only , or MRI. (NOTE: Subject s with prostate cancer may instead have 
evaluable disease using bone scan per PCWG3 criteria and are not required to have 
Response Evaluation Criteria in Solid Tumors [RECIST] measurable disease.)  
19. Life expectancy >  12 weeks . 
20. Eastern Cooperative Oncology Gr oup (ECOG) performance status of 0 to 1 (see 
Appendix 2 ). 
21. Demonstrated adequate organ function, including:  
a. Oxygen saturation ≥ 92% on room air . 
b. Absolute neutrophil count  ≥ 1.5 k/μL, platelets (PLT) ≥ 75 k/μL (PLT ≥  100 k/ μL 
required for chemotherapy arms ), and hemoglobin (Hgb) ≥ 8 g/dL (Hgb ≥  9 g/dL 
for chemotherapy arms ). NOTE: Prior red blood cell transfusion is allowed.  
c. Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥  40 mL/min . 
d. AST/ALT ≤ 3 x ULN (or ≤ 5 x ULN wit h liver metastases) . 
e. Total bilirubin ≤ 1.5 x ULN (or ≤ 3 x ULN with Gilbert’s syndrome) . 
f. Prothrombin time (PT)/international normalized ratio (INR) and activated partial 
thromboplastin time (aPTT) ≤ 1.2 x ULN; fibrinogen ≥ 150 mg/dL . 
22. At least 14 days since last dose of chemotherapy or biological therapy, or tyrosine kinase 
inhibitor or high -dose ( eg, > 10 mg prednisone or equivalent) steroid therapy prior to first 
dose of study treatment . 
23. Resolution of adverse effects from any prior chemotherapy, immunotherapy, or prior 
systemic anti -cancer therapy, radiotherapy, or surgery to Grade 1 or baseline (except 
Grade 2 alopecia and Grade 2 sensory neuropathy) . 
24. Women of childbearing potential and all men must ag ree to use highly effective methods 
of birth control through 120 days after the last dose of study treatment . 
NOTE: Highly effective contraception methods include:  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
67 
- Total abstinence  
- Female sterilization (tubal ligation, bilateral oophorectomy, and/or 
hyster ectomy)  
- Male sterilization, at least 6 months prior to screening  
- Intrauterine device  
- Oral, injected, or implanted hormonal contraception AND barrier methods of 
contraception  
25. Willing to comply with and able to tolerate study procedures . 
5.3. Common Exclusion Cri teria   
26. History of allergy or hypersensitivity to study treatment components. Subject s with a 
history of severe hypersensitivity reaction to any mAb should also be excluded.  
27. Use of investigational agent within 14 days prior to the first dose of study tre atment and 
throughout the study . 
28. Prior surgery or radiotherapy within 14 days of study treatment . 
29. Receiving high -dose ( eg, > 10 mg prednisone or equivalent) systemic steroid therapy or 
any other form of immunosuppressive therapy within 14 days prior to the  first dose of 
study treatment. NOTE: inhaled, intranasal, intraocular, topical, and intraarticular steroids 
are allowed. Transient steroid administration as anti -emetic or chemotherapy  
preconditioning ( eg, for paclitaxel) is allowed per institutional guidelines.  
30. Receiving therapeutic anticoagulation. NOTE: Low molecular weight heparin, Factor Xa 
inhibitors, and low -dose aspirin are allowed for deep vein thrombosis (DVT) prophylaxis.  
31. History of autoimmune disease requiring systemic treatme nt or transplant that requires 
systemic steroids or immunosuppressive agents. NOTE: History of vitiligo, autoimmune 
thyroiditis, or mild psoriasis is allowed.  
32. Subjects who are on steroids for any irAE that has not resolved, Grade 3 or higher irAE, 
and ocul ar or neurologic toxicity of any grade.  
33. Known history of human immunodeficiency virus or other chronic immunodeficiency . 
34. Uncontrolled intercurrent illness including, but not limited to:  
a. Uncontrolled diabetes with hemoglobin A1c ( HgbA1c ) ≥ 8.0%  
b. Ongoing or active bacterial, viral, or fungal infection requiring systemic treatment  
c. Clinically significant congestive heart failure defined by New York Heart 
Association Class 3 or Class 4  
d. Unstable angina, arrhythmia, or myocardial infarction within 6 months prior t o 
screening  
35. Known brain metastases or central nervous system (CNS) involvement. NOTE: Subject s 
with asymptomatic and stable brain metastases following prior treatment may be eligible.  
36. Other active malignancy requiring ongoing treatment . 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
68 
37. Women who are pregnant or breastfeeding.  
38. For Arm 1 and 2 Expansion Cohorts  only (Renal Cell Cancer ): 
a.  Subjects with Lactate Dehydrogenase (LDH) ≥ 1.5x ULN   
5.4. Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently entered/enrolled in the study. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure subjects to meet the Consolidated 
Standards of Reporting Trials publishing requirements and to res pond to queries from regulatory 
authorities. Minimal information includes date of screening, informed consent, reason for screen 
failure (eg, eligibility criteria), and any SAEs.  
Individuals who do not meet the criteria for participation in this study (scr een failure) may be 
rescreened.  
5.5. Subject Adherence to Protocol Schedule  
General study instructions to be discussed or provided by the study staff:  
• Subjects must use highly effective birth control.  
o Women  of childbearing potential and all men should be counseled and must 
agree to use highly effective birth control during treatment through 120 days 
after the last dose of study treatment.  
• Subjects may not receive other investigational or approved anti -cancer  therapy while 
participating in this trial.  
• Subjects must come to the clinic on days defined in Table  1/Table 2, and Table  
3/Table 4 for study test procedures and post -study follow -up contact information.  
• From the first dose of TTX -030 until all procedures are completed on Cycle 2 Day 1, 
subjects should be instructed not to change their concomitant medications to the 
extent possible.  
• On dosing days, subjects should be discharged from the clinic with directions on 
self-administration of medications as needed to ameliorate pot ential delayed reactions 
(which should be described) to study treatment infusion.  
• Subjects should report any concerns of pregnancy immediately.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
69 
6. Investigational Product  
6.1. Investigational Product Description and Administration  
6.1.1.  Investigational Product Descripti on 
The investigational formulation of TTX -030 will be supplied as a sterile, single -use, 
preservative -free liquid containing 200 mg of antibody  (Table 10). The dosage form of TTX -030 
is a clear, colorless liquid formulation containing 30 mg/mL of TTX -030 in 10 mM sodium 
citrate, 280  mM sucrose, 0.02% polysorbate 20, and 1.0 mM methionine, with a pH of 6.5. The 
liquid TTX -030 will be filled into a Type 1 glass serum vial with an elastomeric stopper and 
aluminum over seal with a plastic flip top. The fill volume will be 6.7 mL in a 10-cc glass vial 
stored at temperatures of 2°C to 8°C. TTX -030 wil l be administered IV Q3W , Q2W , or Q4W 
depending on the study arm.  
Table 10:  Investigational Product  
Product name:  TTX -030 
Dosage form:  injection, solution in a vial  
Unit dose:  200 mg/15 mL (30 mg/mL)  
Route of administration:  intravenous infusion  
Physical description:  clear liquid in a serum vial with an elastomeric stopper  
Manufacturer:  ProBioGen AG  
6.1.2.  Other Study Treatments  
TTX -030 will be administered in combination with standard of care regimens for selected 
malignancies ( Table 8). Sites will obtain approved agents listed in Table  11 for combination 
therapy with TTX -030. Pembroliz umab will be provided by Trishula .  
6.1.3.  Investigational Product Administration  
TTX -030 can be admi nistered in an out patient  setting. The infusion should be administered 
under the supervision of a physician. Doses will be administered through an IV line controlled by 
a volumetric pump. TTX -030 should not be co -administered with other medications through  the 
same IV line during the TTX -030 infusion. TTX -030 doses of ≤ 20 mg/kg should be infused 
over 30  to 60  minutes , and TTX -030 doses of > 20 mg/kg may be infused over 60 minutes  (see 
Pharmacy Manual  for details ), unless otherwise revised by the study’s Cohort Review 
Committee. Subjects should be monitored for any infusion -related AE s for 8  hours after the first 
dose and for 1 hour after subsequent doses. If an infusion -related reaction  (IRR)  of Grade 3 or 
above occurs, the medical monitor  should be contacted prior to any further subject dosing.  It is 
recommended to have vital signs check every 1 -hour for 4 hours and then every 2 -hour based on 
clinical conditions.  Vital signs monitoring at subsequent dosing visits may occur as per 
Investigator’s di scretion.  
Monitoring of the subject  should include blood pressure, pulse, temperature, respirations, and 
pulse oximetry. Additionally, subject s should be monitored for infusion -related reactions such as 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
70 
rash, acute allergic reaction, bronchospasm, respirat ory distress, and acute vascular leak 
syndrome.  
Treatment will be administered as presented in  Table  11. Subjects in any combination treatment 
arm ma y receive premedication according to institutional practice.  
Table  11: Treatment Regimen Desc ription  
Arm  Treatment  Dose  Route  Schedule  
1a TTX -030 Loading dose  
40 mg/kg  IVb Day -7 
1 TTX -030 30 mg/kg  IVb  Q3W 
2a TTX -030 Loading dose  
40 mg/kg  IVb Day -7 
2 TTX -030 30 mg/kg  IVb  
 Q3W  
2 Pembrolizumab  200 mg  IVb,  
60 minutes  after TTX -030 Q3W  
4a TTX -030 Loading dose 
40 mg/kg  IVb Day -7 
4 TTX -030 20 mg/kg  IVb,  
prior to  nab-paclitaxel  Q2W  
Days 1 and 15 of 
each 28 -day cycle  
4 Nab-paclitaxel  125 mg/m2 IV over 30 -40 minutes,  
60 minutes  after TTX -030 and prior 
to gemcitabine  Days 1, 8, and 15 of 
each 28 -day cycle  
4 Gemcitabine  1000 mg/m2 IV over 30 -40 minutes , 
immediately after nab -paclitaxel  Days 1, 8, and 15 of 
each 28 -day cycle  
Abbreviations: IV = intravenous, Q = every, RP2D  = recommended Phase 2 dose, W = week(s) . 
a A loading dose of TTX -030 40 mg/kg  is to administer  on Day -7 prior to Cycle 1 Day 1.  
b Refer to the Pharmacy Manual for dosing  instruction.  Infusion duration is dependent on subject’s weight 
and IV bag size  and may be longer than 60 minutes.  
6.2. Preparation/Handling/Storage/Accountability  
The study treatment will be administered by the study personnel; the day and time of study 
treatment administ ration will be recorded by the study personnel.  
6.2.1.  Study Treatment Packaging and Labeling  
The study treatment will be packaged and labeled according to current Good Manufacturing 
Practice. Details of the packaging and labeling of clinical supplies may be foun d in the pharmacy 
manual.  
6.2.2.  Study Treatment Storage  
Cartons will be used for secondary packaging. Each carton will be labeled per regulations with 
the product name, product lot number, recommended storage condition, manufacturer, and the 
Federal Caution Stat ement “Caution: New Drug – Limited by Federal (US) Law to 
Investigational Use Only.” The sponsor’s name and address will also be included.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
71 
TTX -030 vials must be stored at a temperature of 2°C to 8°C and should be protected from light 
and freezing. If store d in a glass -front refrigerator, vials should be stored in the carton. 
Recommended safety measures for preparation and handling of TTX -030 include laboratory 
coats and gloves. After TTX -030 has been prepared for administration, the total storage time 
(comb ination of refrigeration and room temperature) is not to exceed 4 hours.  
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by the sp onsor. If 
concerns regarding the quality or appearance of the study treatment arise, do not dispense the 
study treatment and contact the sponsor immediately.  
6.2.3.  Study Treatment Preparation  
Steps for preparing the study treatment are provided in the pharmacy m anual.  
6.2.4.  Study Treatment Accountability  
The study treatment is to be used only as directed by this protocol. Clinical supplies are not to be 
dispensed to any individual who is not enrolled in the study. An accurate and timely record of the 
receipt of all clinical supplies and dispensing of study treatment to the subject will be 
maintained. This may include (a) documentation of receipt of clinical supplies, (b) study 
treatment dispensing/return reconciliation log, (c) study treatment accountability log, and  (d) all 
shipping service receipts.  
6.2.5.  Study Treatment Handling and Disposal  
If study treatments (those supplied by the sponsor or sourced by the investigator) are to be 
destroyed on site, it is the investigator’s responsibility to ensure that arrangements ha ve been 
made for the disposal ; procedures for proper disposal have been established according to 
applicable regulations, guidelines, and institutional procedures ; and appropriate records of the 
disposal have been documented. The unused study treatment may be destroyed only after being 
inspected and reconciled by the responsible study monitor.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
Only subjects in Arm 1 and Arm 2 Expansion Cohorts will be randomized (as described in 
Section  4.1.1.2 ) and treatment assignment will occur as descri bed in Section 4.3.  
This is an open -label study.  
6.4. Treatment  Compliance  
The study treatment will be administered by the study personnel; the day and t ime of study 
treatment administration will be recorded by the study personnel.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
72 
6.5. Concomitant Therapy  
6.5.1.  Concomitant Medications Allowed During the Study  
On dosing days, subjects should be discharged from the clinic with directions on 
self-administration of medications as needed to ameliorate potential delayed reactions to study 
treatment infusion, such as fever, chills, and myalgia. Medications may include antipyretics and 
antihistamines. All concomitant medications, including self -administered medications, are to be 
recorded.  Concomitant medications are to be collected from screening through 30 days after the 
last dose of study treatment.  
Inhaled, intranasal, intraocular, topical, and intraarticular steroids are allowed. Transient steroid 
administration as a nti-emetic or chemotherapy preconditioning ( eg, for paclitaxel) is allowed per 
institutional guidelines. Supportive care may be given as indicated after a subject experiences 
nausea, vomiting, fever, or diarrhea while on study treatment. Use of supportive care agents must 
be recorded.  Prednisone doses ≤ 10 mg (physiological doses) are permitted.  
Supportive treatments that are indicated for treatment of AEs should be given as medically 
required. Standard supportive medications may be used such as hematopoie tic growth factors to 
treat neutropenia or thrombocytopenia in accordance with American Society for Clinical 
Oncology guidelines.  
Concomitant medications may be necessary in the event of an acute infusion -related  reaction, 
cytokine release syndrome, or ano ther AE as detailed in Section  8.3.6.5.4 . 
Low molecular weight heparin, Factor Xa inhibitors, and low -dose aspirin are allowed for DVT 
prophylaxis.  
6.5.2.  Concomitant Medications Prohibited During the Study  
Concomitant treatments or procedures with any of the following are not allowed while the 
subject is receiving study treatment, unless approved by the sponsor, or as otherwise described in 
the protocol:  
• Any alternative drug treatments or procedures directed toward the treatment of solid 
tumors, including immunotherapy, chemotherapy, and radiation therapy. NOTE: 
Palliative radiation may be allowed during trial on a case -by-case basis – please 
discuss with the medical monitor.  
• Any investigational product, including investigational symptomatic treatment or 
procedures for solid tumors and investigational treatment or procedures for 
non-cancer indications.  
Any concomitant treatment  or procedure requir ed for the subject’s welfare may be given by the 
investigator. However, it is the responsibility of the investigator to ensure that details regarding 
the treatment or procedure are to be recorded.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
73 
7. Discontinuation of Study Treatment  and Subject Discontinuat ion 
7.1. Discontinuation of Study Treatment  
Treatment with TTX -030 may continue until precluded by toxicity, progression, or death.  
For combination arms, if a subject discontinues the pembrolizumab or chemotherapy regimens, 
treatment with TTX -030 may continue i f it remains well tolerated and if approved by the 
investigator  and sponsor . 
For all arms, in the absence of treatment delays due to AE(s), treatment may continue until 1 of 
the following criteria applies:  
• Disease progression (includes radiological or clinical progression).  
• Intercurrent illness that prevents further administration of treatment  
• Unacceptable AE  
• Subject decides to withdraw from the study  
• General or specific changes in the s ubject's condition that render the subject 
unaccept able for further treatment in the judgment of the investigator  
• Subject non -compliance  
• Pregnancy  
o All women of childbearing potential sh ould be instructed to contact the 
investigator immediately if they suspect they might be pregnant ( eg, missed 
or late mens trual period) at any time during study participation 
(see Section  8.3.6.4  for reporting requirements)  
• Termination of the study by sponsor  
• The drug manufacturer can no  longer provide the study treatment  
The reason(s) for protocol therapy discontinuation, the reason(s) for study removal, and the 
corresponding dates must be documented in the eCRF.  
7.2. Subject  Discontinuation/ Withdrawal from the Study  
Any subject can withdraw from the trial at any time.  
Reasons why a subject may discontinue or be withdrawn from the study include lack of efficacy, 
AE, DLT, death, withdrawal by subject, physician decision, study terminated by sponsor, 
protocol deviation, pregnancy, lost to follow -up, or other reasons not otherwise specified within 
this list.  
When a subject discontinues or is withdrawn from the study after receiving ≥ 1 dose of study 
treatment, the investigator will, when possible, perform the procedures indicated for the EOT 
Visit  (Table 2 and Table 4). 
The Sponsor  may terminate enrollment into Arm 1 of the Expansion Cohort (i.e. TTX -030 
monotherapy, see Section  4.1.1.2 ) should there be evidence of a lack of efficacy.  The totality of 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
74 
available data will be used to make this determination, however, should zero responders be seen 
out of the first 16 subjects th e 90% one -sided confidence interval (using exact methods) excludes 
a responder rate of 13.4% or more.  
Subjects who have been consented  or randomized  into Arm 1 before the termination  will 
continue to receive study treatment as per protocol.   
7.3. Lost to Follow -up 
A subject  will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  
The following actions must be taken if a subject  fails to return to the clinic for a required s tudy 
visit:  
• The site must attempt to contact the subject  and reschedule the missed visit as soon as 
possible and counsel the subject  on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject  wishes to and/or should continue in 
the study.  
• Before a subject  is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact with the subject  (where possible, 3 telephone calls and, if 
necessary, a certified letter to the subject ’s last known mailing address or local 
equivalent methods). These contact atte mpts should be documented in the subject ’s 
medical record.  
• Should the subject  continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
75 
8. Study Assessments and Procedures  
All screening  and baseline  assessments must be performed  prior to loading dose/first dose of 
TTX -030. 
Assessments done up to 3 days prior to the loading dose do not need to be repeated. Assessment 
results must be deemed acceptable before the subject is cleared to receive the first dose of study 
treatment.  
Unles s otherwise indicated, laboratory test collections are to be performed before the start of 
study treatment infusion on infusion days.  
COVID -19 guidance from applicable local regulatory authorities will be followed as  
necessary during the study in order to  ensure subject safety. Variance from the study  
assessments schedule may be permitted at the Sponsor’s discretion in consultation with the  
Investigator and will be documented accordingly.  
After safely completing the Study Treatment Period, each subject may  continue to receive dosing 
during the Treatment Extension Period until discontinuation for any reason. Upon 
discontinuation, the subject has a Post -treatment Period that includes an EOT Visit, and 
post-treatment evaluations including both follow -up safety  and survival contact ( Table 1/Table 2, 
and Table 3/Table 4). 
• Arm 1 (dose escalation) has a 21 -day cycle (Q3W) . 
• Arms  1 and  2 expansion  have a 21 -day cycle  (Q3W) plus a 7-day of loading dose . 
• Arm 4 has a 28 -day cycle  (Q2W) plus a 7-day of loading dose .  
8.1. Study Visits  
8.1.1.  Study Visits for Arms 1  and 2 Safety Lead -in and Expansion  
• Arm 1 treatment is TTX -030 as a single agent.  
• Arm 2 treatment is TTX -030 and pembrolizumab.  
Overview of Study Periods for Arms 1  and 2 (21 -Day Cycle)  
Pretreatment Period  
Pretreatment consists of screening  (up to 28 days prior to loading dose /first dose ) and baseline  
(up to 3  days prior to loading dose /first dose ). 
Study Treatment and Treatment Extension Period  
• A loading dose of TTX -030 40 mg/kg  is to administer  on Day -7 prior to Cycle 1 Day  1. 
• After the loading dose, TTX -030 30 mg/kg will be administered every 21 da ys, on Day  1 
of each cycle.  
• Cycle 1 includes assessments on Day 1, Cycle  1 Day  1 (C1D1) (dosing), Day 2, C1D2; 
Day 3, C1D3; Day  8, C1D8; and Day 15, C1D15.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
76 
• Cycle 2 includes assessments on Day 22 + 2 days, C2D1 (dosing) and Day 29 ± 2 days, 
C2D8.  
• Treatment  Extension Period begins with Cycle 3, with treatment on Day 43 ± 2 days, 
C3D1 (dosing), followed by Cycle s 4+, Day 64 ± 2 days, C4D1 (dosing), and every 
21 days thereafter, with dosing on Day 1 of each subsequent cycle.  
Post-treatment P eriod  
• The Post -treatment Period includes the EOT Visit at 30 ± 7 days after the last dose, 
follow -up safety contact at 60 and 90 ± 7 days and a follow -up survival contact at 
180 ± 15 days after last dose.  
8.1.2.  Study Visits for Arm 4 (TTX -030 Q2W , 28-Day Cycle ) 
Arm 4 treatment is TTX -030 and nab -paclitaxel + gemcitabine . 
Overview of Study Periods for Arm 4 (28 -Day Cycle)  
Pretreatment Period  
Pretreatment consists of screening  (up to 28 days prior to loading dose /first dose ) and baseline  
(up to 3  days prior to loading do se/first dose ). 
Study Treatment and Treatment Extension Period  
• A loading dose of TTX -030 40 mg/kg is to administer  on Day -7 prior to Cycle 1 Day 
1. 
• After the loading dose, TTX -030 20 mg/kg will be administered every 14 days, on 
Day 1 and Day 15 of each cy cle.  
• Cycle 1 includes assessments on Day 1, C1D1 (dosing); Day 2, C1D2; Day 3, C1D3; 
Day 8, C1D8  (Gem/NP dosing  only); Day 15, C1D15 (dosing); and Day 22, C1D22.  
• Treatment Extension begins with Cycle 2, with treatment on Day 29 + 2 days, C2D1 
(dosing) , Day 36 ± 2 days , C2D8 ( Gem/NP dosing  only) and Day 43 ± 2 days, 
C2D15 (dosing), and every 14 days thereafter, with TTX -030 dosing on Day 1 and 
Day 15 of each subsequ ent cycle.  
• Treatment Extension continues with Cycle 3, with treatment on Day 57 ± 2 days, 
C3D1 (dosing) , Day 64 ± 2 days, C3D8 ( Gem/NP dosing  only) and Day 71 ± 2 days 
C3D15 (dosing), followed by Cycle s 4+, with treatment on Days 1, 8 ( Gem/NP 
dosing only) and 15  thereafter.  
Post-treatment Period  
• The Post -treatment Period includes the EOT Visit at 30 ± 7 days after the last dose, 
follow -up safety contact at 60 and 90 ± 7 days , and a follow -up survival contact at 
180 ± 15 days after last dose.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
77 
8.2. Efficacy Assessments  
8.2.1.  Tumor Assessment/ Tumor Response Assessment  
Tumor response assessments will be performed as scheduled in Table 1/Table 2, and Table 
3/Table 4.  
Radiological assessment s for subjects with solid tumors include CT scans of the chest, abdomen, 
and pelvis  unless contraindicated . Subjects with prostate cancer will also require bone scans. 
Subjects with lymphoma may be assessed with CT or PET -CT; however, the method for each 
subject’s radiology assessments should remain consistent.  
8.2.1.1.  Criter ia for Response Assessment for Solid Tumors  
To evaluate early signs of activity, iRECIST will be used for solid tumors. Response criteria to 
be determined by the investigator are found in Appendix 3 (Section  11.3).  
Additional response criteria for subject s with prostate cancer are found in Appendix 4  
(Section  11.4).  
Lymphoma will be assessed per LYRIC (see Section  8.2.1.2 ).   
For immunotherapeutics, response assessment may be confounded by a delayed onset of clinical 
effect of these agents allowing for early tum or growth or even the appearance of new lesions 
known as pseudo -progression. Efforts have been made to modify standard response criteria to 
account for the impact of immunotherapeutics on anti -tumor activity  with the utilization of 
iRECIST for solid tumor and LYRIC for lymphoma to evaluate tumor response.  
In an attempt to apply response criteria and optimize response assessments with the use of 
immunotherapeutics, the RECIST Version 1.1 criteria have been modified to include an 
immune -related progressive d isease response category in iRECIST. The addition of the immune 
response (IR) category to the more standard RECIST for solid tumors may provide information 
to the immune response as well as distinguish delayed responses and capturing pseudo 
progression (fl are reaction). A comparison of RECIST and iRECIST response criteria for solid 
tumor is provided in  Section  11.3 (Appendix 3). 
8.2.1.2.  Criteria for Response Assessment for Lymphoma  
Subjects with lymphoma should have their response assessments conducted per LYRIC. 
Response criteria to be determined by the investigator are found in Section  11.5 (Appendix 5). 
The current Lugano criteria have been used for more traditional therapies in lymphoma. The 
proposed provisional modification, LYRIC, for immunomodulatory agents has introduced the 
term “IR”. The term “IR” does not make a  direct reference to the underlying mechanism, 
acknowledging that both a delayed response and an immune -mediated flare (“pseudo 
progression”) can occur in the early treatment period and may be challenging to differentiate 
from progression by physical exami nation or imaging alone. The term provides the flexibility to 
allow subjects to continue treatment past IR in some circumstances with a mandatory subsequent 
evaluation within 12 weeks to confirm or refute true progressive disease.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
78 
A comparison of response based on PET -CT and CT evaluations is provided in  Section  11.5 
(Appendix 5 ). Exceptions to Lugano for the LYRIC response assessments accounting for a 
development of a flare reaction (“pseudo -progression”) and a true progressive disease are 
provided in Section  11.5 (Appendix 5). 
For details on the response criteria and evaluations for lymphomas , see Cheson et al.  2014  and 
Cheson et al.  2016 . 
8.3. Safety Assessments  
8.3.1.  Demographic/Medical History  
Subject demographics and baseline characteristics (including age, sex, race, ethnicity, weight and 
height, disease information, and medical conditions) are to be summarized at screening . 
8.3.2.  Physical Examinations  (Including Symptom -focused Examination)  
A physi cal examination requires assessment of all major body systems to evaluate any new 
clinically significant abnormalities within the following: general appearance, skin, 
head/eyes/ears/nose/throat, neck, heart, lungs, abdomen, extremities, back/spinal, and ly mph 
nodes. This includes worsening of baseline conditions.  
For a symptom -focused examination, only the relevant or affected body system(s) must be 
examined and a full physical examination is not required.  
8.3.3.  Vital Signs  
Sitting blood pressure, pulse rate, res piratory rate, and oral temperature will be measured after 
the subject has been resting for at least 5 minutes. Arterial oxygen saturation will be measured by 
pulse oximetry.  
8.3.4.  Electrocardiograms  
Electrocardiograms (ECGs) will be obtained via 12 -lead ECGs at screening  with the subject in 
semi -recumbent position after 5 minutes of rest. The investigator may perform additional 
unscheduled ECGs to manage or evaluate a suspected AE as clinically necess ary. Unscheduled 
ECGs will be documented.  
8.3.5.  Laboratory Assessments  
Blood samples will be collected for clinical laboratory testing, including complete blood count 
(CBC), chemistry, coagulation, and other tests. Clinical laboratory tests are summarized in  Table 
12. 
Additional or repeated clinical laboratory testing may be performed while on treatment as 
clinically indicated by the investigator. Laboratory assessments may be performed up to 3 days 
prior to the dosing visit specified in Table 1/Table 2, and Table 3/Table 4. Visits conducted 
outside the windows are to be discussed with the medical monito r (or designee). On treatment 
days, samples for clinical laboratory testing sh ould be drawn prior to the infusion.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
79 
Table 12: Clinical Laboratory Tests  
Hematology Tests  Coagulation Tests  
RBC count  PT/INR  
Hgb PTT 
Hematocrit  Fibrinogen (within 14 days of dosing)  
WBC count  Other  
Neutrophils  Serum pregnancy  
Lymphocytes  HgbA1c (at screening  only)  
Monocytes  Creatinine clearance (at screening ) 
Basophils  Thyroid function tests: TSH, T3, free T4, thyroid 
antibody (at baseline , at the loading dose /first 
dose, and every 3 months thereafter)  
Eosinophils  ACTH (at baseline  only)  
PLT FSH (at baseline  only)  
Chemistry Tests  LH (at baseline  only)  
  Sodium  GH (at baseline  only)  
Potassium  Amylase (at baseline  only)  
Chloride  Lipase (at baseline  only)  
Bicarbonate    LDH  (at screening  only)  – for RCC  
Glucose   
Creatinine   
ALT  
AST  
ALP  
GGT   
Lactate dehydrogenase   
Total bilirubin   
Total protein   
Albumin   
BUN   
Calcium   
Phosphorous   
Magnesium   
Creatine kinase   
Uric acid   
Abbreviations: ACTH = adrenocorticotropic hormone, ALT = alanine aminotransferase, ALP = alkaline 
phosphatase, AST = aspartate aminotransferase, BUN = blood urea nitrogen, FSH = follicle -stimulating 
hormone, GGT = gamma -glutamyl transferase, GH = growth hormone, Hgb = hemoglobin, 
HgbA1c  = hemoglobin A1c, INR = international normalized ratio, LH  = luteinizing hormone, PLT = platelets, 
PT = prothrombin time, PTT = pa rtial thromboplastin time, RBC  = red blood cell, TSH = thyroid stimulating 
hormone, WBC = white blood cell , Lactate dehydrogenase (LDH) . 
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
80 
8.3.5.1.  Hematology  
Hematology assessments are included in the clinical laboratory assessments in  Table 1/Table 2, 
and Table 3/Table 4. 
8.3.5.2.  Blood Chemistry  
Chemistry is included in the clinical laboratory assessments in the Table 1/Table 2, and Table  
3/Table 4. 
8.3.5.3.  Urinalysis  
Urinalysis is not required for this study but allowed for pregnancy testing.  
8.3.5.4.  Virus Serology  
Virus serology is not required.  
8.3.5.5.  Drug Screen  
Drug screen is not required.  
8.3.5.6.  Pregnancy Screen  
For women of childbearing potential, pregnancy test (serum or urine, per institutional practice) 
will be administered at screening , baseline , and on C2D1 and the first day of each subsequent 
cycle.  
8.3.6.  Adverse Events an d Serious Adverse Events  
Any subject who receives at least 1 dose of study treatment will be included in the evaluation for 
safety. Safety will be assessed by physical examinations, vital signs, and laboratory assessments. 
Safety will also be evaluated usi ng the proportion of subjects requiring modifications of the 
infusion schedule . 
Safety and tolerability will be evaluated by the incidence, severity, seriousness, type, and 
causality of AEs that occur during the treatment and follow -up periods.  
The incide nce of AEs and SAEs will be evaluated for each dose level and for all subjects 
combined. Subjects are to be followed for AEs that begin or worsen after start of study treatment 
through EOT or 90 days (± 7 days) after the last dose of study treatment, which ever is later.  
“Lack of efficacy” or “failure of expected pharmacological action” per se will not be reported as 
an AE or SAE; nor will progressive disease. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or c linical sequelae resulting from lack of 
efficacy will be reported as AE or SAE if they fulfill the definition of an AE or SAE.  
Clinical AEs will be graded according to the NCI CTCAE Version 5.0. Adverse events are to be 
monitored and collected for the dura tion of study treatment until 90 days after the last dose.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
81 
8.3.6.1.  Definition of Adverse Events  
8.3.6.1.1.  Adverse Event  
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related.  
An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign 
(eg, an abnormal laboratory finding), symptom, or disease temporally associated with the use of 
a treatment and  does not imply any judgment about causality. An AE can arise with any use of 
the treatment  (eg, off-label use, use in combination with another treatment) and with any route of 
administration, formulation, or dose, including an overdose.  
All AEs that occur after any subject has been enrolled, before treatment, during treatment, or 
within 90 days following the cessation of treatment, whether or not the events are related to the 
study, must be recorded on the eCRF provided by the sponsor.  
8.3.6.1.2.  Suspected Adverse Reaction  
Suspected adverse reactions are a subset of all AEs for which there is r easonable possibility that 
the treatment caused the AE. Reasonable possibility means that there is evidence to suggest a 
causal relationship between the treatment  and the AE. A suspected adverse reaction implies a 
lesser degree of certainty about causality  than adverse reaction, which means any AE caused by a 
treatment.  
The principal investigator is responsible for determining whether there is a reasonable possibility 
that the treatment caused the AE and  will capture the causality assessment in the eCRF.  
8.3.6.1.3.  Adverse Reaction  
An adverse reaction is any AE caused by a treatment. Adverse reactions are a subset of all 
suspected adverse reactions where there is reason to conclude the treatment caused the event.  
8.3.6.1.4.  Unexpected  
An AE or suspected adverse reaction is considered “unexpected” if it is not listed in the IB or is 
not listed at the specificity or severity that has been observed. The sponsor is responsible for 
determining whether an event meets the definition of “unexpected,” based on adverse reactions 
listed in the sponsor’s IB.  
8.3.6.1.5.  Serious Adverse Event  
An SAE is an AE occurring during any study period (baseline, treatment, washout, or follow -up), 
and at any dose of the study treatment, comparator, or placebo, that fulfils 1 or more of the 
following:  
• It result s in death  
• It is immediately life -threatening  
• It requires in -patient hospitalization or prolongation of existing hospitalization  
• It results in persistent or significant disability or incapacity  
• It results in a congenital abnormality or birth defect  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
82 
• It is an important medical event that may jeopardize the subject or may require medical 
intervention to prevent 1 of the outcomes listed above  
All SAEs that occur after any subject has been enrolled, before treatment, during treatment, or 
within 90 days followin g the cessation of treatment, whether or not they are related to the study, 
must be recorded on eCRF provided by the sponsor.  
8.3.6.1.6.  Further AE and SAE Definitions  
Wherever possible, a specific disease or syndrome rather than individual associated signs and 
sympt oms should be identified. However, if an observed or reported sign or symptom is not 
considered a component of a specific disease or syndrome by the investigator, it should be 
recorded as a separate AE. Laboratory data are to be collected as stipulated in this protocol. 
Clinical syndromes associated with laboratory abnormalities are to be recorded as appropriate 
(eg, diabetes mellitus rather than hyperglycemia).  
Scheduled hospitalizations or elective surgical procedures will not be considered as AEs or 
SAEs . Complications associated with scheduled procedures are considered AEs or SAEs.  
An abnormal test finding will be classified as an AE if one or more of the following criteria are 
met: 
• The test finding is accompanied by clinical symptoms.  
• The test finding n ecessitates additional diagnostic evaluation(s) or medical/surgical 
intervention; including significant additional concomitant treatment or other therapy. 
NOTE: Simply repeating a test finding, in the absence of any of the other listed criteria, 
does not c onstitute an AE.  
• The test finding leads to a change in study treatment dosing or discontinuation of subject 
participation in the clinical research study.  
• The test finding is considered an AE by the investigator.  
8.3.6.1.7.  Other Adverse Event  
Other AEs will be ident ified by the sponsor and, if applicable, also by the Clinical Study Team 
Physician during the evaluation of safety data for the clinical study report. Significant AEs of 
particular clinical importance, other than SAEs and those AEs leading to discontinuati on of the 
subject from the study, will be classified as other AEs. For each other AE, a narrative may be 
written and included in the clinical study report.  
8.3.6.2.  Relationship to Study Treatment  
An investigator who is qualified in medicine must make the determina tion of relationship to the 
investigational product for each AE (unrelated, possibly related, or probably related). The 
investigator should decide whether, in his or her medical judgment, there is a reasonable 
possibility that the event may have been cause d by the study treatment. If no valid reason exists 
for suggesting a relationship, then the AE should be classified as “unrelated.” If there is any valid 
reason, even if undetermined, for suspecting a possible cause -and-effect relationship between the 
study treatment and the occurrence of the AE, then the AE should be considered “related.”  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
83 
If the relationship between the AE/SAE and the study treatment is determined to be “possible” or 
“probable ,” the event will be considered to be related to the study treat ment for the purposes of 
expedited regulatory reporting.  
8.3.6.3.  Recording Adverse Events  
Adverse events spontaneously reported by the subject and/or in response to an open question 
from the study personnel or revealed by observation will be recorded during the st udy at the 
investigational site. Clinically significant changes in laboratory values, blood pressure, and pulse 
need not be reported as AEs. However, abnormal values that constitute an SAE or lead to 
discontinuation of administration of study treatment mus t be reported and recorded as an AE. 
Information about AEs will be collected from the signing of consent form until the end of the 
study. Serious adverse event information will be collected from signing of consent form until 
90 days following the last dose  of study treatment. The AE term should be reported in standard 
medical terminology when possible. For each AE, the investigator will evaluate and report the 
onset (date and time), resolution (date and time), intensity, causality, action taken, serious 
outcome (if applicable), and whether or not it caused the subject to discontinue the study . 
Adverse event grading will be defined by the NCI CTCAE Version 5.0. In the event the NCI 
CTCAE Version 5.0 criterion does not apply, the general severity descriptions of mild, moderate, 
severe, life -threatening and death will be used as listed below by NCI CTCAE:  
Grade 1 Mild : asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2 Moderate : minimal, loc al, or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living .a 
Grade 3 Severe or medically significant but not immediately life -threatening : 
hospitalization or prolongation of hospitalization indicated; disab ling; limiting self -care 
activities of daily living .b 
Grade 4 Life -threatening consequences : urgent intervention indicated.  
Grade 5 Death related to AE.  
a Instrumental activities of daily living  refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  
b Self-care activities of daily living  refer to bathing, dressing, and undressing; feeding self; using the toilet; 
taking medications; and not bedridden.  
It is important to distinguish between serious and  severe AEs. Severity is a measure of intensity , 
whereas seriousness is defined by the criteria under Section 8.3.6.1.5 . An AE of severe intensity 
may not be considered serious.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
84 
8.3.6.3.1.  Pregnancy  
Should a pregnancy occur, it must be reported to and recorded by the sponsor. Pregnancy in itself 
is not regarded as an AE unless there is a suspicion that a study treatment may have interfered 
with the effectivenes s of a contraceptive medication.  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth, or 
congenital abnormality) must be followed up and documented even if the subject was 
discontinued from the study.  
All reports of congenital abnormalities/birth defects are SAEs. Spontaneous miscarriages should 
also be reported and handled as SAEs. Elective abortions without complications should not be 
handled as AEs.  
8.3.6.4.  Reporting Adverse Events  
All AEs (e.g., including COVID -19 symptom s) and SAEs will be collected from the time the  
subject signs informed consent through 90 days after the last dose of TTX -030 or until initiation 
of a new systemic anticancer therapy, whichever occurs first. Positive COVID -19 test result will 
be collected as a medical event and submitted as SAE .  
 
Any SAEs considered possibly or probably related to the study treatment and discovered by the 
investigator at any time after the study should be reported. All SAEs must be reported to the 
sponsor within 1 business  day of the first awareness of the event. The investigator must 
complete, sign, and date the SAE pages ; verify the accuracy of the information recorded on the 
SAE pages with the corresponding source documents ; and send a copy to the contact information 
listed on the SAE forms .  
Additional follow -up information, if required or available, should all be faxed to the sponsor 
within 1 business day of receipt , and this should be completed on a follow -up SAE form and 
placed with the original SAE information and ke pt with the appropriate section of the eCRF 
and/or study file.  
The sponsor is responsible for notifying the relevant regulatory authorities of certain events. It is 
the investigator’s responsibility to notify the Institutional Review Board ( IRB) or Indepen dent 
Ethics Committee ( IEC) of all SAEs that occur at his or her site. Investigators will also be 
notified of all unexpected, serious, treatment -related events (7/15 Day Safety Reports) that occur 
during the clinical trial. Each site is responsible for not ifying its IRB or IEC of these additional 
SAEs.  
8.3.6.4.1.  SAE Reporting  
The investigator is obligated to report immediately to the sponsor or designee each SAE that 
occurs during this study, within 24 hours from knowledge of the event, whether or not it is 
considered study treatment related. All requested supplementary documen ts (eg, discharge 
summary and autopsy report)  and relevant data ( eg, ECGs, laboratory tests, discharge 
summaries, and postmortem  results) must be faxed to the  number on the SAE form  within 
24 hours after available to the sponsor or sponsor’s designee. If any questions or considerations 
regarding SAE arise, the sponsor’s medical monitor or designee should be consulted.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
85 
The information provided in a SAE report should be as complete as possible, but contain a 
minimum of the following:  
• A short des cription of the AE (diagnosis) and the reason why the AE was categorized as 
serious  
• Subject identification and treatment  
• Investigator’s name and phone number (if applicable)  
• Name of the suspect medicinal product and dates of administration  
• Assessment of c ausality  
If all information about the SAE is not yet known, the investigator will be required to report any 
additional information within  24 hours as it becomes available.  
All SAEs will be evaluated by the sponsor’s medical monitor or designee.  
The invest igators must notify their governing IRB of any SAEs.  
8.3.6.4.1.1. Serious and Unexpected Suspected Adverse Reaction  
For any suspected adverse reaction that is both serious and unexpected (not documented in the 
IB or package insert), an Investigational New Drug (IND) sa fety report or revision to the IB may 
be issued to inform all investigators involved in any study with the same study treatment.  
8.3.6.4.2.  Post-treatment Safety Follow -up 
In this study, all AEs occurring after the informed consent is signed will be captured on the 
eCRF. All subjects should be instructed to report AEs or SAEs occurring up to 30 (± 7) days 
after the last dose of study treatment. Unresolved study treatment -related AEs and SAEs at the 
time of treatment discontinuation, or new study treatment -related AEs and SAEs that occur 
during the 30 -day postdose  timeframe, will be followed until they have, in opinion of the 
investigator, resolved to baseline, have stabilized, or are deemed to be irreversible.  
8.3.6.5.  Adverse Events of Special Interest  
8.3.6.5.1.  Adverse Events from Com mercial Study Agents  
For AEs related to any of the commercially available agents used in combination treatment in 
this study, please refer to the discussion in Sectio n 4.2.2  and the individual package inserts 
referenced ther e. 
8.3.6.5.2.  Infections  
Follow National Comprehensive Cancer Network guidelines for the prevention and treatment of 
cancer -related infections ( Baden et al.  2012 ).  
8.3.6.5.3.  Tumor Lysis Syndrome  
Tumor lysis syndrome (TLS) is defined by both laboratory criteria and by clinical features. It 
most commonly occurs after initiation of cytotoxic  therapy in individuals  with aggressive 
lymphomas and acute lymphoblastic leukemia but can occur spontaneously and with other tumor 
types that have high proliferate rate or large tumor burden.  
 TTX-030-001 Version 8 (Decemb er 15, 2020 ) 
CONFIDENTIAL  
 
86 
For individuals  who are at risk for TLS, please monitor and se lect prophylaxis methods based on 
institutional guidelines. Guidelines commonly include IV hydration, hypouricemic agents ( eg 
allopurinol, rasburicase), frequent monitoring of urine output, and serial assays of electrolytes 
and serum uric acid.  
The followi ng algorithmic approach to risk assessment and monitoring of tumor lysis syndrome 
should also be used as guidance (Figure 11): 
 TTX-030-001 Version 8 (December  15, 2020)  
CONFIDENTIAL  
 
87 
Figure 11: Algorithmic Approach to Risk Assessment of Tumor Lysis Syndrome  

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
88 
8.3.6.5.4.  Cytokine Release Syndrome  
Cytokine release syndrome (CRS) is a potentially severe immune reaction that may occur in 
response to immunotherapies. The largest risk factor is high tumor load. Symptoms may include 
high fevers, rigors, myalgia, headache, nausea, vomiting, malaise, hypot ension, rash, dyspnea, 
hypoxia, and tachycardia. Elevations in serum aminotransferases and bilirubin can be seen, and, 
in some cases, disseminated intravascular coagulation, capillary leak syndrome, and 
hemophagocytic lymphohistiocytosis -like syndrome have  been reported.  
Management of CRS depends on the severity and may include interruption of the infusion, 
discontinuation of therapy, symptomatic treatment, IV fluids, and ventilator and/or pressor 
support, as well as corticosteroids and anti -cytokine thera py (Lee et al.  2014 ). Vigil ant 
supportive care is recommended including empiric treatment of concurrent bacterial infections 
and maintenance of adequate hydration and blood pressure for every subject  regardless of CRS 
grade.  
The following treatment algorithm for management of CRS i s recommended by Lee et al.  2014 : 
 
In the event of an acute infusion -related  reaction/CRS, the infusion of study treatment will be 
stopped,  and the subject will be closely monitored until resolution of the reaction. Drugs that 
may be used to facilitate resolution and permit resumption of study treatment administration 

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
89 
include epinephrine and oth er vasopressors, acetaminophen, antihistamines 
(eg, diphenhydramine), opiates for pain ( eg, short -term meperidine), supplemental oxygen, IV 
fluids, and corticosteroids.  For acute infusion -related  reactions less than Grade 3, resumption of 
study treatment a dministration at a slower infusion rate may be considered at the investigator’s 
discretion.  
Cytokine release syndrome may have a delayed onset following the completion of the infusion. 
Study subjects must be instructed to contact their study site immediate ly if they develop a fever.  
The lack of any clinical symptoms related to CRS in Trishula  cynomolgus monkey PK studies 
may indicate a low potential for this effect. However, serum cytokine levels were monitored after 
the first and last administration of TTX -030 in the GLP cynomolgus monkey safety study.   
8.3.6.5.5.  Immune -related Adverse Events  
(Content for this section has been adapted from UpToDate, Postow M;Wolchok J, 2018 .) 
Checkpoint inhibition is associated with irAEs, including dermatologic, gastrointest inal, hepatic, 
endocrine, and other inflammatory events. These irAEs are typically transient but occasionally 
can be severe or life -threatening. In general, treatment of moderate or severe irAEs requires 
interruption of the checkpoint inhibitor and the use  of corticosteroid immunosuppression. 
Treatment is based upon the severity of the observed toxicity.  
• For subject s with Grade 2 (moderate) immune -mediated toxicities, treatment with the 
checkpoint inhibitor should be withheld and should not be resumed unti l symptoms or 
toxicity is Grade 1 or less. Corticosteroids (prednisone 0. 5 mg/kg/day or equivalent) 
should be started if symptoms do not resolve within a week.  
• For subject s experiencing Grade 3 or 4 (severe or life -threatening) immune -mediated 
toxicities, treatment with the checkpoint inhibitor should be permanently 
discontinued. High doses of corticosteroids (prednisone 1 -2 mg/kg/day or equivalent) 
should be given. When symptoms subside to Grade 1 or less, steroids can be 
gradually tapered over at least 1  month.  
Subjects who will benefit from corticosteroids generally do so within days. If symptoms do not 
clearly improve, particularly after approximately 3 days w ith IV steroids, administering 
infliximab (5 mg/kg) rather than continuing with a prolonged course of high -dose IV 
corticosteroids is suggested. If symptoms persist after the first infliximab dose, a second dose of 
infliximab (5 mg/kg) can be repeated 2 weeks after the initial dose.  
Fatigue  
• Fatigue is among the most common side effect seen and is generally mild. Severe 
fatigue is rare as a side effect of checkpoint inhibitors. When fatigue is present, it is 
important to exclude thyroid, pituitary, and other endocrine disorders, such as primar y 
adrenal insufficiency.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
90 
Infusion -related Reactions  
• Mild infusion -related side effects have been reported in up to 25% of individuals  
treated with anti -PD-1 or anti -PD-L1 agents. The reported incidence of severe or 
life-threatening infusion -related reacti ons has been less than 2%. Premedication with 
acetaminophen and an antihistamine may be considered as needed.  
Dermatologic and Mucosal Toxicity  
• Dermatologic toxicity is the most common irAE associated with checkpoint 
inhibitors. Approximately 30% to 50% o f individuals  will have dermatologic 
complications. Alopecia has been reported in approximately 1% to 2% of cases. For 
most individuals , dermatologic toxicity is the earliest irAE experienced, with onset an 
average of 3.6 weeks after treatment initiation.  
• Oral mucositis and/or complaints of dry mouth may also occur. Oral candidiasis 
remains an important consideration in the differential diagnosis, particularly if an 
individual  has been on oral corticosteroids for management of other irAEs. In some 
individua ls, oral corticosteroid rinses and lidocaine have been effective.  
• Most checkpoint inhibitor rashes can be treated with topical corticosteroid creams. If 
pruritus is a prominent symptom, oral antipruritics ( eg, hydroxyzine or 
diphenhydramine) can be helpful . Severe rashes (Grade 3/4) should be managed with 
oral corticosteroids, and treatment with checkpoint blockade should be held as per 
established management algorithms. Any rash that does not promptly resolve with 
corticosteroid creams or shows signs of bl istering should be evaluated promptly by a 
dermatologist and biopsy considered.  
Diarrhea/Colitis  
• Diarrhea is a common clinical complaint in individuals  undergoing treatment with 
checkpoint -blocking antibodies and most commonly presents approximately 6  week s 
into treatment. Subjects being treated with a checkpoint inhibitor should be counseled 
on the importance of maintaining oral hydration if diarrhea develops. If symptoms 
persist for more than 3 days or increase and no infectious causes are identified, 
prompt assessment and use of oral or IV corticosteroids are required.  
• Mild (Grade 1) symptoms (fewer than 4 stools per day over baseline) can be managed 
symptomatically. Some clinicians feel that the American Dietary Association colitis 
diet and anti -motility  agents (loperamide or oral diphenoxylate atropine sulfate) can 
be helpful for mild symptoms. Oral or rectal budesonide may be helpful in the early 
treatment of mild noninfectious diarrhea symptoms that persist but do not escalate 
after 2 to 3 days of diet ary modification and anti -motility agents.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
91 
• Colonoscopy may be helpful if Grade 2 symptoms (increase of 4 to 6 stools per day 
over baseline) or greater occur or in situations where the diagnosis is unclear. 
Treatment should be initiated if colitis is observ ed. 
• For individuals  with severe or life -threatening enterocolitis (Grade 3 or 4, increase of 
7 or more stools per day over baseline or other complications), treatment with 
checkpoint inhibitor should be permanently discontinued. High doses of 
corticosteroids (prednisone 1 -2 mg/kg/day or equivalent) should be given.  
• If individuals  do not improve with IV corticosteroids after approximately 3  days on 
IV steroids, infliximab at a dose of 5 mg/kg Q2W is typically recommended. The 
dose and schedule o f infliximab in this setting is based upon experience treating 
individuals  with inflammatory bowel disease. In cases refractory to infliximab, 
mycophenolate may be needed.  
• In very rare cases, colitis can result in bowel perforation, potentially requiring 
colostomy.  
• Prophylactic treatment with the matrix -release corticosteroid budesonide is not 
recommended for the prevention of diarrhea/colitis. This approach was studied as a 
way to reduce the incidence and/or severity of diarrhea in a double -blind, 
placebo -controlled Phase 2 study and the rates of diarrhea were similar in both study 
arms.  
Hepatotoxicity  
• Elevations in serum levels of the hepatic enzymes, AST and ALT , may be observed. 
Most episodes involve asymptomatic laboratory abnormalities, but occasional ly 
individuals  have an associated fever. Rarely, elevations in total bilirubin are seen as 
well, usually in association with a prolonged period of AST and ALT increase. 
Among individuals  that develop hepatic -related toxicities, the most common time of 
onset is 8 to 12 weeks after initiation of treatment, although early or delayed events 
may also be seen.  
• Hepatic function (transaminases and bilirubin) should be monitored prior to each dose 
of checkpoint inhibitor. When an individual  has an elevated AST and/o r ALT, 
exclusion of viral or other drug -induced causes of hepatitis is important. If no other 
etiology is obvious, then prompt treatment with corticosteroids following an 
established algorithm is the next step. Hepatitis may persist for quite some time and  
may require prolonged or repeated corticosteroid tapers (a minimum of 3 weeks of 
treatment is suggested) and/or additional immunosuppression.  
• Grade 2 hepatic toxicity: AST or ALT > 2.5 times the ULN but ≤  5 times the ULN, or 
total bilirubin > 1.5 times th e ULN but ≤ 3 times the ULN. Treatment with the 
checkpoint inhibitor should be withheld.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
92 
• Grade 3 or greater hepatic toxicity: AST or ALT > 5 times the ULN, or total bilirubin 
> 3 times the ULN. Treatment should be permanently discontinued.  
• In rare cases, e levations in AST and ALT are refractory to corticosteroid therapy, and 
mycophenolate mofetil (500 mg every 12 hours) may be administered concurrently 
with corticosteroids. The use of antithymocyte globulin therapy has also been 
described.  
• Infliximab should  not be given to individuals  with elevated AST/ALT since 
infliximab itself carries a risk of hepatotoxicity.  
Pneumonitis  
• Pneumonitis is an uncommon but potentially severe or fatal complication of treatment 
with checkpoint inhibitor immunotherapy. Drug -induced pneumonitis is a diagnosis 
of exclusion, and alternative diagnoses, including infection and malignancy, need to 
be excluded.  
• An empiric approach to treatment includes the following:  
o For asymptomatic, Grade 1 pneumonitis, clinicia ns generally withhold drug 
for 2 to 4  weeks with close follow -up. If symptoms arise or there is 
radiographic progression, corticosteroids are appropriate.  
o Subjects with Grade 2 or higher pneumonitis should have their drug withheld 
and be treated using corticosteroids w ith close follow -up. Additional 
immunosuppression may be used in individuals  with worsening of 
pneumonitis, although the benefit of this approach is uncertain.  
Endocrinopathies  
• Inflammation of the pituitary, thyroid, or adrenal glands as a result of checkpoint 
blockade often presents with nonspecific symptoms such as nausea, headache, 
fatigue, and vision changes. The most common endocrinopathies are hypothyroidism, 
hyperthyroidis m, and hypophysitis.  
• Thyroid function should be monitored prior to each dose of a checkpoint inhibitor. 
Hypothyroidism and hyperthyroidism should be managed per standard clinical 
guidelines and an endocrinologist should be consulted.  
• Typically, hypophysit is is manifested by clinical symptoms of fatigue and headache. 
The diagnosis is established by low levels of the hormones produced by the pituitary, 
including adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), 
follicle -stimulating hormo ne (FSH), luteinizing hormone (LH), growth hormone 
(GH), and prolactin. When hypophysitis is suspected, a course of high -dose 
corticosteroids (1  mg/kg of prednisone daily) given during the acute phase may result 
in reversal of the inflammatory process in s ome cases and prevent the need for longer 
term hormone replacement. In most individuals , however, long -term supplementation 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
93 
of the affected hormones is necessary due to secondary hypothyroidism (treated with 
levothyroxine) or secondary hypoadrenalism (trea ted with replacement doses of 
hydrocortisone, typically 20 mg each morning and 10 mg each evening). In some 
cases, individuals  can be successfully weaned from replacement steroids over time.  
Adre nal Insufficiency  
• The most critical endocrinopathy is adrena l insufficiency, which can cause 
dehydration, hypotension, and electrolyte imbalances (hyperkalemia, hyponatremia) 
and constitutes an emergency. Adrenal insufficiency is rare and has been reported in 
0.7% of individuals  treated in randomized clinical trial s. When an adrenal crisis is 
suspected, IV corticosteroids and immediate hospitalization is warranted. 
Consultation with an endocrinologist, aggressive hydration, and evaluation for sepsis 
are also critical.  
Type 1 Diabetes Mellitus  
• Treatment with checkp oint inhibitors has been associated with acute onset of type 1 
diabetes mellitus in approximately 0.2% of cases. It is important to monitor glucose 
with each dose of immunotherapy.  
Renal  
• Acute renal injury is a rare complication of checkpoint inhibitor imm unotherapy. 
Discontinuation of checkpoint inhibitor immunotherapy and treatment with 
corticosteroids are indicated for individuals  with severe renal injury. The most 
common reported underlying pathology is acute tubulointerstitial necrosis, but acute 
interstitial nephritis, immune complex glomerulonephritis, and thrombotic 
microangiopathy have also been observed. Acute renal injury due to checkpoint 
inhibitor therapy has been managed by discontinuing immunotherapy and 
administering a course of corticosteroi ds, typically 1  mg/kg tapering over 1 -2 months. 
Rechallenging with checkpoint inhibitor after resolution of the renal injury has been 
successful in some cases ( Wanchoo et al.  2017 ). 
Exocrine Pancreas  
• Monitoring serum amylase and lipase in asymptomatic individuals  is not 
recommended un less pancreatitis is suspected clinically. Corticosteroid treatment is 
not indicated in individuals  with modest asymptomatic elevations in serum amylase 
and lipase, as long as there are no other signs or symptoms of pancreatic 
inflammation.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
94 
Neurologic  
• A wide range of neurologic syndromes have been associated with checkpoint 
blockade neurotoxicity , which  is estimated to occur in approximately 1 -3% of 
individuals . Serious neurologic irAEs should be treated with corticosteroids. 
Consultation with neurology is  indicated to consider additional treatment such as 
plasmapheresis and IV Ig.  
Cardiotoxicity  
• Cardiotoxicity ( eg, myocarditis) may develop in the absence of a history of 
significant cardiac risk factors and may be associated with a more general myositis as 
well as other irAEs. High -dose steroids have been used to treat cardiac complications, 
but symptoms may progres s in some cases despite aggressive therapy. Immediate 
transfer to a coronary care unit or, if available, cardiac transplant unit should be 
considered for individuals  with elevated troponin or conduction abnormalities. The 
early institution of cardiac trans plant rejection doses of steroids (methylprednisolone 
1 g every day) and the addition of mycophenolate, infliximab, or antithymocyte 
globulin should be considered in individuals  without an immediate response to 
high-dose steroids. Mechanical circulatory su pport may also be considered in severe 
cases when deemed clinically appropriate.  
Hemat ologic  
• Red cell aplasia, neutropenia, thrombocytopenia, acquired hemophilia A, and 
cryoglobulinemia have been described in individuals  treated with checkpoint 
inhibitors . As with other irAEs, the standard approach is initial corticosteroid 
treatment with addition of other immune -suppressing agents if symptoms are 
steroid -refractory.  
Ophthalmologic  
• Cytotoxic T -lymphocyte -associated protein 4 ( CTLA -4) blockade with ipilimum ab 
has been associated with eye inflammation, which can be manifested by episcleritis, 
conjunctivitis, uveitis, or orbital inflammation. An ophthalmology consultation is 
recommended, and treatment with topical corticosteroids ( eg, 1% prednisolone 
acetate s uspension) may be helpful. Oral corticosteroids can be used for severe 
(Grade 3 or 4) for refractory cases.  
Rheumatologic and Musculoskeletal  
• A wide range of rheumatologic toxicities has been observed with checkpoint 
inhibition immunotherapy. These inclu de inflammatory arthritis, salivary gland 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
95 
dysfunction (sicca syndrome), and inflammatory myositis, among others. The 
incidence of these side effects has not been clearly determined.  
8.4. Pharmacokinetics  
PK assessments are for TTX -030, whether administered as a single agent or in combination with 
other agents.  
8.4.1.  Pharmacokinetic Blood Sample Collection  
The serial sampling scheme for TTX -030 concentration assessments scheduled in Table  1/Table  
2, Table 3/Table 4, and Table 5/Table 6 will contribute  to the characterization of the TTX -030 
PK profile. Blood will be  collected in the vacutainers specified in the Laboratory Manual. Serum 
will be harvested from these collections and stored for subsequent analysis. Samples from each 
collection period will be shipped to the analytical laboratory selected by the sponsor an d 
analyzed for concentrations of TTX -030 by validated methods. Instructions for processing and 
shipping samples will be provided in a separate Laboratory Manual. All sampling should be 
collected as close as possible to the sample collection times specified . The actual time and date 
of each blood sample will be recorded. If a subject has a dosing interruption or delay for any 
reason, PK sampling may be delayed or skipped after discussion with the sponsor. If the infusion 
was interrupted or a sample was not d rawn, the reason will be documented on the eCRF.  
Post-infusion samples should be obtained from a site other than the infusion site ( ie, contralateral 
arm) on infusion days.  
The number of samples taken, volume required for each analysis, and timing of the P K sampling 
may change during the course of the study as additional data emerge.  
8.4.2.  Pharmacokinetic Sample Analysis  
Serum concentrations of TTX -030 will be determined by a validated 
electrochemiluminescence -based method at the time point s listed in Table 1/Table 2, Table 
3/Table 4, and Table 5/Table 6.  
TTX -030 concentration data will be tabulated and summarized for each cycle at which PK are to 
be measured. Descriptive statistics will include means, medians, ranges, and standard deviations, 
as appropriate. Dose -exposure relationships will be characterized. Additional analyses may be 
conducted if they further address the PK objectives.  
PK parameters for TTX -030 will be estimated by fitting a  2-compartment IV  infusion model to 
the serum concentration -time data using Phoenix 64 WinNonlin. T he serum PK parameters are 
listed in Table 13. 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
96 
Table 13: Serum  Pharmacokinetic Parameters to be Computed  
Parameter  Definition  
t1/2 terminal elimination half -life 
Cmax maximum serum  observed concentration  
Vss volume of distribution at steady state  
CL apparent total body clearance of the drug from serum  
AUC  Area under the curve ( AUC )  
Concentrations below the lower limit of quantitation will be treated as 0.00 for descriptive 
statistics and noncompartmental PK analysis. Values for missing PK samples will not be imputed 
unless supported by PK principles ( eg, concentration[s]) prior to dosing or in the elimination 
phase following decline below the assay lower limit of quantitation and will be identified as 
“missing” in the data listings.  
8.5. Pharmacodynamics  
8.5.1.  Pharmacodynamic Blood Samples  
Pharmacodynamic blood samples should occur at the same time as PK blood draws or tumor 
biopsy when applicable as shown in Table 1/Table 2, Table 3/Table 4, and Table 5/Table 6. 
Detailed instructions for pharmacodynamic blood sample collection, processing,  and shipping 
will be provided to the study sites in a separate Laboratory Manual.  
Peripheral blood mononuclear cells , whole blood,  and serum and/or plasma will be analyzed for 
pharmacodynamic readouts, including TTX -030 relevant target - and 
mechanism -of-action -related biomarkers.  
Pro-inflammatory cytokine release will be measured as a marker of immune activation. 
Additionally, several exploratory analyses are planned. Whole blood will be collected to enable 
immunoprofiling, measurements of lymphocyte activ ation status, and analysis of CD39 receptor 
occupancy by the test article. Additionally, recent reports ( Giannakis et al.  2017 ) have suggested 
that elevated presence of adenosine and its metabolites in serum may correlate with intratumoral 
CD39 activity. Therefore, potential exploratory biomarkers may include the detection of 
adenosine and inosine using liquid chromatogra phy-tandem mass spectrometry techniques or 
similar alternatives.  
8.5.2.  Pharmacodynamic Tissue Samples  
Subjects may consent to undergo pretreatment biopsy or may provide archival tumor tissue 
(either a paraffin embedded tissue block or ≥ 10 unstained slides) obtained fr om a procedure that 
was performed any time prior to first dose .  
Fresh and/or archival tumor tissue is optional for dose escalation; fresh tumor biopsy at screening 
and on -treatment is mandatory for safety lead -in arms and expansion coho rts. If a subject is 
clinically contraindicated for tumor biopsy, discuss with Medical Monitor. If a subject has had a 
biopsy within 90 days with no intervening treatment  prior to the loading dose/first dose of TTX -
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
97 
030, that tissue can be used for this stu dy and the subject does not need to repeat a baseline 
biopsy.  
Follow -up tissue biopsies will occur on C2D1 ( -7 days ) [Table  1/Table 2 and Table 3/Table 4 
Invasive procedures that require general anesthesia should not be performed t o obtain a biopsy 
specimen. If a surgical procedure is performed for a clinical indication , a sample may be used for 
research purposes. During the course of treatment , a decision may be made to perform the 
on-treatment biopsy earlier than Cycle 2 Day 1 ( -7 days)  if there is evidence to suggest a 
possibility that there will be no available tumor for biopsy due to a rapid clinical response. 
Similarly, tumor biopsy may be delayed if there is evidence of a delayed response.  
When PK and pharmacodynamic sampling are scheduled on days when tissue samples (tumor 
biopsy) are to be obtained, every effort will be made to schedule the assessments together.  
Archival/pretreatment and on -treatment tumor biopsies will be collected and e mbedded in 
paraffin. Expression of CD39 will be assessed by immunohistochemistry. Additional analysis 
may include immunohistochemistry staining for markers of TIL populations ( eg, CD3, CD8, 
CD73, FoxP3, or CD68), functional markers (Ki67), or immune checkp oints ( eg, PD-L1). 
Additionally, expression analysis of tumor tissue may be performed using Nanostring™ or 
Illumina RNA -seq. 
Other TTX -030-relevant targets and mechanism -of-action -related biomarkers may be examined 
using available assays. Tissue blocks or slides from fresh biopsies will be retained to research 
disease pathways. Any future use of samples following study completion will be in compliance 
with the Guidance on Informed Consent for In Vitro  Diagnostic Device Studies Using Leftover 
Human Specimens  that are Not Individually Identifiable Guidance for Sponsors, Institutional 
Review Boards, and Food and Drug Administration Staff ( FDA, 2006 ). Tissue blocks from 
archival biopsies will be returned to the archival facility from which it was originally received. 
Other TTX -030-relevant targets and mechanism -of-action -related biomarkers may be examined 
using available assays.  
Detai led instructions for tissue sample preparation and shipping will be provided to the study 
sites as needed in a separate laboratory manual.  
8.6. Immunogenicity Assessments  
8.6.1.  Anti -drug Antibody Assessments  
Formation of ADA against TTX -030 will be evaluated in serum  samples collected from all 
subject s, whether administered as a single agent or in combination with other agents.  
8.6.2.  Blood Sample Collection  
Serum samples will be collected for the purpose of ADA analysis from all subject s as scheduled 
in Table 1/Table 2, Table 3/Table 4, and Table 5/Table 6. Blood will be collected in the 
vacutainers specified in the laboratory manual a nd serum extracted as specified. Actual time and 
date of each blood draw are to b e reco rded. Samples from each scheduled collection period will 
be shipped to the analytical laboratory selected by the sponsor and analyzed for ADA reactivity 
to TTX -030. 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
98 
Addi tionally, serum samples should also be collected at the final visit from subjects who 
discontinued study treatment or were withdrawn from the study. These samples will be tested by 
the sponsor or sponsor’s designee.  
8.6.3.  Analysis of ADA Formation  
Immunogenicity  results will be analyzed descriptively by summarizing the number and 
percentage of subjects who develop detectable anti -TTX -030 antibodies  (population defined as 
per Table 16). The immunogenicity titer will be reported for samples confirmed positive for the 
presence of anti -TTX -030 antibodies.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
99 
9. Statistical Considerations  
9.1. Statistical Hypotheses  
Details of the statistical model are included in Section  11.6 (Appendix 6). 
A primary objective of the trial is to determine the MTD and/or RP2D for each arm. Dose 
escalation  (Arm 1)  will be conducted according to a mCRM for doses up to 10 mg/kg and 
according to a 3  + 3 design for doses > 10 mg/kg, with the aim of estimating the dose -toxicity 
relationship and determining the MTD. The MTD will be defined as the dose that has a 
model -estimated DLT rate closest to 30% and also has less than 55% probability of a DLT rate 
exceeding 30%. The log -odds of a DLT will be mode led across the dose levels with a 
2-parameter logistic regression model.  
The model will be fit to the available data following each dosing cohort to support escalation 
decisions. The observed DLT data will be summarized by dose (within each 
dose-escalation /safety lead -in arm) and reported along with the model fit. Summaries from the 
model will include the posterior means and 95% confidence  intervals (CI) for each dose along 
with the posterior probability that the DLT rate exceeds 30%.  
The RP2D was determine d based on the totality of data, including the estimated MTD, plus other 
endpoints such as observed efficacy, PK, and other AEs.  
Descriptive summary statistics will be presented. Longitudinal data will be presented by 
appropriate time intervals, such as m onthly or quarterly depending on the nature of the data.  
The efficacy in subjects treated with TTX -030 as a single agent or in combination with specified 
regimens will be evaluated and analyzed using the endpoints listed in  Table 14. 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
100 
Table 14: Efficacy Endpoints  
Efficacy Endpoint  Definition  
Best Overall Response (BOR)  Best response recorded after the start of the study 
treatment /randomization  
Objective  Response Rate (ORR)  Confirmed  partial response or confirmed  complete response  
Duration of Response (DOR)  Time from documentation of tumor response to disease 
progression  
Time to Progression (TTP)  Time from the start of study treatment /randomization  until 
objective tumor progression; TTP does not include deaths  
Time to Tumor Response (TTR)  Time from the start of study treatmen t/randomization  to the 
first documentation of an object ive response  
Progression -Free Survival (PFS)  Time from the start of study treatment /randomization  until 
objective tumor progression or death  
Disease Control Rate (DCR)  Percentage of subjects who have achieved complete 
response, partial response , or stabl e disease for at least 
6 weeks  
Overall Survival (OS)  Time from the start of study treatment /randomization  until 
death from any cause and is measured in the Efficacy 
Evaluable  Population  
 
9.2. Statistical Considerations for Arm 1 and 2 Expansion Cohorts  
In Arm 1 and 2 Expansion Cohort s (n = 25 subjects  each) subjects with advanced or metastatic 
RCC with a clear -cell component and previously treated with anti-PD-(L)1 therapy and TKI 
therapy, will be randomized 1:1 t o TTX -030 or TTX -030 and pembrolizumab . These agents will 
be administered at the doses and schedules identified in the safety lead -in. 
• Arm 1: TTX -030 (n = 25)  
• Arm 2: TTX -030 and pembrolizumab (n = 25)  
The primary objective of this randomization procedure is to obtain unbiased estimates of safety 
and efficacy parameters of TTX -030 plus pembrolizumab compared with TTX -030. For 
example, a 25% improvement in ORR ( ie, ORR Δ) in Arm 2 relative to Arm 1 (assuming a 15% 
ORR in Arm 1) will h ave an 80% CI of (9%, 41%) and a power of 76%. See Table 15. 
Demographic and baseline characteristics will be summarized by treatment arm for all 
randomized subject s. Descriptive summaries of continuous data will be presented by the group 
mean, standard deviation, median, minimum, and maximum. Descriptive summaries of discrete 
data will be presented by the category counts as frequencies and percentages.  
An estimate of the difference between the ORR in the two arms will be computed along with its 
90% CI and 80% CI. The Mantel -Haenszel test will be used to compare the ORR between the 
two treatment arms at the two -sided significance level of 5% and 10%.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
101 
PFS and OS will be analyzed when 65% of the 50 subject s have experienced a PFS event and an 
OS event , respectively. Data for a subject  without disease progression or deat h as of the clinical 
data cutoff date will be censored at the time of the last tumor assessment (or at the date of 
randomization plus 1 day if no tumor assessment was performed after the baseline visit). Data 
from a subject  who is lost to follow -up will be  included in the analysis and censored on the last 
date of tumor assessment that the subject  was known to be progression free or death. A stratified 
Cox proportional -hazards model will be used to estimate the hazard ratio  and its 90% CI and 
80% CI. The two -sided stratified log -rank test will be used to compare PFS and OS between the 
two treatment arms. Kaplan -Meier methodology will be used to estimate the PFS curve and OS 
curve as well as the median PFS and OS for each treatment arm.  
Safety analyses will be  conducted in all randomized subject s who received at least one dose of 
TTX -030 or pembrolizumab. Safety analyses will be performed by treatment arm and will be 
based on actual treatment received. Specifically, a subject  will be included in Arm B in the sa fety 
analyses if the subject  receives any amount of pembrolizumab, regardless of the initial treatment 
assignment at randomization. Safety endpoints will include incidence, nature, and severity of 
adverse events (using NCI CTCAE v 5.0), including SAEs  and AEs of special interest.  
Table 15: Power for Study Design for Several Possible True Underlying Delta 
ORR Values  
 
 True Underlying ORR Δ 
13%  17%  21%  25%  
Power to detect ORR Δa 44% 55% 66% 76% 
80% CI (-2%, 28%)  (2%, 32%)  (6%, 36%)  (9%, 41%)  
Abbreviations:  CI = confidence interval , ORR = objective response rate.  
aTwo-sided  = 0.20.  
Notes: Arm A is assumed to have an ORR of 15%. Results are based on 25 subject s in each arm.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
102 
9.3. Populations for Analyses  
The following populations are defined for statistical analyses  (Table 16). 
Table 16: Analysis Populations  
Population  Population Definition  
Enrolled Population  All subjects who sign an ICF. 
Safety Population  All subjects who receive at least 1 dose or any partial dose of study 
treatment . 
Efficacy  Evaluable Population  All treated subjects with measurable disease at baseline  and 1 of the 
following: 1) at least 1 on -treatment tumor assessment, 2) clinical 
progression, or 3) death.  
MTD Ana lysis Population  All subjects dosed at the MTD (or the highest dose tested if the 
MTD is not determined) in the Safety Population who have the valid 
baseline  tumor assessment showing measurable disease, and at least 
1 valid post -baseline  tumor assessment. Any subject who has a 
major inclusion/exclusion deviation, major dosing deviation, or 
major protocol conduct deviation that impacts MTD assessment will 
be excluded from the MTD Analysis  Population . A subject who 
withdraws from the study during Cycle 1 for reasons other than a 
DLT will be replaced  and will be excluded from the MTD Analysis  
Population.  
PK Population  All subjects who receive at least 1 dose of study treatment and have, 
in the opinion of the pharmacokineticist, sufficient data for PK 
analy sis. 
Biomarker/Pharmacodynamic 
Population  All subjects who receive at least 1 dose of study treatment and have 
available biomarker data . 
Immunogenicity Population  All subjects who receive at least 1 dose of study treatment and have 
available ADA data . 
DLT Evaluable Population  All subjects who receive 1 infusion during the treatment cycle , 
completed the DLT evaluation period,  and are DLT evaluable.  
Abbreviations: ADA = anti -drug antibodies, DLT = dose -limiting toxicity, ICF = informed consent form, 
MTD  = maximum tolerated dose, PK  = pharmacokinetic.  
9.4. Interim Analyses  
No formal interim analysis is planned.  
An informal interim analysis will be performed when 16 subjects treated in Arm 1 of the 
Expansion Cohort (i.e. TTX -030 monotherapy, see Section  4.1.1.2 ) have had 2 response 
evaluations completed or experienced progression.  The Sponsor may terminate enrollment into 
Arm 1 Expansion should there be evide nce of a lack of efficacy.  The totality of available data 
will be used to make this determination, however, should zero responders be seen out of the first 
16 subjects the 90% one -sided confidence interval (using exact methods) excludes a responder 
rate of  13.4% or more.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
103 
10. Regulatory, Ethical, and Study Oversight Considerations  
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with International Conference on Harmonisation/ Good 
Clinical Practice ( GCP ), applicable regulatory requirements and the sponsor’s policy on 
bioethics.  
10.1. Criteria for Study Termination  
The sponsor or designee may suspend or terminate the study or part of the study at any time for 
any reason.   
If the investigator suspends or terminates the study, the investigator will promptly inform the 
sponsor or designee and the IRB/IEC and provide them with a detailed written explanation. The 
investigator will destroy all unused (after final study treatmen t accountability has been 
performed) and partially used investigational product per site standard operating procedures. 
Upon study completion, the investigator will provide the sponsor or designee, IRB/IEC, and 
regulatory agency with final reports and summ aries as required by regulations. For IND studies, 
or when the data will be used in support of an IND, the investigator must submit a written report 
to the sponsor or designee and the IRB/IEC within 3 months after the completion or termination 
of the study . 
Study enrollment may be paused at any time for safety reasons by the sponsor and/or Cohort 
Review Committee. In the event enrollment is suspended, the decision as to whether subjects 
who have already undergone dosing may be made on a case -by-case decisio n in consultation 
with the Cohort Review Committee. Subjects who have already been treated with TTX -030 will 
be followed throughout the study.  
Enrollment and treatment with the study treatment may be temporarily suspended for death that 
is not related to disease progression (timeframe) or underlying disease. Re -initiation of 
enrollment will be considered depending on the determination of the caus e of death.  
10.2. Protocol Adherence and Amendment  
The treating physician or other involved health care professionals will apply due diligence to 
avoid protocol deviations. The protocol should be amended and updated as needed throughout 
the course of the study. Any change or addition to the protocol requires a written protocol 
amendment that must be approved by the sponsor, the treating physician, and the relevant 
IEC/IRB before implementation, unless the amendment is safety related. Safety -related 
amendments wil l be implemented immediately and documented with a Note to File. 
Amendments affecting only administrative aspects of the study do not require formal protocol 
amendments or IEC/IRB approval, but the IEC/IRB must be kept informed of such 
administrative chang es. 
10.3. Investigator Compliance  
The protocol and the proposed informed consent form (ICF) must be reviewed and approved by 
a properly constituted IRB/IEC  or equivalent board before the study start. A signed and dated 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
104 
statement that the protocol and informed co nsent have been approved by the IEC/IRB must be 
given to the sponsor before study initiation. Prior to study start, the treating physician is required 
to sign a protocol signature page confirming agreement to conduct the study in accordance with 
these docu ments and all the instructions and procedures found in this protocol and to give access 
to all relevant date and records to the sponsor’s representatives or designees, IECs/IRBs, and 
regulatory authorities as required. If an inspection of the clinical site  is requested by a regulator 
authority, the investigator must inform the sponsor immediately that this request has been made.  
10.4. Institutional Review Board or Independent Ethics Committee  
The final study protocol, including the final version of the ICF, must be approved or given a 
favorable opinion in writing by an IRB or IEC as appropriate. The investigator must submit 
written approval to the sponsor before he or she can enroll any subject into the study.  
The investigator is responsible for informing the IRB or IEC of any amendment to the protocol 
in accordance with local requirements. In addition, the IRB or IEC must approve all advertising 
used to recruit subjects for the study. The protocol must be re -approved by the IRB or IEC upon 
receipt of amendments an d annually, as local regulations require.  
The investigator is also responsible for providing the IRB with reports of any reportable serious 
adverse drug reactions from any other study conducted with the study treatment. The sponsor 
will provide this inform ation to the investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or IEC according to local regulations and guidelines.  
10.5. Financial Disclosure  
Investigators and sub -investigators will provide the spon sor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing in formation on financial interests during the course of the study and for 
1 year after completion of the study.  
10.6. Informed Consent  
The investigator(s) at each center will ensure that the subject is given full and adequate oral and 
written information about the  nature, purpose, and possible risk and benefit of the study. Subjects 
must also be notified that they are free to discontinue from the study at any time. The subject 
should be given the opportunity to ask questions and allowed time to consider the informa tion 
provided.  
The subject’s signed and dated informed consent must be obtained before conducting any study 
procedures.  
The investigator(s) must maintain the original, signed ICF. A copy of the signed ICF must be 
given to the subject.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
105 
10.7. Data Protection  
The sponsor  maintains confidentiality standards by assigning a unique study -specific number to 
each subject enrolled in the study. This means that subject names are not included in data sets 
that are transmitted to any sponsor  location.  
Subject medical informat ion obtained by this study is confidential and may be disclosed to third 
parties only as permitted by the ICF (or  separate authorization for use and disclosure of personal 
health information) signed by the subject or as permitted or required by law.  
Medica l information may be given to a subject’s personal physician or other appropriate medical 
personnel responsible for the subject’s welfare, for treatment purposes.  
Data generated by this study must be available for inspection upon request by representatives  of 
national and local health authorities, the sponsor  or its designee, and  the IRB/IEC for each study 
site, as appropriate.  
10.8. Committee Structure  
The investigator must obtain IRB approval for the investigation. Initial IRB approval and all 
materials approve d by the IRB for this study including the consent form and recruitment 
materials must be maintained by the investigator and made available for inspection.  
10.9. Dissemination of Clinical Study Data  
The standard flow of the clinical study data from collection to clinical study report is illustrated 
in Figure 12. 
Figure 12: Transmission of Electronic Data  
 
Abbreviations: eCRF = electronic case report form.  
Data will be transcribed from source into a validated 21 CFR Part 11 compliant, electronic data 
capture system using single data entry. Extern al data will also be imported into the system. PK 
data will be merged into the database using SAS or Excel transfers. Data originators, as well as 
system administrators, will be trained, authorized, and each assigned an individual identifier 

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
106 
(username  and password). Electronic tools (prompts), as well as data review and query, will be 
used to alert users to and correct for missing data, data inconsistencies, inadmissible values, 
entries out of range, and to request additional data as applicable . An audit trail will be maintained 
to record data entries and edits. Data originators will have access to their data during study 
conduct and will be provided a read -only copy of the final data, audit trail, and queries in a 
human readable file suitable f or long term storage.  
The investigator and any vendors will permit study -related monitoring, audits, IRB review, and 
regulatory inspection(s) by providing direct access to source data/documents. Data entered into 
the eCRF will be available to the parties r esponsible for study data management (sponsor, 
contract research organization) as it is entered and can be exported into files compatible with 
SAS and Excel, among other data formats.  
Subject data necessary for analysis and reporting of this study will be transferred via a validated 
procedure into a validated database or data system ( eg, SAS), to enable the data to be 
restructured into industry standards. Clinical data management will be performed in accordance 
with applicable sponsor or designee’s standard s and data cleaning procedures. This is applicable 
for data recorded on eCRF as well as for data from other sources. Examples of other data would 
be the medical glossary coding ( eg, AEs, medication) that will be performed with internationally 
recognized an d accepted dictionaries. Additional details are recorded in the monitoring and data 
management documentation.  
10.10.  Data Quality Assurance  
To ensure compliance with GCP and all applicable regulatory requirements, the sponsor may 
conduct a quality assurance audit . Please see  Section  10.11  for more details regarding the audit 
process.  
10.11.  Inspection of Records  
Authorized representatives of the sponsor, a regulatory authority, an IEC , or an IRB may visit the 
site to perform audits or inspections, including source data verification. The purpose of a sponsor 
audit or inspection is to systematically and independently examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, GCP guidelines of the International 
Conference on Harmonisation, and any applicable regulatory requirements. The investi gator 
should contact the sponsor immediately if contacted by a regulatory agency about an inspection.  
The sponsor will be allowed to conduct site visits to the investigation facilities for the purpose of 
monitoring any aspect of the study. The investigator  agrees to allow the monitor to inspect the 
study treatment storage area, study treatment stocks, treatment accountability records, subject 
charts and study source documents, and other records relative to study conduct.  
10.12.  Retention of Records  
The investigato r must maintain all documentation relating to the study for a period of 2 years 
after the last marketing application approval, or if not approved, for 2 years following the 
discontinuance of the test article for investigation. If it becomes necessary for t he sponsor or the 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
107 
regulatory authority to review any documentation relating to the study, the investigator must 
permit access to such records.  
10.13.  Study and Site Start and Closure  
Before an investigational site can enter a subject into the study, a representat ive of the sponsor 
will visit the investigational study site to:  
• Determine the adequacy of the facilities  
• Discuss with the investigator(s) and other personnel their responsibilities with regard 
to protocol adherence and the responsibilities of the sponsor or its representatives. 
This will be documented in a Clinical Study Agreement between the sponsor and the 
investigator.  
During the study, a monitor from the sponsor or represe ntative will have regular contacts with 
the inv estigational site, for the followi ng: 
• Provide information and support to the investigator(s).  
• Confirm that facilities remain acceptable.  
• Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that study treat ment accountability 
checks are being performed.  
• Perform source data verification. This includes a comparison of the data in the eCRF 
with the subject’s medical records at the hospital or practice and other records 
relevant to the study. This will require d irect access to all original records for each 
subject ( eg, clinic charts).  
• Record and report any protocol deviations not previously sent to the sponsor.  
• Confirm AEs and SAEs have been properly documented on eCRFs and confirm any 
SAEs have been forwarded to  the sponsor and those SAEs that met criteria for 
reporting have been forwarded to the IRB.  
The monitor will be available between visits if the investigator(s) or ot her staff needs 
information or advice.  
10.14.  Publication Policy  
The sponsor’s policy is to publish or otherwise communicate the results of its hypothesis testing 
clinical studies, regardless of outcome, for compound(s) being investigated that are later 
approved for marketing. Hypothesis -testing clinical studies are tho se studies intended to provide 
meaningful results by examining prestated questions using predefined statistically valid plans for 
data analysis, thereby providing firm evidence of safety and/or efficacy to support product 
claims.  
Exploratory studies, in co ntrast, serve to set direction for possible future studies. They have 
significant statistical limitations, provide only preliminary information about a disease, 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
108 
condition, or product, and are not designed to provide final conclusions on product claims. The  
sponsor does not commit to publish or otherwise communicate the results of every exploratory 
study because this information is of an exploratory nature and often highly proprietary. However, 
if information from an exploratory study is of significant medic al importance, the sponsor will 
publish or otherwise communicate the results.  
The sponsor’s decision to publish or otherwise publicly communicate the results of this study 
will be made in accordance with all applicable laws, regulations, and sponsor polici es regarding 
publication and communication of clinical study results.  
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
109 
11. Appendices  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
110 
11.1. Appendix 1: Protocol Amendment History  
 
Version 
Number  Section Number 
or Title  Description of Change  Reason for Change  
7.0 Entire document  Minor spelling, grammar, punctuation, 
capitalization, abbreviations, and other 
formatting edits were made throughout the 
document  Consistency  
7.0 Entire document  Tizona Therapeutics, Inc. to Trishula 
Therapeutics, Inc.  Change company name to 
Trishula (Tizona’s spin -out 
company)  
7.0 Sponsor 
Approval Page  Update Medical Monitor  Personnel change  
7.0 Section 1.1  Synopsis: Revised to align with protocol body  Consistency  
7.0 Section 1.2  Modified study schema to reflect updated 
study design  Consistency  
7.0 Section 1.3  Schedule of assessments:  
- update Tables 1 -4  
- remove Tables 5 -6 
- add missing D8 gem/nab dosing visits to 
Arm 4  
- add COVID -19 AE collection guidanace  
- removed optional sampling for PK and PD 
correlative blood sample at C1D3   
- for consistency with tex t in 
protocol  
- to align with RP2D dosing 
schedules  
-for clarity and consistency  
 
 
- additional safety monitoring  
7.0 Section 2.2.2  
Section 2.2.3  
Section 2.3   Update clinical data and rationale for RP2D 
dose and schedule  RP2D dose selection  
7.0 Section 4.1  
Section 4.1.1.2  
Section 4.5  
Section 4.10  
Section 4.17  
Section 4.18  -Remove Arm 3  
-Update “n” for expansion arms  -Update study design as a 
similar population is being 
evaluated in another Trishula 
protocol (TTX -030-002) 
-Clarity  
7.0 Section 4.1.1.1  
Section 4  Update DLT evaluation period and RP2D 
dose and schedule  To reflect RP2D dose and 
schedule  
7.0 Section 4.4  Remove dose schedule scenarios  To reflect established RP2D 
dose and schedule  
7.0 Section 4.13  Update dose delays guidance  Safety monitoring  
7.0 Section 5.1  Inclusion Criteria:  
-remove Arm 3 criteria  Consistency due to removal of 
Arm 3  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
111 
7.0 Section 6.1.3  Add vital signs checks for infusion -related -
reaction (IRR) management  Safety monitoring  
7.0 Section 6.5.2  Remove mCRPC requirement  Consistency due to removal of 
Arm 3  
7.0 Section 7.2  
Section 9.4  Add Arm 1 Expansion rule for termination  Efficacy analysis  
7.0 Table 11  
Section 8  
Section 8.1  Remove Arm 3 and update dose and schedules  To reflect established RP2D 
dose and schedule  
7.0 Section 8  
Section 8.3.6.4  Add COVID -19 guidance for AEs/SAEs 
management  Safety monitoring  
7.0 Section 8.4.2  Update Table 13 for PK sample analysis  Clarity  
7.0 Section 8.5.2  
Section 1.3  Update timing for archival tumor biopsy 
collection from 45 to 90 days  Recruitment flexibility  
7.0 Section 6.3  Update ADA analysis  Program consistency  
7.0 Section 11.1  Update protocol amendment history  Consistency  
6.0 Entire document  Updated protocol to a new template  Update  
6.0 Entire document  Minor spelling, grammar, punctuation, 
capitalization, and other formatting edits were 
made throughout the document  Consistency  
6.0 Section 1.1  Synopsis: Revised to align with protocol body  Consistency  
6.0 Section 1.2  Modified study schema to reflect updated 
study design  Consistency  
6.0 Section 1.3  Schedule of assessments:  
- clarified CT/CT -PET scans  
- update Table 2 for tumor assessments and 
serum tumor -associated markers to be 
collected Q2M to Q9W (21 -day cycle)  
- add clinical laboratory test to be collected at 
C1D3  
- removed optional sampling for PK and PD 
correlative blood sample at C1D3  
- add PD -L1 to serum tumor -associated  
markers at screening  
- Included dose modification for Arm 4 for 
gemcitabine/nab -paclitaxel   
- for consistency with text in 
protocol  
- to align with 21 -day cycle 
visits  
 
 
- additional safety monitoring  
 
- optional samples removed  
 
- to assess for this ser um 
tumor -associated marker  
- to allow dose modification in 
case of toxicities  
6.0 Section 1.3  
Section 8.3.5  Clarify that  fibrinogen is only required for 
eligibility  (within 14 days of dosing)  To align with inclusion 
criterion  
6.0 Section 2.1.3  Updated indications of pembrolizumab  New indications have been 
approved since the original 
version of the protocol  
6.0 Section 3  
 Updated objectives and endpoints for Arm 1 
and Arm 2 Expansion Cohorts  To align with randomized 
expansion cohorts  
6.0 Section 4.4  Modified loading dose language to remove 
reference to Q2W and Q1W (loading dose on 
Day -14 or Day -7 only).  Clarification  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
112 
6.0 Section 4.1.1.2  
Section 4.3  
Section 4.17  Modified study design for A rm 1 and Arm 2 
expansion from single arm cohort expansion 
to randomized 1:1 to TTX -030 or TTX -030 
and pembrolizumab in subjects with advanced 
or metastatic RCC with a clear -cell 
component and previously treated with up to 3 
lines of prior therapies, includ ing anti -PD-L1 
therapy and TKI therapy.  To allow for clearer decision 
making than single arm 
expansion  
6.0 Section 5.1  Modified the disease -specific inclusion 
criteria for Arm 1 and Arm 2 Expansion 
Cohorts  Defining of subject 
populations  
6.0 Section 5.1  Modified inclusion criteria for Arm 3 to 
clarify the type of prior therapy and to clarify 
that subjects had not previously received 
docetaxel  Clarify population  
6.0 Section 5.3  Updated exclusion criteria to exclude:  
Subjects who are on steroi ds for any irAE that 
has not resolved, and Grade 3 or higher irAE, 
and ocular or neurologic toxicity of any grade.  For subject safety  
6.0 Section 6.1.2  Clarified that pembrolizumab would be 
provided by Tizona  Clarity  
6.0 Section 6.3  Updated randomization section to refer to 
treatment assignment and randomization for 
Arm 1 and Arm 2 Expansion Cohorts  To align with randomized 
expansion cohorts  
6.0 Section 6.5.1  Clarified allowed prednisone dose  Clarity  
6.0 Section 6.13  Updated treatment regim en description table 
to include optional loading dose  Consistency  
6.0 Section 7.3  Added section entitled Lost to Follow Up  To define and address lost to 
follow -up subjects  
6.0 Section 8.2.1  Clarified that CT scans are to be performed 
unless contraindicated  Subject safety  
6.0 Section 8.3.6  Clarified that AEs/SAEs are to be 
monitored/followed until EOT or 90 days 
(rather than 30 days) after the last dose  Consistency with safety 
follow -up contact at 60 and 90 
days after the last dose  
6.0 Secti on 8.4.2  Updated description of PK parameter 
estimation  Clarity  
6.0 Section 9.1  Updated definitions of efficacy endpoints to 
from start of study treatment rather than from 
time of randomization  Modified since the study is not 
randomized (except for Arm 1 
and 2 Expansion Cohorts)  
6.0 Section 9.2  Added statistical considerations for Arm 1 and 
Arm 2 Expansion Cohorts  Added due to modified study 
design  
6.0 Section 9.3  Changed “Response Evaluable Po pulation” to 
“Efficacy Evaluable Population” and “Per -
protocol Population” to “MTD Analysis 
Population”. In addition, revised the definition 
of the DLT Evaluable Population  Clarity  
6.0 Section 11.3  Replaced the comparison of RECIST and 
iRECIST table with the version from Seymour 
et al. 2017  Clarity  
5.0 Section 2.2.2  Summarized clinical safety data up to first 
3 subjects in the 40  mg/kg from Study 
TTX -030-001 To support 40 mg/kg dose 
level  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
113 
5.0 Synopsis, 
Section 1.3, 
Section 5.1, 
Section 5.4, 
Section 5.11, 
Section 6.6, 
Table 4, Sections 
9.1-9.3. Added text to allow for a TTX -030 loading 
dose to be explored  
Added Schedule of Assessments for loading 
dose visit (Tables 7 -12) 
Added PK time points to reflect the loading 
dose intervals (Tables 13 -15) Based on PK and reaching 
functional trough 
concentration  
4.0 Synopsis  Revised to align with protocol body  Consistency  
4.0 List of 
Abbreviations, 
Section 2.1.5, 
Section 4.2, 
Section 10.7.2  Replaced plasma with serum for PK -related 
items  PK parameters are/were 
measured in serum  
4.0 Section 2.2  Summarized clinical safety data up to 
20 mg/kg from Study TTX -030-001  To support the 20  mg/kg dose  
4.0 Section 2.1.2, 
Section 5.1, 
Section 5.2, 
Section 5.4, 
Section 5.5, 
Section 5.6, 
Section 5.10, 
Section 5.11, 
Section 5.12, 
Section 5.13, 
Section 5.15, 
Section 5.17, 
Section 6.2, 
Section 13  Added 2 higher dose levels (20 and 40 mg/kg) 
for monotherapy dose escalation (Arm 1) and 
allowed for several doses and schedules to be 
tested (added Q2W and  Q4W).  
Changed the combination -therapy dose -
escalation arms (Arms 2 -4) to safety lead -in 
arms. These arms are to start at the RP2D to 
be identified in the monotherapy dose -
escalation arm (Arm 1). Modified the text 
throughout the protocol to reflect this ch ange.  
Added a study design schema (Figure 10).  Based on PK and safety higher 
doses and varying schedules 
are being explored  
4.0 Section 6.1  Modified the disease -specific inclusion 
criteria for Arm 3 and Arm 4.  Defining of subject 
populations  
4.0 Section 6.6, 
Section 6.7, 
Section 9, 
Section 10.5, 
Section 10.5.1, 
Section 10.5.2, 
Section 10.6.2, 
Section 10.6.3, 
Section 10.7.1, 
Section 10.7.2, 
Section 10.8.1, 
Section 10.8.2, 
Section 10.9, 
Section 10.10  Added Schedule of Assessments for the Q4W 
schedule – Arm 1 (Table 11/Table 12) and 
included Arm 1 in the existing Schedule of 
Assessments for Q2W schedule 
(Table  9/Table 10).  
Added PK sampling interval tables for Q3W 
schedule (Table 13), Q2W schedule 
(Table  14), and Q4W schedule (Table 15).  Added to support the varying 
schedules being explored  
3.0 Protocol 
Approval Page  Replaced Angela Shen with Joyson 
Karakunnel as medical monitor  New Chief Medical Officer  
3.0 Synopsis  Revised to align with protocol body  Consistency  
3.0 Section 5.1, 
Section 5.2, 
Section 5.7, 
Section 5.11, Added text to indicate that a traditional 3 + 3 
dose-escalation design will be implemented 
for doses > 10 mg/kg  Due to evaluation of higher 
doses than anticipated  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
114 
Section 5.16, 
Section 13  
2.0 Section 5.11  Clarification of DLT definition  Request from FDA  
2.0 Section 6.1, 6.2  Clarification of eligibility criteria #1, 4, and 
25 Request from FDA  
2.0 Section 8.3, 8.4  Guidance provided on management of TLS 
and CRS  Request from FDA  
2.0 Section 5.18  
Section 9  
Table 8, 10  Added follow -up safety contact at 60 and 90 
days (± 7 days) after last dose of study drug  Request from FDA  
2.0 Table 7  Corrected footnotes d and e  Correction of typo  
1.1 Section 2.1  Updated data from non -human primate PK 
study  Final report completed  
 
DOCUMENT HISTORY  
Document  Date  
Version 8.0 Amendment 8 (Trishula)  15 Dec 2020  
Version 7.0 Amendment 7 (Trishula)  12 Oct 2020  
Version 6.0 Amendment 6 2 Jan 2020  
Version 5.0 Amendment 5  22 Nov 2019  
Version 4.0 Amendment 4  21 Oct 2019  
Version 3.0 Amendment 3  12 Sep 2019  
Version 2.0 Amendment 2  28 Dec 2018  
Version 1.1 Amendment 1  24 Oct 2018  
Original Protocol  01 Oct 2018  
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
115 
11.2. Appendix 2: Eastern Cooperative Oncology Group Performance 
Status  
 
Grade  Description  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light housework , office work  
2 Ambulatory and capable of all self -care; but unable to carry out any work activities. Up 
and about more than 50% of waking hours  
3 Capable of only limited self -care; confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot c arry on any self -care. Totally confined to bed or chair  
5 Dead  
Source: Oken et al.  1982 . 
 
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
116 
11.3. Appendix 3: RECIST and  iRECIST  
 
Comparison of RECIST and iRECIST  
 RECIST 1.1  iRECIST  
Definitions of 
measurable and 
nonmeasurable 
disease; numbers and 
site of target disease  Measurable lesions are ≥ 10 mm in 
diameter (≥ 15 mm for nodal lesions); 
maximum of 5 lesions (2 per organ); all 
other disease is considered non -target 
(must be ≥ 10 mm in short axis for nodal 
disease)  No change from RECIST 1.1; however, new 
lesions are assessed as per RECIST 1.1 but 
recorded separately on the case report form 
(but not included in the sum of lesions for 
target lesions identified at baseline)  
CR, PR, or S D Cannot have met criteria for progression 
before CR, PR, or SD  Can have had iUPD (1 or more instances), 
but not iCPD, before iCR, iPR, or iSD  
Confirmation of CR 
or PR  Only required for non -randomized trials  As per RECIST 1.1  
Confirmation of SD  Not required  As per RECIST 1.1  
New lesions  Result in progression; recorded but not 
measured  Results in iUPD but iCPD are only assigned 
on the basis of this category if at next 
assessment additional new lesions appear or 
an increase in size of new lesions is s een 
(≥ 5 mm for sum of new lesion target or any 
increase in new lesion non -target); the 
appearance of new lesions when none have 
previously been recorded can also confirm 
iCPD  
Independent blinded 
review and central 
collection of scans  Recommended in some circumstances 
(eg, in some trials with progression -
based endpoints planned for marketing 
approval)  Collection of scans (but not independent 
review) recommended for all trials  
Confirmation of 
progression  Not required (unless equivocal)  Required  
Consideration of 
clinical status  Not included in assessment  Clinical stability is considered when 
deciding whether treatment is continued 
after iUPD  
Abbreviations:  CPD = confirmed progressive disease; CR = complete response; iRECIST = immune -related  Resp onse 
Evaluation Criteria in Solid Tumors; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; 
SD = stable disease; UPD  = unconfirmed progressive disease. NOTE: “i” indicates immune responses assigned using iRECIST.  
Source : Seymo ur et al.  2017 . 
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
117 
11.4. Appendix 4: Response Criteria for Metastatic Prostate Cancer 
(Based on Prosta te Cancer Clinical Trials Working Group 3 
Criteria)  
 
Prostate -specific Antigen  
As long as  subject safety is the primary concern, in the absence of other indicators of disease 
progression, therapy should not be discontinued solely on the basis of a rise in PSA.  
PSA progression is defined as the date that a 25% or greater increase and an absolu te increase of 
2 ng/mL or more from the nadir are documented and confirmed by a second value obtained 3 or 
more weeks later. Where no decline from baseline is documented, PSA progression is defined as 
a 25% increase from the baseline value along with an in crease in absolute value of 2 ng/mL or 
more after 12 weeks of treatment.  
Bone  
Record post -treatment changes as either “no new lesions” or “new lesions.”  
Progressing disease on bone scan is considered when at least 2 new lesions are observed. If these 
2 or more new lesions are identified at the first post -treatment bone scans, progression remains 
unconfirmed unless at least 2 additional new lesions appear at a subsequent time point at least 
6 or more weeks later (“2  + 2” rule). This is intended to account fo r bone scan flare response that 
is generally seen at earlier time points. If progression (defined as at least 2 new lesions on bone 
scan) is first identified at a time point beyond the first post -treatment bone scan ( ie, beyond the 
typical flare response w indow), then these 2 (or more) lesions should be confirmed on a 
subsequent bone scan, performed at least 6 weeks later. When further progression is documented 
on the confirmatory scan, the date of progression recorded for the trial is the date of the first  scan 
that shows the change.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
118 
Prostate Cancer Clinical Trials Working Group Outcome Measures  
Variable  Prevent/Delay Endpoints  
PSA Decline from baseline: record time from start of therapy to first 
PSA increase that is ≥ 25% and ≥ 2  ng/mL above the nadir and that 
is confirmed by a second value 3 or more weeks later ( ie, a 
confirmed rising trend)a 
No decline from baseline: PSA progression ≥ 25% from baseline 
and ≥ 2  ng/mL increase from baseline after 12 weeks  
Soft-tissue lesions  Use iRECIST criteria  
Bone  The appearance of approximately 2 new lesions, and, for the first 
reassessment only, a confirmatory scan performed 6 or more weeks 
later that shows at leas t 2 or more additional new lesions (“2  + 2” 
rule).  
 
If progression (2 or more new lesions) is identified at a time point 
beyond the first post -treatment scan, then these lesions must be 
confirmed on a subsequent scan.  
 
The date of progression is the date of the first scan that shows the 
change  
Abbreviations: iRECIST = immune -related Response Evaluation Criteria in Solid Tumors, 
PSA = prostate -specific antigen.  
a Particularly important when anticipated effect on PSA is delayed or for biologic therapies.  
Source:  Scher et al.  2016  
 
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
119 
11.5. Appendix 5: Response Criteria for Lymphoma  
 
Comparison of Response Based on PET -CT and CT  
Response and Site  PET -CT-Based Response  CT-Based Response  
Complete  Complete metabolic response  Complete radiologic 
response (all of the 
following)  
Lymph nodes and 
extralymphatic sites  Score 1, 2, or 3a with or without a 
residual mass on 5 -PSb 
 
It is recognized that in Waldeyer’s 
ring or extranodal sites with high 
physiological uptake or with 
activatio n within spleen or marrow, 
eg, with chemotherapy or myeloid 
colony stimulating factors, uptake 
may be greater than normal 
mediastinum and/or liver. In this 
circumstance, complete metabolic 
response may be inferred if uptake at 
sites of initial involvement is no 
greater than surrounding normal 
tissue even if the tissue has high 
physiological uptake  Target nodes/nodal masses 
must regress to ≤ 1.5 cm in 
LDi 
 
No extralymphatic sites of 
disease  
Non-measured lesion  N/A Absent  
Organ enlargement  N/A Regress to normal  
New lesions  None  None  
Bone marrow  No evidence of FDG -avid disease in 
marrow  Normal by morphology; if 
indeterminate, 
immunohistochemistry  
negative  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
120 
Response and Site  PET -CT-Based Response  CT-Based Response  
Partial  Partial metabolic response  Partial remission (all of  the 
following)  
Lymph nodes and 
extralymphatic sites  Score 4 or 5b with reduced uptake 
compared with baseline  and residual 
mass(es) of  any siz e  
At interim these findings suggest 
responding dise ase 
 
At End of Treatment these findings 
indicate residual disease  ≥ 50% decrease in SPD of 
up to 6 target measurable 
nodes and extranodal sites  
When a lesion is too small to 
measure on CT, assign 5 mm 
× 5 mm as the default value  
When no longer visible, 
0 mm × 0 mm  
For a node >  5 mm × 5 mm, 
but smaller than normal, use 
actual measurement for 
calculation  
Non-measured lesions  N/A Absent/normal, regressed, 
but no increase  
Organ enlargement  N/A Spleen must have regressed 
by > 50% in length beyond 
normal  
New lesions  None  None  
Bone marrow  Residual uptake higher than uptake 
in normal marrow but reduced 
compared with baseline  (diffuse 
uptake compatible with reactive 
changes from chemotherapy 
allowed). If there are persistent focal 
changes in the marrow in the context 
of a nodal response, consideration 
should be given to further evaluation 
with MRI or biopsy, or an interval 
scan N/A 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
121 
Response and Site  PET -CT-Based Response  CT-Based Response  
No response or stable 
disease (SD)  No metabolic response  Stable disease  
Target nodes/nodal 
masses, extranodal 
lesions  No response: score 4 or 5 with no 
significant change in FDG uptake 
from baseline , at interim or End of 
Treatment  Stable disease: < 50% 
decrease from baseline  in 
SPD of up to 6 dominant, 
measurable nodes and 
extranodal sites; no criteria 
for PD are met  
Non-measured lesions  N/A No increase consistent with 
progression  
Organ enlargement  N/A No increase consistent with 
progression  
New lesions  None  None  
Bone marrow  No change from baseline  N/A 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
122 
Response and Site  PET -CT-Based Response  CT-Based Response  
Progressive disease  Progressive metabolic disease  Progressive disease 
requires at least 1 of the 
following  
Individual target 
nodes/nodal masses, 
extranodal lesions  Score 4, 5 with an increase in 
intensity of uptake from baseline  
and/or new FDG -avid foci consistent 
with lymphoma at interim or End of 
Treatment assessment  PPD progression:  
An individual node must b e 
abnormal with:  
• LDi >1.5 cm  
• Increase by ≥50% from 
PPD nadir  
An increase in LDi or SDi 
from nadir  
• 0.5 cm for lesions ≤ 2 cm  
• 1.0 cm for lesions > 2 cm  
In the setting o f 
splenomegaly, the splenic 
length must increase by 
> 50% of the extent of its  
  prior increase beyond 
baseline  (eg, a 15 cm spleen 
must increase to > 16 cm). If 
no prior splenomegaly, must 
increase by at least 2 cm 
from baseline  
New or recurrent 
splenomegaly  
Non-measured lesions  None  New or clear progression of 
pre-existing non -meas ured 
lesions  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
123 
Response and Site  PET -CT-Based Response  CT-Based Response  
New lesions  New FDG -avid foci consistent with 
lymphoma rather than another 
etiology, eg, infection, inflammation. 
If uncertain regarding etiology of 
new lesions, biopsy or interval scan 
may be considered  Regrowth of previously 
resolved lesion s 
A new node > 1.5 cm in any 
axis 
A new extranodal  site 
> 1.0 cm in any axis if less 
than 1.0 cm in any axis, its 
presence must be 
unequivocal and must be 
attributable to lymphoma  
Assessable disease of any 
size unequivocally 
attributable to lymphoma  
Bone marrow  New or recurrent FDG avid foci  New or recur rent 
involvement  
Abbreviations: 5 -PS = 5 -point scale, CT = computed tomography, FDG = fluorodeoxyglucose, LDi = longest 
transverse diameter of a lesion, MRI = magnetic resonance imaging, N/A = not a pplicable , PD = progressive 
disease, PET = positron emiss ion tomography, PPD = cross product of the LDi and perpendicular diameter, 
SDi = shortest axis perpendicular to the LDi, SPD = sum of the product of the perpendicular diameters for 
multiple lesions.  
a Score 3 in many individuals  indicates a good prognosis with standard treatment, especially if at the time of an 
interim scan. However, in trials involving PET where de -escalation is investigated, it may be preferable to 
consider score 3 as inadequate  response (to avoid under -treatment).  
Measured dominant lesions: Up to 6 of the largest dominant nodes, nodal masses , and extranodal lesions selected 
to be clearly measurable in 2 diameters. Nodes should preferably be from disparate regions of the body an d 
should include, where applicable, mediastinal and retroperitoneal areas. Non -nodal lesions include those in solid 
organs, eg, liver, spleen, kidneys, lungs, etc., gastrointestinal involvement, cutaneous lesions of those noted on 
palpation. Non -measured l esions: any disease not selected as measured, dominant disease and truly assessable 
disease should be considered not measured. These sites include any nodes, nodal masses, and extranodal sites not 
selected as dominant, measurable , or which do not meet the requirements for measurability but are still 
considered abnormal. In addition, they include  truly assessable disease , which is any site of suspected disease 
that would be difficult to follow quantitatively with measurement, including pleural effusions, asc ites, bone 
lesions, leptomeningeal disease, abdominal masses , and other lesions that cannot be confirmed and followed by 
imaging. In Waldeyer’s ring or in extranodal sites, eg, gastrointestinal tract, liver, and bone marrow, FDG uptake 
may be greater than mediastinum with complete metabolic response but should be no higher than surrounding 
normal physiologic al uptake, eg , with marrow activation due to chemotherapy or myeloid growth factors.  
b PET 5 -PS: 1 , no uptake above background; 2, uptake ≤ mediastinum; 3, uptake >  mediastinum, but ≤  liver; 4, 
uptake modera tely > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake 
unlikely to be related to lymphoma.  
 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
124 
Features Distinguishing Between Lugano and LYRIC  
Criteria  Complete 
Response  Partial 
Response  Progressive Disease  
LYRIC  Same as 
Lugano  Same as 
Lugano  As with Lugano with the following exceptions:  
IR 
IR(1): > 50% increase in SPD in first 12 weeks  
IR(2): < 50% increase in SPD with  
New lesion(s), or  
> 50% increase in PPD of a lesion or set of lesions at any 
time during treatment  
IR(3): Increase in FDG uptake without a concomitant 
increase in lesion size meeting criteria for PD.  
Abbreviations: FDG = fluorodeoxyglucose , IR = immune response; LYRIC = LYmphoma  Response to 
Immunomodulatory Therapy Criteria, PD = progressive disease; PPD = cross product of the longest transverse 
diameter of a lesion and perpendicular diameter; SPD = sum of the product of the diameters.  
Source: Cheson et al.  2016  
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
125 
11.6. Appendix 6: Adaptive Design Report for the Phase I Dose Escalation 
Study of TTX -030 in Patients  with Lymphoma or Solid Tumor 
Malignancies  
 
Note: This appendix only applies to the monotherapy dose -escalation portion of the study.  
Submitted to Trishula  
By Berry Consultants  
 
 
1.0 Introduction  
2.0 Dose Escalation  
2.1 Overview  
2.2 DLT Observation Period  
2.3 Dose -Toxicity Model  
2.4 Dose Escalation Rules  
2.4.1  Entry into the Study  
2.4.2  Assignment of Dose Levels  
2.5 Interim Monitoring  
2.5.1  Safety Monitoring  
2.5.2  Success in Identifying the MTD  
3.0 Example Trials  
4.0 Single Agent Operating Characteristics  
4.1 Simulation Assumptions  
4.2 Simulation Scenarios  
4.2.1  All Doses Safe  
4.2.2  No Do ses Safe  
4.2.3  True MTD = 2 mg/kg  
4.2.4  True MTD = 5 mg/kg  
4.2.5  True MTD = 8 mg/kg  
4.2.6  True MTD = 3 mg/kg  
4.2.7  True MTD = 6 mg/kg  
5.0 Combination Operating Characteristics  
5.1 First Dosing Cohort Behavior  
5.2 Operating Characteristics  
 
1.0 Introduction  
This is a Phase I dose -escalation study of TTX -030 in patients  with lymphoma or solid tumor 
malignancies. The primary objective of this trial is to characterize the dose -toxicity relationship 
and to estimate the maximum tolerated dose (MTD) that will help determine the RP2D for each 
arm. Dose escalation to determine the MTD will be conducted according to a modified continual 
reassessment method (mCRM). The single -agent  investigation may enroll up to 21 subjects. 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
126 
Safety lead -in combination investigations may enroll up to 12 subjects. The single -agent and the 
combinatio n investigations will be conducted independently and identically with the exception of 
the starting dose.   
2.0 Dose Escalation  
2.1 Overview  
The primary objective of the dose escalation portion of the study is to estimate an MTD to help 
determine the RP2D.  We target a dose -limiting toxicity (DLT) rate of 30% and define the MTD 
as the highest safe dose where the DLT rate is closest to 30%.   
There are a total of 11 possible dose levels between 0.5 mg/kg and 10 mg/kg. Dose levels are 
shown in Table 1 . These i nclude a set of primary dose levels (indicated by asterisks) as well as 
several intermediate dose levels.  
Table 1 : Dose Levels   
Dose in mg/kg  Dose Level 
Modeled as  
( vd) 
0.5* 1 
1.5* 2 
2 3 
3* 4 
4 5 
5 6 
6* 7 
7 8 
8 9 
9 10 
10* 11 
 
Dose escalation will be conducted according to a mCRM. Dose escalation is also conducted 
according to a set of rules that govern entry into the study and assignment of dose level. These 
rules allow skipping untried dose levels provided they are estimated t o be safe. The trial is 
continuously monitored for safety and for early stopping for successfully identifying the MTD.  
2.2 DLT Observation Period  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
127 
The DLT observation period, for the purpose of dose -escalation, is one cycle. One cycle is 
3 weeks in length f or the single agent. Once a subject has completed this first cycle DLT 
observation period, the subject will be considered to have complete DLT information for the 
purposes of making dose escalation decisions for the next subject enrolling into the trial.   
2.3 Dose -Toxicity Model  
For each dose we model the log -odds of a DLT, π, at each dose level with a 2 -parameter model,  
log(πd
1−πd)=α+β(vd). 
where v d is the modeled dose level as show in Table 1 .   
We place the following prior distributions on the model parameters:  
[α
ln(β)]~N[[μα
μβ],[σα2ρσασβ
ρσασβσβ2]] 
where  
μα = −4 and σα= 2.5  
μβ= −1.6 and σβ = 0.9  
ρ = 0. 
Figure 1 shows 100 draws from the prior dose -toxicity curve. The solid blue line corresponds to 
the mean probability of a DLT at each dose. The dotted blue l ines correspond to 95% confidence  
interval (CI) for the probability of a DLT at each dose. The MTD based on the prior distribution 
is 9 mg/kg, but with large uncertainty.   
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
128 
 
Figure  1: Prior dose -toxicity curve . The solid blue line represents the mean probability of a DLT 
at each dose. The gray lines represent draws from the prior distribution. The dotted blue lines 
show the 95% confidence  interval around the probability of DLT at each dose level. The dotted 
red line is at 30% for reference.  
The model will be updated as frequently as necessary. In particular, the model may be updated as 
each dosing cohort is treated and assessed for DLT. When the model is updated, the distributions 
of all parameters are updated u sing Markov chain Monte Carlo methods and the MTD is 
estimated based on the posterior probability of DLT at each dose.   
Additionally, we define a dose as safe if there is at least a 45% probability that the DLT rate is 
less than 30%,  
Pr(π vd < 30%) > 45%.  
If the DLT rate is estimated to be exactly 30%, the Pr(πd < 30%) will be approximately 50%. 
Therefore, only doses with a mean estimated DLT rate close to 30% will be considered safe by 
this definition.  
0.0 0.2 0.4 0.6 0.8 1.0
DosePr Tox
0.5 1.5 2 3 4 5 6 7 8 9 10
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
129 
2.4 Dose Escalation Rules  
2.4.1 Entry into the Study  
Dose escalation for the single agent begins with a run -in of a single subject on the 0.5 mg/kg 
dose. Beginning with the next subject enrolled, this trial will enroll in dosing cohorts. Dosing 
cohorts will be 2 subjects until the first Grade 2 toxicity rela ted to study treatment or a DLT is 
observed. After that, dosing cohorts will be 3 subjects.  
Dose escalation for the combinations may begin at a higher dose level depending on which dose 
levels have already been determined to be safe in the single -agent  investigation. For the 
combination investigations, enrollment will begin with dosing cohorts.  
2.4.2 Assignment of Dose Levels  
The dose -toxicity model will be used to determine which doses are safe and to assign subjects to 
doses, ie, to assign subjects to the  highest safe dose. However, assignment of dose levels is also 
governed by rules concerning the speed of dose escalation and rules that determine what untried 
dose levels may be skipped.  
When the dose is escalated, it may only escalate to the highest safe dose that is no more than a 
100% increase over the current dose level. The only exception to this is the escalation from the 
0.5 mg/kg dose to the 1.5 mg/kg dose. Therefore, the fastest dose escalation for the single agent 
that could occur would be 0.5 mg/ kg to 1.5 mg/kg, then 3 mg/kg, 6 mg/kg , and then finally to 
10 mg/kg (skipping all intermediate dose levels). If the dose must be de -escalated, the dose will 
de-escalate to the highest safe dose regardless of how large a decrease in dose level.  
As long as no Grade 2 toxicity related to study drug or DLT has yet been observed, there must be 
complete DLT information on at least 2 subjects at the current dose level in order to escalate 
(with the exception of the single subject required at the 0.5 mg/kg dose fo r the single agent). 
Once the first Grade 2 toxicity related to study drug or DLT is observed in the trial, there must be 
complete DLT information on at least 3 subjects at the current dose level in order to escalate.  
2.5 Interim Monitoring  
Dose escalatio n will be continuously monitored for safety and for success in identifying the 
MTD. In this section, we describe the prespecified rules to stop the dose -escalation early. If the 
dose-escalation is not stopped early, dose escalation will stop when the maxim um number of 
subjects has been enrolled. This is 25 subjects for the single agent and 12 subjects for each 
combination. At that time, the MTD will be the highest safe dose as estimated by the dose 
toxicity model.   
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
130 
2.5.1 Safety Monitoring  
If no doses are safe, dose escalation will stop and no MTD will be declared. Formally if all  
Pr(d < 30%) < 45% for all v d = 1,…11  
then the trial will stop early for safety.  
2.5.2 Success in Identifying the MTD  
Dose escalation may be stopped early when we are s ufficiently confident the MTD has been 
identified. We define this as having 6 subjects with complete DLT information at the current 
estimate of the MTD.   
 
  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
131 
3.0 Example Trials  
In this section we show a single simulated trial in order to illustrate the dose -toxicity modeling 
and dose escalation decisions of the mCRM.   
Figure 2 shows the allocation of the first 3 subjects in the trial. The trial begins with the single 
agent with a single subject run -in on the 0.5 mg/kg dose level. This subject experiences no 
toxicity and the dose is escalated. Dosing cohorts begin after this single subject run -in. The first 
dosing cohort of size 2 is enrolled at the 1.5 mg/kg dose. Neither of thes e subjects experience s a 
toxicity event. The highest safe dose is estimated to be 10 mg/kg ; however , the largest increase 
allowed is a 100% increase.   
 
Figure 2:  Example trial with 3 total subjects enrolled. The left panel shows subject allocation 
where each dot represents one subject. The right panel shows the dose -toxicity model estimates. 
The solid red line is the mean and the dotted red lines show the 95% confidence  interval. The 
black horizontal reference line is at 30% for reference and the black ve rtical reference line 
indicates the highest safe dose.  
 

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
132 
 
Figure 3:  Example trial with 5 total subjects enrolled. The left panel shows subject allocation 
where each dot represents one subject. The right panel shows the dose -toxicity model estimates. 
The so lid red line is the mean and the dotted red lines show the 95% confidence  interval. The 
black horizontal reference line is at 30% for reference and the black vertical reference line 
indicates the highest safe dose.  
The next dosing cohort is enrolled at 3 m g/kg (Figure 3). One of these subjects experiences a 
DLT. The highest safe dose level is now estimated to be 4 mg/kg. When either a Grade 2 toxicity 
related to study drug or a DLT is observed, the dosing cohort size must expand to 3  subjects. 
Because 3 mg/ kg is still considered safe , a third subject is added to the 3 mg/kg dose (Figure 4).  

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
133 
 
Figure 4:  Example trial with 6 total subjects enrolled. The left panel shows subject allocation 
where each dot represents one subject. The right panel shows the dose -toxicity model estimates. 
The solid red line is the mean and the dotted red lines show the 95% confidence  interval. The 
black horizontal reference line is at 30% for reference and the black vertical reference line 
indicates the highest safe dose.   
This thir d subject does not experience a DLT, and the highest safe dose is now 5 mg/kg 
(Figure  4), one of the intermediate doses. The observed toxicity results in the model slowing 
down the escalation so that the next dose is a 67% increase from the current dose. A  dosing 
cohort of 3  subjects is enrolled at the 5 mg/kg dose (Figure 5).   

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
134 
 
Figure 5:  Example trial with 9 total subjects enrolled. The left panel shows subject allocation 
where each dot represents one subject. The right panel shows the dose -toxicity mode l estimates. 
The solid red line is the mean and the dotted red lines show the 95% confidence  interval. The 
black horizontal reference line is at 30% for reference and the black vertical reference line 
indicates the highest safe dose.   
One of the subjects at 5 mg/kg experiences a DLT (Figure 5). The 5 mg/kg remains the highest 
safe dose , and a second dosing cohort of 3 subjects is added to the 5 mg/kg dose (Figure 6).  

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
135 
 
Figure 6:  Example trial with 12 total subjects enrolled. The left panel shows subject allocation 
where each dot represents one subject. The right panel shows the dose -toxicity model estimates. 
The solid red line is the mean and the dotted red lines show the 95% confidence  interval. The 
black horizontal reference line is at 30% for reference and the black vertical reference line 
indicates the highest safe dose.  
We have now observed 1 DLT out of 6 subjects on the 5 mg/kg dose (Figure 6). The highest safe 
dose is 7 mg/ kg. A dosing cohort of 3 subjects is added to 7 mg/kg , and 2 of these subjects 
experience a DLT (Figure 7).  

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
136 
 
Figure 7:  Example trial with 15 total subjects enrolled. The left panel shows subject allocation 
where each dot represents one subject. The right panel shows the dose -toxicity model estimates. 
The solid red line is the mean and the dotted red lines show the 95% confidence  interval. The 
black horizontal reference line is at 30% for reference and the black vertical reference line 
indicates the highest safe dose.  
The dose is de-escalated,  and the highest safe dose is 5 mg/kg (Figure 7). There are already 
6 subjects with compl ete DLT information at 5 mg/kg and this trial stops early for having 
identified the MTD.  
4.0 Single -Agent Operating Characteristics  
We evaluate the design by clinical trial simulation. We hypothesize several possible underlying 
truths of the dose -toxicity  curve and  determine how the trial will behave in those scenarios. For 
example, if all the doses were toxic, we would want the trial to recognize that all doses were 
unsafe and stop as soon as possible. If the smaller doses are safe and a higher dose is in  truth the 
MTD, we would like the algorithm to identify a dose near the MTD as much as possible. The 
same design can ideally handle different scenarios. Note that this ideal is difficult to achieve in 
practice with any Phase 1 design due to the small sampl e sizes.  
4.1 Simulation Assumptions  
We consider 7 scenarios for the dose -toxicity relationship to characterize the mCRM for 
different possible underlying truths for the probability of DLT at each dose level. Each scenario 
assumes the probability of Grade 2  toxicities related to study drug are a constant increase from 

 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
137 
the probability of DLT on the log -odds scale. For technical reasons, simulations always assume 
that the run -in subject assigned to the 0.5 mg/kg dose level experiences no Grade 2 toxicity or 
DLT. This subject is included in the simulations as a “pseudo -subject” and as such is not 
reflected in the mean sample size or mean number of DLT operating characteristics presented 
below.   
4.2 Simulation Scenarios  
Figure 8 shows the different simulation sc enarios used to characterize the performance of the 
mCRM. We consider a scenario in which all doses are considered safe, a scenario in which no 
doses are considered safe, and then explore other dose -toxicity curves where the true MTD is in 
various location s across the dose range.   
 
Figure 8:  Dose -toxicity scenarios. The red line indicates the probability of DLT,  and the pink 
line indicates the probability of a Grade 2 or higher toxicity. The horizontal line is at 30% for 
reference.  
  
0.0 0.2 0.4 0.6 0.8 1.0All Safe
DoseProbability of Toxicity
0.5 2 3 4 5 6 7 8 9 10Pr(DLT)
Pr(G rade2)
0.0 0.2 0.4 0.6 0.8 1.0None Safe
DoseProbability of Toxicity
0.5 2 3 4 5 6 7 8 9 10
0.0 0.2 0.4 0.6 0.8 1.02mg
DoseProbability of Toxicity
0.5 2 3 4 5 6 7 8 9 10
0.0 0.2 0.4 0.6 0.8 1.05mg
DoseProbability of Toxicity
0.5 2 3 4 5 6 7 8 9 100.0 0.2 0.4 0.6 0.8 1.08mg
DoseProbability of Toxicity
0.5 2 3 4 5 6 7 8 9 10
0.0 0.2 0.4 0.6 0.8 1.03mg
DoseProbability of Toxicity
0.5 2 3 4 5 6 7 8 9 10
0.0 0.2 0.4 0.6 0.8 1.06mg
DoseProbability of Toxicity
0.5 2 3 4 5 6 7 8 9 10
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
138 
4.1.1 All Doses Safe  
In this scenario all doses are considered safe. The true MTD is 10 mg/kg with a DLT rate of 
18%. The 10 mg/kg dose is the dose most likely to be selected as the MTD. There is a 97% 
probability of selecting 10  mg/kg dose as the MTD. The total mean number of  subjects in this 
scenario is 13.7. The mean samples sizes per dose reflect the skipping rules that allow untried 
doses to be skipped. On average, most subjects are allocated to the primary dose levels, with 
fewer subjects allocated to the intermediate dos e levels.  
Scenario 1: All Doses Safe  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.00 0.00 0.00 0.01 0.01 0.02 0.03 0.05 0.08 0.12 0.18 
Mean N  0 2.0 0.0 2.0 0.0 0.1 2.2 0.0 0.5 0.3 6.5 
Mean 
DLTs  0.00 0.00 0.00 0.01 0.00 0.00 0.07 0.00 0.04 0.04 1.16 
Pr(MTD)  0 0 0 0 0 0 0 0.003  0.02 0.02 0.97 
 
4.1.2 No Doses Safe  
In this scenario, none of the dose levels would be considered safe. The lowest dose level, 
0.5 mg/kg has a DLT rate of 49%. This lowest dose is selected as the MTD with 12% 
probability. There is a 69% probability of stopping for toxicity and selecting no d ose as the 
MTD. The total mean number of subjects in this scenario is 9. The operating characteristics of 
this scenario may be slightly more aggressive than in truth due to the simulation assumption that 
the first run -in subject on the 0.5 mg/kg dose level  does not experience a toxicity.   
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
139 
Scenario 2: No Doses Safe  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.49 0.55 0.60 0.64 0.67 0.70 0.72 0.74 0.76 0.78 0.79 
Mean N  2.7 4.0 0.5 1.6 0.1 0.1 0.1 0.0 0.0 0.0 0.0 
Mean 
DLTs  1.3 2.2 0.3 1 0.0 0.1 0.0 0.0 0.0 0 0.0 
Pr(MTD)  0.12 0.14 0.01 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
4.1.3 True MTD = 2 mg/kg  
In this scenario the true MTD is 2 mg/kg with a DLT rate of 26%. This dose is declared as the 
MTD with 31% probability. The 3 mg/kg dose is slightly more likely to be selected as the MTD. 
The 3 mg/kg dose has a true DLT rate of 41% is selected as the MTD w ith 41%  probability. The 
probability of selecting a dose within 1 dose level of the true MTD is 22%  + 31% + 41% = 94%. 
A mean of 5 subjects are enrolled at the 3 mg/kg dose and a mean of 2  DLTs are observed. The 
total mean number of subjects in this scenar io is 14.5.  
Scenario 3: 2 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.08 0.15 0.26 0.41 0.59 0.74 0.85 0.92 0.96 0.98 0.99 
Mean N  0.5 3.9 2.8 4.8 0.5 1.3 0.6 0.0 0.0 0.0 0.0 
Mean 
DLTs  0.0 0.6 0.7 2.0 0.3 0.9 0.5 0.0 0.0 0.0 0.0 
Pr(MTD)  0.02 0.22 0.31 0.41 0.01 0.01 0.00 0.00 0.00 0.00 0.00 
 
4.1.4 True MTD = 5 mg/kg  
The true MTD in this scenario is 5 mg/kg with a true DLT rate of 29%. This dose is the mostly 
likely to be selected as the MTD and is selected with 25% probability. There is 57% probability 
of selecting a dose within 1 dose level of the true MTD. The total mean number of subjects is 
17.6.  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
140 
Scenario 4: 5 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.08 0.11 0.14 0.18 0.23 0.29 0.35 0.43 0.50 0.57 0.65 
Mean N  0.1 2.7 0.5 3.6 1.0 2.8 2.9 1.2 1.3 0.5 1.0 
Mean 
DLTs  0.0 0.3 0.1 0.7 0.2 0.8 1.0 0.5 0.7 0.3 0.6 
Pr(MTD)  0.00 0.02 0.03 0.16 0.10 0.25 0.22 0.09 0.07 0.02 0.02 
 
4.1.5 True MTD = 8 mg/kg  
The true MTD in this scenario is 8 mg/kg with a true DLT rate of 26%. This dose is selected as 
the MTD with 22% probability. The 10 mg/kg dose, which has a true DLT rate of 41% is 
selected as the MTD with 46% probably. A mean of 4.2 subjects are enrolled a t the 10 mg/kg 
dose and a mean of 1.7 DLTs are observed. The total mean sample size in this scenario is 17.6.  
Scenario 5: 8 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.02 0.03 0.04 0.06 0.08 0.11 0.15 0.20 0.26 0.33 0.41 
Mean N  0.0 2.2 0.1 2.5 0.1 0.8 3.0 1.1 2.6 1.1 4.2 
Mean 
DLTs  0.0 0.1 0.0 0.2 0.0 0.1 0.5 0.2 0.7 0.4 1.7 
Pr(MTD)  0.00 0.00 0.00 0.01 0.00 0.03 0.09 0.10 0.22 0.08 0.46 
 
4.1.6 True MTD = 3 mg/kg  
The true MTD in this scenario is 3 mg/kg with a DLT rate of 24%. This dose is the most likely to 
be selected as the MTD and is selected with 56% probability. The total mean sample size in this 
scenario is 16.  
Scenario 6: 3 mg/kg  
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
141 
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.03 0.06 0.13 0.24 0.40 0.60 0.76 0.87 0.94 0.97 0.99 
Mean N  0.1 2.6 1.6 5.4 2.0 2.5 1.6 0.0 0.2 0.0 0.0 
Mean 
DLTs  0.0 0.2 0.2 1.3 0.8 1.5 1.2 0.0 0.2 0.0 0.0 
Pr(MTD)  0.00 0.03 0.15 0.56 0.18 0.08 0.01 0.00 0.00 0.00 0.00 
 
4.1.7 True MTD = 6 mg/kg  
The true MTD in this scenario is 6 mg/kg with a true DLT rate of 27%. This dose is the most 
likely to be selected as the MTD and is selected with 38% probability. The total mean sample 
size in this scenario is 18.6.  
Scenario 7: 6 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.02 0.03 0.05 0.08 0.12 0.18 0.27 0.38 0.50 0.62 0.73 
Mean N  0.0 2.2 0.1 2.7 0.6 2.4 4.4 1.8 2.4 0.5 1.6 
Mean 
DLTs  0 0.1 0.0 0.2 0.1 0.4 1.2 0.7 1.2 0.3 1.2 
Pr(MTD)  0.00 0.00 0.00 0.02 0.05 0.23 0.38 0.16 0.13 0.02 0.02 
 
5.0 Combination Operating Characteristics  
In the section we describe the behavior of the mCRM for the combination in the case that the 
starting dose is higher. If the starting dose is a low dose, the behavior will be very similar to that 
described for the single agent. The highest starting dose fo r the combination is likely to be 
5 mg/kg dose. Therefore, in this section we describe the behavior of the mCRM assuming this 
higher starting dose.  
5.1 First Dosing Cohort Behavior  
At the 5  mg/kg starting dose, the dosing cohort will be size 2. If no DLTs are observed, the dose 
may escalate to the 10 mg/kg dose. If 1 DLT is observed, the dosing cohort will add 1  subject  to 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
142 
be size 3. If out of a dosing cohort of 3 subject s, only 1 DLT is observed the dose will escalate to 
7 mg/kg. If 2 DLTs are observe d out of a dosing cohort of 3 subject s, the dose will de -escalate to 
1 mg/kg and if 3 DLTs are observed the dose will de -escalate to 0.5  mg/kg.  
5.2 Operating Characteristics  
We simulate the behavior of the design where the starting dose is 5 mg/kg assuming  the same 
true dose -toxicity scenarios as described for the single agent. Generally , we see similar trends in 
behavior to the single -agent  escalation in terms of correctly identifying the MTD. Several 
scenarios show that should 5 mg/kg be an unsafe dose, t he mCRM is able to de -escalate to safe 
doses.  
Scenario 1: All Doses Safe  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.00 0.00 0.00 0.01 0.01 0.02 0.03 0.05 0.08 0.12 0.18 
Mean N  0.0 0.0 0.0 0.0 0.0 2.1 0.2 0.3 0.1 0.3 6.4 
Mean 
DLTs  0.00 0.00 0.00 0.00 0.00 0.04 0.01 0.01 0.01 0.04 1.18 
Pr(MTD)  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.05 0.92 
 
Scenario 2: No Doses Safe  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.49 0.55 0.60 0.64 0.67 0.70 0.72 0.74 0.76 0.78 0.79 
Mean N  1.2 2.1 0.3 0.5 0.1 3.1 0.6 0.1 0.0 0.0 0.2 
Mean 
DLTs  0.54 1.16 0.19 0.31 0.06 2.16 0.46 0.04 0.01 0.00 0.12 
Pr(MTD)  0.04 0.09 0.04 0.03 0.02 0.01 0.01 0.00 0.00 0.00 0.00 
 
Scenario 3: 2 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
143 
True 
Pr(DLT)  0.08 0.15 0.26 0.41 0.59 0.74 0.85 0.92 0.96 0.98 0.99 
Mean N  1.3 3.1 1.2 1.8 0.2 3.1 0.4 0.0 0.0 0.0 0.1 
Mean 
DLTs  0.10 0.45 0.32 0.75 0.09 2.30 0.37 0.01 0.00 0.00 0.09 
Pr(MTD)  0.04 0.26 0.20 0.29 0.08 0.01 0.00 0.00 0.00 0.00 0.00 
 
Scenario 4: 5 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.08 0.11 0.14 0.18 0.23 0.29 0.35 0.43 0.50 0.57 0.65 
Mean N  0.1 0.7 0.2 1.0 0.4 3.6 2.0 1.0 0.3 0.2 2.0 
Mean 
DLTs  0.01 0.06 0.02 0.20 0.09 1.03 0.69 0.44 0.13 0.12 1.31 
Pr(MTD)  0.01 0.02 0.03 0.09 0.19 0.18 0.20 0.12 0.08 0.02 0.06 
 
Scenario 5: 8 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.02 0.03 0.04 0.06 0.08 0.11 0.15 0.20 0.26 0.33 0.41 
Mean N  0.0 0.1 0.0 0.1 0.0 2.8 1.1 1.2 0.6 0.5 4.4 
Mean 
DLTs  0.00 0.00 0.00 0.01 0.00 0.28 0.16 0.25 0.14 0.20 1.84 
Pr(MTD)  0.00 0.00 0.00 0.01 0.02 0.05 0.09 0.14 0.16 0.11 0.43 
 
Scenario 6: 3 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
144 
True 
Pr(DLT)  0.03 0.06 0.13 0.24 0.40 0.60 0.76 0.87 0.94 0.97 0.99 
Mean N  0.6 2.3 1.1 2.7 0.6 3.4 0.8 0.0 0.0 0.0 0.3 
Mean 
DLTs  0.02 0.12 0.13 0.66 0.22 2.04 0.65 0.00 0.00 0.00 0.29 
Pr(MTD)  0.01 0.07 0.12 0.40 0.31 0.07 0.00 0.00 0.00 0.00 0.00 
 
Scenario 7: 6 mg/kg  
 0.5 1.5 2 3 4 5 6 7 8 9 10 
True 
Pr(DLT)  0.02 0.03 0.05 0.08 0.12 0.18 0.27 0.38 0.50 0.62 0.73 
Mean N  0.0 0.2 0.0 0.5 0.3 3.9 2.0 1.5 0.3 0.2 2.6 
Mean 
DLTs  0.00 0.01 0.00 0.04 0.03 0.70 0.54 0.57 0.16 0.15 1.86 
Pr(MTD)  0.00 0.00 0.01 0.02 0.11 0.22 0.27 0.21 0.09 0.03 0.04 
 
 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
145 
12. References  
ABRAXANE®. (nab-paclitaxel) [prescribing information]. Summit, NJ: Celgene Corporation. 
2018.  
 
Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel 
checkpoint inhibitor targets. Immunological reviews. 2017;276(1):121 -44. 
 
Antonioli L, Hask ó G, Fornai M, Colucci R, Blandizzi C. Adenosine pathway and cancer: where 
do we go from here? Expert opinion on therapeutic targets. 2014;18(9):973 -7. 
 
Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, et al. Prevention 
and treatment o f cancer -related infections. Journal of the National Comprehensive Cancer 
Network. 2012;10(11):1412 -45. 
 
Bastid J, Cottalorda -Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. 
ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene. 2 013;32(14):1743 -51. 
 
Bono MR, Fernandez D, Flores -Santibanez F, Rosemblatt M, Sauma D. CD73 and CD39 
ectonucleotidases in T cell differentiation: Beyond immunosuppression. FEBS letters. 
2015;589(22):3454 -60. 
 
Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5' -triphosphate 
and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacology 
& therapeutics. 2006;112(2):358 -404. 
 
Boyd -Tressler A, Penuela S, Laird DW, Dubyak GR. Chemotherapeutic drugs induce ATP 
release via caspase -gated pannexin -1 channels and a caspase/pannexin -1-independent 
mechanism. The Journal of biological chemistry. 2014;289(39):27246 -63. 
 
Cai XY, Wang XF, Li J, Dong JN, Liu JQ, Li NP, et al. High expression of CD39 in gastric 
cancer r educes patient outcome following radical resection. Oncology letters. 2016;12(5):4080 -6. 
 
Canale FP, Ramello MC, Nunez N, Araujo Furlan CL, Bossio SN, Gorosito Serran M, et al. 
CD39 Expression Defines Cell Exhaustion in Tumor -Infiltrating CD8(+) T Cells. C ancer 
research. 2018;78(1):115 -28. 
 
Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the 
Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. 
Blood. 2016;128(21):2489 -96. 
 
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. 
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and 
non-Hodgkin lymphoma: the Lugano classification. Journal of clinical oncology. 
2014;32(27):3059 -68. 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
146 
 
Chiappori A, Williams C, Creelan B, Tanvetyanon T, Gray J, Haura E, et al. Phase I/II study of 
the A2AR antagonist NIR178 (PBF -509), an oral immunotherapy, in patients (pts) with 
advanced NSCLC  (Abstract) . Journal of clinical oncology. 2018;36:9089.  
 
Deagli o S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation 
catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. 
The Journal of experimental medicine. 2007;204(6):1257 -65. 
 
Di Virgilio F, Falzoni S, Gi uliani AL, Adinolfi E. P2 receptors in cancer progression and 
metastatic spreading. Current opinion in pharmacology. 2016;29:17 -25. 
 
Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC. CD39 and control of 
cellular immune responses. Purinergic sign alling. 2007;3(1 -2):171 -80. 
 
Eppell BA, Newell AM, Brown EJ. Adenosine receptors are expressed during differentiation of 
monocytes to macrophages in vitro. Implications for regulation of phagocytosis. Journal of 
immunology. 1989;143(12):4141 -5. 
 
FDA. Cente r for Drug Evaluation Research (CDER) and Center for Biologics Evaluation and 
Research. FDA Guidance for Industry: Guidance on Informed Consent for In Vitro Diagnostic 
Device Studies Using Leftover Human Specimens that are Not Individually Identifiable 
Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff. . 
2006.  
 
FDA. Center for Drug Evaluation Research (CDER) and Center for Biologics Evaluation and 
Research. FDA Guidance for Industry: Estimating the Maximum Safe Start ing Dose in Initial 
Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005.  
 
Feng L, Sun X, Csizmadia E, Han L, Bian S, Murakami T, et al. Vascular CD39/ENTPD1 
directly promotes tumor cell growth by scavenging extracellular adenosine triphospha te. 
Neoplasia (New York, NY). 2011;13(3):206 -16. 
 
GEMZAR®. (gemcitabine) [prescribing information]. Indianapolis, IN: Lilly USA, LLC. 2017.  
 
Giannakis M, Li H, Jin C, Gopal S, Desai K, Horak C, et al. Metabolomic correlates of response 
in nivolumab -treated renal cell carcinoma and melanoma patients  (Abstract) . Journal of clinical 
oncology. 2017;35(15_suppl):3036.  
 
Hask ó G, Kuhel DG, Salzman AL, Szabo C. ATP suppression of interleukin -12 and tumour 
necrosis factor -alpha release from macropha ges. British journal of pharmacology. 
2000;129(5):909 -14. 
 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
147 
Haskó G, Szabó C, Németh H, Kvetan V, Pastores S, Vizi E. Adenosine receptor agonists 
differentially regulate IL -10, TNF -alpha, and nitric oxide production in RAW 264.7 
macrophages and in endotoxem ic mice. J ournal of  immunol ogy. 1996;157(10):4634 -40. 
 
Hotson D, Powderly J, Emens L, Forde P, Hellmann M, Fong L, et al. Clinical activity of 
adenosine A2A receptor (A2aR) inhibitor CPI -444 is associated with tumor expression of 
adenosine pathway genes an d tumor immune modulation. [oral presentation]. In: Proceedings of 
the 32nd Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2017); 2017 
Nov 8 -12; National Harbor, MD. J ournal of  immunother apy of  cancer 2017;5(Suppl 2):86. 
Abstract nr O4 . 
 
IMFINZI®. (durvalumab) [prescribing information]. Wilmington, DE: AstraZeneca 
Pharmaceuticals LP. 2018.  
 
Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, et al. Identification and 
characterization of CD39/vascular ATP diphosphohydro lase. The Journal of biological 
chemistry. 1996;271(51):33116 -22. 
 
KEYTRUDA®. [pembrolizumab] prescribing information. Whitehouse Station, NJ: Merck 
Sharp & Dohme Corp. subsidiary of Merck & Co., INC. 201 9. 
 
Koziak K, Sevigny J, Robson SC, Siegel JB, Kaczm arek E. Analysis of CD39/ATP 
diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. 
Thrombosis and haemostasis. 1999;82(5):1538 -44. 
 
Lapierre M, Dejou C, Paturel C, Michaud H, Gros L, Bensussan A, et al. Abstract 3218: 
Disruption of the CD39 immune checkpoint pathway increases the efficacy of various anticancer 
therapies in syngeneic mouse models . Cancer research. 2016;76(14 Suppl):Abstract 3218.  doi: 
10.1158/1538 -7445.AM2016 -3218.  
 
Lappas CM, Sullivan GW, Linden J. Adenosin e A2A agonists in development for the treatment 
of inflammation. Expert opinion on investigational drugs. 2005;14(7):797 -806. 
 
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the 
diagnosis and management of cytokine re lease syndrome. Blood. 2014;124(2):188 -95. 
 
Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the 
chemotherapy -induced anticancer immune response by the ecto -ATPase CD39. 
Oncoimmunology. 2012;1(3):393 -5. 
 
Minguet S, Huber M,  Rosenkranz L, Schamel WW, Reth M, Brummer T. Adenosine and cAMP 
are potent inhibitors of the NF -kappa B pathway downstream of immunoreceptors. European 
journal of immunology. 2005;35(1):31 -41. 
 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
148 
Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, et a l. A2A adenosine receptor 
may allow expansion of T cells lacking effector functions in extracellular adenosine -rich 
microenvironments. Journal of immunology. 2009;183(9):5487 -93. 
 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxic ity and 
response criteria of the Eastern Cooperative Oncology Group. American journal of clinical 
oncology. 1982;5(6):649 -55. 
 
Overman M, LoRusso P, Strickler J, Patel S, Clarke S, Noonan A, et al. Safety, efficacy and 
pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in 
advanced colorectal cancer (CRC) or pancreatic cancer (panc)  (Abstract) . Journal of clinical 
oncology. 2018;36  (15 Suppl) :4123.  
 
Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of 
extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PloS one. 
2008;3(7):e2599.  
 
Pinna A. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials 
from the newly approved istradefylline to drugs in early development and those already 
discontinued. CNS drugs. 2014;28(5):455 -74. 
 
Postow M, Wolchok J. UpToDate. Toxicities associated with checkpoint inhibitor 
immunotherapy. https://www.uptodate.com/contents/patient -selection -criteria -and-toxicities -
associated -with-checkpoint -inhibitor -immunotherapy . Accessed January 29, 2018.  
 
Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, et al. Purinergic 
control of T cell activation by ATP released through pannexin -1 hemichannels. Science 
signaling. 2008;1(39):ra6.  
 
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizaz i K, et al. Trial Design and 
Objectives for Castration -Resistant Prostate Cancer: Updated Recommendations From the 
Prostate Cancer Clinical Trials Working Group 3. Journal of clinical oncology. 
2016;34(12):1402 -18. 
 
Seymour L, Bogaerts J, Perrone A, Ford R , Schwartz LH, Mandrekar S, et al. iRECIST: 
guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet 
Oncology. 2017;18(3):e143 -e52. 
 
Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Muller CE, et al. CD39/ENTPD1 expression by 
CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. 
Gastroenterology. 2010;139(3):1030 -40. 
 
Takenaka MC, Robson S, Quintana FJ. Regulation of the T Cell Response by CD39. Trends in 
immunology. 2016;37(7):427 -39. 
 
 TTX-030-001 Version 8 (December 15, 2020)  
CONFIDENTIAL  
 
149 
TAXOTERE®. (docet axel) [prescribing information]. Bridgewater, NJ: Sanofi -Aventis U.S. 
LLC A Sanofi Company 2015.  
 
Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse Renal Effects of 
Immune Checkpoint Inhibitors: A Narrative Review. American journal o f nephrology. 
2017;45(2):160 -9. 
 
Whiteside TL. The role of regulatory T cells in cancer immunology. ImmunoTargets and 
therapy. 2015;4:159 -71. 
 
Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, et al. Autocrine regulation of T -cell 
activation by ATP r elease and P2X7 receptors. FASEB journal. 2009;23(6):1685 -93. 
 
Zhang H, Conrad DM, Butler JJ, Zhao C, Blay J, Hoskin DW. Adenosine acts through A2 
receptors to inhibit IL -2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of 
cyclic adenosin e 3',5' -monophosphate and phosphatases. Journal of immunology. 
2004;173(2):932 -44. 
 
Zhao H, Bo C, Kang Y, Li H. What Else Can CD39 Tell Us? Frontiers in immunology. 
2017;8:727.  
 
 